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Abstract 
Lung cancer is worldwide one of the most common cancer diseases with a high mortality 
rate. There is thus an urgent need for improving radiotherapy for these patients. 
Radiotherapy for lung cancer patients is challenging because the tumor and organs at risk 
(OARs) move with the breathing motion. Deep-Inspiration-Breath-Hold (DIBH) is a 
technique that potentially can improve the treatment for these patients. DIBH is frequently 
and routinely used for breast cancer treatments. However, it is still an experimental method 
for lung cancer patients e.g. due to preconceptions about their incapability to comply with 
the DIBH technique. For DIBH, the patients are guided to hold their breath almost at their 
maximum inspiration level during imaging and treatment. This leads to reduction of the 
breathing motion which decreases the movement of the tumor and OARs. It also expands 
the lung tissue which is beneficial with respect to sparing the healthy lung from radiation. 
In order to ensure that the tumor is receiving the prescribed dose, safety margins are added 
to the gross tumor volume (GTV). The size of the margins depends on the uncertainties 
related to the patient setup, target delineation, respiration, other internal motion, etc. These 
extra margins result in larger irradiated volumes, increasing the risk of radiation-induced 
side effects.  By reducing the uncertainties and thereby the margins, the healthy tissue can 
be spared from unnecessary radiation. The respiratory uncertainties can potentially be 
reduced by the DIBH method for the lung cancer patients.  
The overall aim of the clinical part of this thesis was to clarify the potential benefit of 
offering DIBH gating, compared to free-breathing (FB), for lung cancer patients. 
Particularly, the benefits for locally advanced non-small cell lung cancer (NSCLC) patients 
were explored. For the dosimetric part of the thesis, the dosimetric aspects of correct dose 
calculations in heterogeneous patient-like geometries were studied. 
The clinical aspects of DIBH were evaluated in three different studies, where planning 
and setup verification images acquired in both FB and DIBH were evaluated.    
In adaptive radiotherapy (ART) the treatment plan is adapted to geometrical changes of 
the patient over the course of treatment. However, defining anatomical structures for 
treatment planning is a time consuming process prone to large uncertainties. In order to 
save time and to reduce the uncertainties during ART, image registrations between the 
planning computed tomography (CT) and the subsequently acquired images may facilitate 
the delineation process. Study I investigated the uncertainties related to automatic deform 
image registrations between the planning CT and the setup images acquired at the 
accelerator, and the extra CTs acquired over the course of treatment. The studied algorithm 
was found not to be adequate enough to correct for image artifacts and large anatomical 
deformations present in the images. Furthermore, no difference between DIBH and FB was 
observed.  
Study II investigated different image based setup verification protocols. The goal was to 
minimize the applied setup margins. It was found that soft-tissue registration on the tumor 
volume resulted in the smallest planning target volume (PTV), irrespectively of FB and 
DIBH. Setup uncertainties were however introduced during DIBH, but the resulting PTV 
in DIBH was nevertheless smaller compared to FB. We speculate the increased uncertainty 
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was due to some patients tended to arch with their back to compensate for their insufficient 
compliance to reach the breath-hold amplitude level. 
Study III investigated the clinical dosimetric benefit of DIBH treatments, planned using 
a commercial Anisotropic-Analytical-Algorithm (AAA) dose calculation algorithm. 
Detailed Monte Carlo (MC) simulations were carried out for this purpose. DIBH resulted 
in better dose sparing of the OARs, compared to FB. However, the MC simulations 
revealed similar inferior target dose coverage between MC and AAA irrespectively of FB 
and DIBH treatment plans. This observation is therefore related to the treatment planning 
dose calculation algorithm rather than the breathing adapted treatment technique.   
The dosimetric aspects of complex dosimetry in heterogeneous patient-like geometries 
were explored in two different studies in the thesis. In order to investigate known 
calculation issues in the thorax region, a thoracic-like phantom was designed and 
constructed to obtain detailed dosimetry information in heterogeneous clinically relevant 
geometries. The lungs of the phantom were constructed in low-density balsa wood, the 
body in Poly(methyl methacrylate) (PMMA), and the bone in high-density delrin. 
Study IV investigated the performance of AAA, using a plastic scintillator detector 
system and the well-defined heterogeneous phantom. The treatment planning system (TPS) 
calculated doses agreed for the least complex cases, while for the more complex cases dose 
deviations ≥ 4% were observed. The dosimetric challenges in TPS calculations for 
clinically relevant geometries were underpinned.  
For lung cancer treatments, tumor volume changes during radiotherapy are well known. 
Due to incorrect scatter calculations by the TPS, the dosimetric challenges increase when 
tumor and field sizes decrease. The philosophy of radiotherapy is to deliver the same 
prescribed dose to the tumor volume, irrespective of the size of the tumor.  
Study V investigated the dosimetric challenges for the TPS in the heterogeneous 
thoracic-like geometry and its dependence on tumor size. Thus, a change of tumor size and 
resulting plan adaption over the course of a treatment was simulated. For this purpose, 
tumor inserts of different sizes (ranging from 1-8 cm in diameter) was used in the 
phantom. Severe dose deviations were observed, especially for small tumor sizes ≤ 2 cm in 
diameter. Our results imply that there exist severe tumor-size dependency, which 
potentially could have implications on the radiotherapy treatment planning of lung cancer.    
This thesis concludes that the clinical gain of DIBH is not always beneficial over FB 
treatments. There were additionally identified severe tumor-size dependent dose deviations 
that were large enough to potentially have implications for lung cancer radiotherapy 
treatment planning. The scintillator system and the heterogeneous phantom provide a 
promising tool for critical evaluation of complex radiotherapy calculations and dose 
delivery. 
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Resumé (in Danish) 
Lungecancer er den næst-hyppigeste kræftsygdom i Danmark, med ca. 4500 nye tilfælde i 
2012, hvor ca. 18% af patienterne med lungecancer blev henvist til strålebehandling. 
Dødeligheden blandt patienter med lungecancer er højere end ved de fleste andre former 
for cancer, og 5 års overlevelsen er kun 12%. Der er derfor et presserende behov for 
forbedring af strålebehandling til patienter med lungekræft. Strålebehandling af lunge-
tumorer er vanskelig, fordi tumoren bevæger sig med vejrtrækningen. Deep-Inspiration-
Breath-Hold (DIBH) gating er en teknik, som potentielt kan forbedre strålebehandlingen af 
patientgruppen. DIBH bruges rutinemæssigt til brystcancer-patienter, men det er stadigt en 
eksperimentel metode til lungecancer-patienter. Ved DIBH gating vejledes patienterne i at 
holde vejret tæt på deres maksimale inspiration i den tid (15-30 sekunder) strålebehandling 
og billeddannelse varer. Dette fører bland andet til en dæmpning af tumorens bevægelse og 
en udvidelse af lungevævet, hvilket er en fordel med hensyn til at skåne det rask lunge 
væv. Ved planlægning af stråleterapi appliceres margener omkring tumoren for at sikre at 
den planlagte dosis levereres til tumorvolumen og, at der tages højde for de usikkerheder 
der er under planlægning og behandling (for eksempel på grund af respiration, andre organ 
bevægelser, lejringsusikkerheder af patienten etc.). De ekstra margener resulterer i at et 
større område omkring tumoren bestråles, hvilket øger risikoen for toksicitet i tilstødende 
normalt væv. Ved at bruge DIBH gated stråleterapi kan det bestrålede volumen omkring 
tumoren potentielt reduceres, og derved kan rask lungevæv og omkringliggende risiko-
organer bedre skånes for stråling. Dette kan gøre det muligt at øge stråledosis til 
kræftvævet uden at give for meget dosis til risikoorganerne.  
Formålet med den kliniske del i denne afhandling var at afklare den mulige kliniske 
gevinst ved at tilbyde DIBH gating til patienter med lokalt-avanceret lungecancer. Tre 
forskellige studier er udført hvor planlægnings- og opstillingsbilleder optaget i DIBH og 
frit åndedræt (free-breathing, FB) er evalueret. 
Under behandlingsforløbet over flere uger kan det ske at anatomien i patienterne ændrer 
sig, og det kan derfor være nødvendigt at adaptere planen undervejs. At definere det 
anatomiske volumen til planlægning af strålebehandling er en vigtig og tidskrævende 
proces som tillige indeholder store usikkerheder. For at spare tid og mindske 
usikkerhederne forbundet med anatomidefinition, kan planlægnings-CT billedet registreres 
med den nye CT-skanning, eller de daglige setup verifikationsbillederne taget på 
acceleratoren. Efterfølgende kan de oprindelige strukturer propageres til de nye billeder. I 
Studie I undersøges usikkerheder relateret til automatisk deform billederegistrering brugt 
til det formål at propagere anatomiske strukturer. Vi fandt at den deforme registrerings-
algoritme ikke var tilstrækkelig god til at korrigere for billedartefakter, som forstyrrede 
billedet eller store anatomiske forandringer. Endvidere fandt vi ikke nogen forskel mellem 
DIBH og FB.  
I Studie II undersøges forskellige daglige setup verifikationsprotokoller med det formål 
at mindske de applicerede margener. Ved mindre margener kan det friske omkringliggende 
væv bedre skånes for stråledosis, hvilket giver en bedre behandling for patienterne. Vi 
fandt at den billedbaserede opstillingsprotokol, der resulterede i det mindste planlagte 
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bestrålingsvolumen (planning target volume, PTV) var baseret på bløddelsmatch på 
tumoren, uanset FB eller DIBH. Vi fandt også at DIBH introducerede større afvigelser i 
længderetningen i forhold til frit åndedræt. Dette mener vi har at gøre med at patienterne 
kompenserer sin dybe indånding med at bue ryggen for at opnå det vejrtrækningsniveau, 
der var forudbestemt i planlægningsstadiet. Dog var det resulterende DIBH PTV imidlertid 
mindre i forhold til det i FB. 
I Studie III undersøges den kliniske dosimetriske gevinst med DIBH i forhold til FB. 
Udover almindelige dosberegninger udførtes også mere detaljerede Monte Carlo 
simuleringer for at opnå mere korrekte dosisberegninger i heterogene geometrier. Vi fandt 
at DIBH resulterede i bedre beskyttelse af risikoorganer fra unødvendig bestråling end FB. 
Dog viste Monte Carlo simuleringerne at dosisdækningen af tumorvolumen ikke 
modsvarede den dosis, der var planlagt, hvor der var lige så dårlig dosisdækning for FB 
som for DIBH. Dette problem med dosisdækningen af tumorvolumen er derfor relateret til 
dosberegningsalgoritmens begrænsninger og ikke til den vejrtrækningsteknik, der var 
brugt.  
Formålet med den tekniske del i denne afhandling var at udvikle og anvende et 
målefantom for klinisk relevant dosimetri i heterogene geometrier. Det er velkendt at de 
fleste kommercielle dosisberegningssystemer ikke kan udføre korrekte beregninger af 
hvordan stråling spredes og absorberes i kroppen, når der forekommer store forskelle 
mellem densiteter og atomnummer. De største unøjagtigheder er i overgangen mellem 
forskellige materialer. Et målefantom, der simulerer en lungecancer-patient, er derfor 
udviklet med formålet at udføre uafhængige dosiskontroller af kliniske strålebehandlings-
planer i veldefinerede heterogene og homogene geometrier. Lungerne simuleres af 
balsatræ med lav densitet, kroppen af plexiglas, og knogle af delrin med høj densitet. 
Arbejdet med at udvikle dette fantom er en del af det europæiske fælles forskningsprojekt 
”Metrology for radiotherapy using complex radiation field” som er finansieret i fællesskæb 
af landene indenfor EMRP (European Metrology Research Programme) indenfor 
EURAMET og EU. Udviklingen af et menneskelignende fantom til at evaluere 
dosisberegningssystemer indgår i arbejdspakke 6 ”Methods for verification of treatment 
planning systems in anthropomorphic phantoms”.  
I Studie IV undersøges et kommercielt dosisberegningssystem ved brug af 
scintillationsdosimetri og det heterogene menneskelignende målefantom. Forskellige 
fantomkonfigurationer og behandlingsplaner med varieret kompleksitet evalueredes. Vi 
fandt god overensstemmelse med de mindst komplekse geometrier, mens der var 
dosisafvigelser over 4% i de mere komplekse tilfælde. Vores resultater understreger, at der 
er dosimetriske udfordringer i det kommercielle dosisplanlægningssystem. Scintillations-
systemet sammen med den særlige phantom er et lovende redskab til evaluering af levering 
af komplekse og klinisk relevante strålebehandlingsplaner. 
Udfordringen med at beregne korrekt dosis er størst for små felter, og for geometrier 
med store inhomogeniteter på grund af ukorrekt beregning af spredt stråling. Det er kendt, 
at tumorer mindskes eller øges i størrelse over behandlingsforløbet. Formålet med 
strålebehandling er at levere den samme ordinerede dosis til tumorvolumen, uanset 
størrelsen af tumoren, og uanset hvilken patient det er. I Studie V undersøges derfor 
dosimetrien ved forskellige tumorstørrelser i målefantomet. Lungetumorer med størrelser 
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mellem 1-8 cm i diameter var positioneret i center i fantomet, og omgivet af balsatræ med 
lav densitet. Vi fandt alvorlige dosisberegningsproblemer, specielt for små tumorer ≤ 2 cm 
i størrelse. Vores resultater indikerer derfor at der er en alvorlig tumor-størrelse 
afhængighed, der potentielt kunne påvirke planlægningen af strålebehandlingen af 
lungepatienter.  
Denne afhandling konkluderer, at den kliniske gevinst ved at behandle med DIBH ikke 
altid er bedre end at give behandlingen i FB. Der blev endvidere identificeret alvorlige 
tumor-størrelse afhængige dosisafvigelser, der potentielt kunne påvirke planlægningen af 
strålebehandlingen af lungepatienter. Det udviklede målefantom og scintillator viser et 
stort potentiale til at evaluere dosisberegninger i heterogene geometrier bestrålede med 
både simple og komplekse klinisk relevante behandlingsplaner. 
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1 Thesis objectives and outline 
Radiotherapy for lung cancer patients is a challenging task. Breathing motion moves the 
target and the organs at risk during treatment, increasing the positional uncertainty that 
affects the treatment outcome negatively. The patient geometry is heterogeneous, with 
large density variations between lung-tissue, soft-tissue, and bone-tissue in the thorax 
region. Large density variations result in known dose calculation issues for most 
commercial treatment planning systems. The absorbed dose delivered to lung cancer 
patients is therefore of special interest since their soft-tissue tumors frequently are 
embedded in low-density material that affect the dose calculations.  
Lung cancer patients are normally treated while breathing freely, known as the Free-
Breathing (FB) method. Deep-Inspiration-Breath-Hold (DIBH) is a gating method 
routinely used for breast cancer patients to mitigate the breathing motion. This reduces the 
positional uncertainties related to the breathing motion. DIBH is however still an 
experimental method for lung cancer patients and needs to be further investigated for this 
group of patients. The planning of radiotherapy is regularized by target dose coverage and 
the dose constraints of the radiosensitive organs at risk (OARs) closely located to the 
tumor volume. Thus it is imperative that the absorbed dose can be accurately predicted in 
the heterogeneous region of the lung tumor. One of the most widespread dose calculation 
algorithm used for treatment planning is the Anisotropic-Analytical-Algorithm (AAA). 
This algorithm is therefore investigated in the current work. There are however, known 
calculation issues of AAA in heterogeneous geometries. Monte Carlo (MC) is one method 
utilized in this thesis that has the potential to accurately calculate the dose in 
heterogeneous geometries. Another method employed in this thesis, is detailed dosimetry 
by a well-defined in-house designed phantom and scintillator detector system. For lung 
cancer treatments, tumor volume changes occur frequently and rapidly over the course of 
treatment. However, known incorrect scatter calculations are carried out by AAA, where 
the dosimetric challenges are increased when the tumor and field sizes decrease. The goal 
with radiotherapy is to deliver the same prescribed dose to the tumor, irrespective of the 
size of the tumor. In order to investigate this further, tumor inserts embedded in low-
density medium was used in the phantom to simulate different tumor sizes.  
The overall aim of this thesis was to address the following topics related to irradiation 
of heterogeneous lung cancer geometries, represented by enrolled lung cancer patients or a 
specially designed phantom mimicking heterogeneous lung cancer setups, with varying 
tumor sizes. The influence of breathing motion was additionally evaluated for the clinical 
cases. 
1. Study the performance of a deform image registration software based on a 
modified Demon’s algorithm for contour propagation on both FB and DIBH CT 
and Cone-beam CT (CBCT) images. 
2. Investigate the influence of DIBH versus FB on different pre-treatment image-
based setup verification protocols and assess the impact on the resulting planning 
target volumes (PTVs). 
Thesis objectives and outline 
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3. Determine the dosimetric impact of DIBH compared to FB for complex 
treatment plans, and benchmark the impact against detailed MC simulations.  
4. Develop a well-defined thoracic-like phantom enabling detailed scintillator 
dosimetry measurements in heterogeneous and homogeneous setups simulating 
clinical relevant lung cancer geometries. 
5. Assess calculation issues present in a commercial treatment planning system for 
heterogeneous geometries relevant for lung cancer radiotherapy. For this 
purpose, an in-house developed scintillator detector system and the well-defined 
thoracic-like phantom were used. 
The main parts of the thesis consist of background chapters, followed by discussion, 
perspectives and conclusion, related publications, bibliography, and technical phantom 
details and clinical protocol details in the appendices.  
Chapter 2 gives an introduction to lung cancer, describes the most relevant aspects of 
radiotherapy, and how to account for breathing motion and daily patient 
variations. 
Chapter 3 describes theory of image registrations for medical physics applications, where 
focus is on deformable image registration in radiotherapy. Common validation 
measures are stated. 
Chapter 4 deals with the theoretical aspects of absorbed dose calculations, simulations, 
and measurements. Interaction processes of ionizing radiation with matter, 
inhomogeneity calculation corrections, the calibration method and stem-effect 
removal method for scintillator dosimetry are described.  
Chapter 5 explains the clinical methods carried out in more detail. A pre-clinical DIBH 
study is presented, and the respiratory coaching and treatment workflow is 
described in more detail. 
Chapter 6 describes the design of a thoracic-like phantom, analogous to a lung cancer 
patient for fiber-coupled organic plastic scintillator dosimetry.  
Chapter 7 serves as the conclusion of this thesis, summarizing the main conclusions and 
findings of the project. 
Chapter 8 is a paper presented at the XVII International Conference on the Use of 
Computers in Radiation Therapy 2013 (ICCR2013). The work is published in the 
Journal of Physics: Conference Series. The performance of a deformable image 
registration software based on a modified Demon’s algorithm for contour 
propagation was investigated for three lung cancer cases. Analyzed CT and 
CBCT images were acquired during both FB and DIBH breathing. 
Chapter 9 is a paper submitted for Radiotherapy & Oncology. The influences of DIBH 
versus FB on three different pre-treatment CBCT image-based setup verification 
protocols were investigated, in terms of obtaining the smallest PTV. 
Chapter 10 is a paper submitted for Radiotherapy & Oncology. The dosimetry of complex 
treatments for locally advanced non-small cell lung cancer patients treated in FB 
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or DIBH was investigated. Detailed MC simulations were carried out and 
compared against, less accurate, dose calculations carried out by a commercial 
dose calculation algorithm. 
Chapter 11 is a paper presented at the 8
th
 International Conference on 3D Radiation 
Dosimetry (IC3DDose). The work is published in the Journal of Physics: 
Conference Series. The specially designed thorax phantom was used for 
scintillator dosimetry in homogeneous and heterogeneous setups, mimicking a 
lung cancer patient. Clinical relevant treatment plans of different complexities 
were measured and compared to calculations.  
Chapter 12 is an unpublished study describing dosimetry issues for small tumor sizes in a 
heterogeneous setup. Tumor-size dependency was explored for different 
treatment techniques. For this purpose, scintillator dosimetry was carried out in 
the thoracic-like phantom, mimicking a lung cancer patient with lung tumors of 
different tumor sizes. Clinical relevant treatment plans of different complexities 
were measured and compared to calculations. 
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2 Lung cancer 
Lung cancer is worldwide one of the most common cancer diseases with a high mortality 
rate (Figure 1). Compared to other Nordic countries, the rate of lung cancer incidence is 
the highest in Denmark, where approximately 4500 persons were diagnosed in 2012 [1]. 
This is likely due to the fact that smoking prevalence is more common in Denmark, 
especially for women. The incidence rate for women in Denmark the last 10 years has 
increased by 1%/year, while it has decreased about 1%/year for men, approaching an equal 
state between the sexes (Figure 2). This tendency is due to the fact that the smoking habits 
nowadays are equal between the sexes [2]. Half of the lung cancer patient population is 
older than 69 years, and 5% are older than 85 years (Figure 2). Co-morbidities are thus 
complicated influential factors affecting the treatment outcome.  
(a.) Incidence (b.) Mortality 
  
 
Figure 1. World cancer incidence and mortality in 2012. Source: GLOBOCAN 2012 [3]. 
 
 
 
 Figure 2. Age-specific and age-standardized lung cancer mortality in 
Denmark. Values for men and women are separated. The figures are 
based on data from the NORDCAN database [1,4]. 
 
In Denmark, about 18% of the lung cancer patients are referred to radiotherapy [5]. The 
mortality rate is higher than for most other types of cancer, and the 5-year-survival in 2012 
was only 12%. Hence, there is an urgent need for improving radiotherapy for lung cancer 
patients.  
Lung cancer - Treatments 
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2.1 Treatments  
The tumors are classified according to the TNM-classification (staging of primary Tumor, 
nearby lymph Nodes, and distant Metastasis), where stage I-II represent local disease, 
stage III locally advanced, and stage IV advanced disease [6]. Lung cancer can be stratified 
into two groups: Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer 
(NSCLC).  
2.1.1 SCLC 
SCLC is an aggressive disease with highly proliferating cells, which accounts for about 
15% of all the lung cancer cases [5]. These patients are often treated with radiotherapy and 
chemotherapy with quick and good response. However, relapse is very common for these 
patients, and the overall survival is low.  
2.1.2 NSCLC 
NSCLC accounts for about 78% of all the lung cancer cases. The choice of treatment 
depends on the tumor size, location, and whether there is involvement of lymph nodes. 
Surgery, radiotherapy, chemotherapy and targeted treatments, alone or in combination, are 
used to treat NSCLC. Most stage I-II tumors are treated with surgery where the lobe or a 
section of the lobe is removed. The survival rate is increased if postoperative chemo-
therapy is administrated, known as “adjuvant chemotherapy”. NSCLC patients with stage 
III tumors that cannot be operated are typically treated with chemotherapy in combination 
with radiotherapy in concomitant or sequential regimes. Stage IV patient are treated with 
radiotherapy to mitigate their pain, known as “palliative care”. Chemotherapy is often 
delivered to the patients prior to surgery or radiotherapy, in order to shrink the tumor size 
before the other treatment starts. This form of treatment is known as “neoadjuvant 
treatment”. The tumor shrinkage makes it easier to remove the tumor during surgery, or 
increase the effectiveness of radiation, since healthy radiosensitive organs at risk (OARs) 
closely situated to the tumor can be saved from unnecessary radiation. Patients with 
advanced lung cancer with certain molecular biomarkers may receive treatment with a 
targeted drug alone or in combination with chemotherapy.  
2.2 Radiotherapy of locally advanced NSCLC 
It is beneficial to treat lung cancer with high doses of radiotherapy [7,8]. However, high 
doses can lead to severe radiation-induced side effects, mainly lung toxicity [9,10]. 
NSCLC patients with peripheral local disease which cannot be operated due to their 
general condition can be treated with stereotactic radiotherapy, where a high radiation dose 
in few fractions (hypofractionation) is delivered. Also alternative fractionation schedules 
such as delivering radiotherapy twice daily (hyperfractionation) has been evaluated with 
good results, but it is not very commonly carried out due to the logistical challenge in the 
clinics and the increased hassle for the patients. If the stage I-II tumors are centrally 
located or the patient has locally advanced disease involving lymph nodes (stage III), their 
treatment cannot be hypofractionated due to the risk of inducing acute side effects. To 
avoid this, these patients are currently only treated with 2 Gy / fraction in 30-33 fractions, 
resulting in a total dose of 60-66 Gy [11].  
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2.3 Aspects of radiotherapy treatment planning 
The goal of radiotherapy is to obtain local tumor control, without radiation-induced side 
effects. In the early days, lung tumors were treated with simple anterior-posterior treatment 
fields, or an open-field box technique to achieve acceptable target dose coverage. The 
major problem with these techniques was the unnecessary radiation dose delivered in 
tissue other than the tumor volume, which increased the risk of radiation-induced side 
effects. The treatment was then restrained by the toxicity, rather than the local tumor 
control. The treatment techniques have become more advanced, where conformal patient-
specific dose distributions minimizing the dose delivered to the adjacent OARs is 
achievable by Intensity-Modulated-Radiation-Therapy (IMRT) and Volumetric-
Modulated-Arc-Therapy (VMAT). 
2.3.1 Target definition 
Three dimensional (3D) Computed Tomography (CT) and Positron Emission Tomography 
(PET) are nowadays standard imaging devices utilized to visualize the anatomy, the tumor 
and the functional processes within the body in 3D. Modern treatment planning is utilizing 
this 3D anatomical information to design patient-specific treatment plans. The target 
delineation is an estimate of the true Gross Tumor Volume (GTV), and is much affected by 
image artifacts present during the delineation process [12,13].  
In order to ensure that the tumor is receiving the prescribed dose, safety margins are 
added to the GTV. To account for the extension of clinical microscopic disease a Clinical 
Target Volume (CTV) is created by adding a margin to the GTV. This margin is based on 
experience from histological examinations. Clinical practice at Herlev Hospital is to add an 
isotropic margin of 5 mm. The Planning Target Volume (PTV) is a geometrical concept 
introduced by the International Commission on Radiation Units and Measurements (ICRU) 
for treatment planning and evaluation [14]. With this margin, the absorbed dose 
distribution can be shaped to ensure that the prescribed absorbed dose is delivered to the 
CTV with a clinically acceptable probability, despite geometrical uncertainties such as 
organ motion and setup variations, etc. In a similar way, ICRU recommend to apply 
planning risk volumes (PRVs) to the OARs to ensure that they do not get overdosed during 
treatment.  
2.3.2 Error definitions and margin calculations 
Errors in radiotherapy can occur both during the planning process and the treatment 
delivery process. Anatomical misalignments can be expressed in terms of the overall group 
mean (GM), systematic (Σ) and random (σ) errors, according to van Herk [15]. In the 
absence of significant biases, the GM will be close to zero. The systematic error is a 
measure of the reproducibility of the setup among patients. It is introduced in the planning 
process, and is present during each treatment fraction. The systematic error is defined as 
the standard deviation of the GM of the patient population. The random error is due to day-
to-day variations and is a measure for the reproducibility of setups between treatment 
fractions. It is defined as the root mean square of the standard deviations of intra-patient 
shifts. Treatment execution (random) variations lead to a blurring of the dose distribution, 
Lung cancer - Aspects of radiotherapy treatment planning 
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while treatment preparation (systematic) deviations lead to a displacement of the dose 
distribution with respect to the CTV [16].  
The most common margin concept to use is population based CTV to PTV margins to 
account for all the present uncertainties over the course of treatment [15,16]. The margin 
formulas suggested by van Herk (the CTV to PTV margin, eq. 2.1) and McKenzie (the 
PRV margin, eq. 2.2) are based on the systematic, Σ, and random, σ, error components, 
measureable over the course of treatment for a patient population.  
pp  
22
PTV 5.2Margin  (2.1) 
where σp is the penumbra factor, and the parameter β=1.64 assures delivery of 95% of 
the prescribed dose to 90% of the patient population [17]. 
Current practice at Herlev Hospital is to apply a PRV margin to the spinal cord, since 
this organ is one of the most radiosensitive organs in the body. Since the spinal cord is a 
serial OAR, and the treatments in this work were delivered as three dimensional IMRT or 
RA plans, the PRV margins for the spinal cord were calculated according to the 
McKenzie’s formula [18]: 
 5.05.2Margin OAR  (2.2) 
To take into account the intra-fractional motion in the margin calculations, all the 
systematic and all random components were added in quadrature, according to [15,16]:   
2
Intra
2
Inter   (2.3) 
2
Intra
2
Inter    (2.4) 
Some uncertainties affecting the size of the applied CTV to PTV margin if not 
corrected for are; the respiratory motion (baseline shifts and daily variations) [19,20], other 
internal organ motion, setup uncertainties [21–27], anatomical deformations (weight loss, 
tumor growth/shrinkage, anatomical changes such as atelectasis, pneumonitis, and pleural 
effusion) [26], and target definitions (inter- and intra-observer variations, and image 
artifacts) [12,28]. Identifying and minimizing these uncertainties can permit shrinkage of 
the CTV to PTV margin. This will in turn minimize the irradiated volume and reduce the 
irradiation of OARs, decreasing the risk of radiation-induced side effects during 
radiotherapy. A smaller PTV will also allow for higher target dosage.  
2.3.3 Treatment toxicity 
To avoid radiation toxicity, radiation dose constraints of the adjacent OARs, such as the 
spinal cord, the heart, the healthy lung, the esophagus, and the plexus brachialis are applied 
during the treatment planning process (Table 1). 
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Table 1. Current dose constraints for NSCLC patients at the Department of Oncology at 
Herlev Hospital. 
Priority DVH constraints V5 Gy V20 Gy V45 Gy V50 Gy V55 Gy V66 Gy < D > 
1 Spinal cord   = 0%     
1 PRV Spinal cord    = 0%    
2 Total lung ≤ 60%a ≤ 35%     ≤ 20 Gy 
2 Healthy lung ≤ 40%       
3 Heart    ≤ 20%   ≤ 46 Gy 
3 Esophagus     ≤ 30% a  = 0% b ≤ 34 Gy a 
4 Plexus brachialis      = 0%  
DVH, dose volume histogram; PRV, planning risk volume; <D>, mean dose; V5Gy, V20Gy, 
V45Gy, V50Gy, V55Gy, V66Gy percentage of an organ volume receiving at least 5 Gy, 20 
Gy, 45 Gy, 50 Gy, 55 Gy, respectively. a. Aimed for, but it is not the primarily goal.  
b. Absorbed doses up to 70 Gy are allowed in small volumes (< 1 cm3). 
2.4 Breathing adapted radiotherapy 
The respiratory motion is an important challenge for lung cancer patients, influencing both 
imaging and treatment delivery. The breathing motion is required to be considered during 
both the treatment planning process and the treatment delivery [29,30]. 
2.4.1 4DCT imaging 
A tool to measure the breathing motion is four-dimensional (4D) respiratory correlated CT 
imaging (4DCT) [31,32]. The respiratory signal is recorded during the scanning procedure 
by either an external or internal marker, flow or temperature differences of the breath [33]. 
The breathing signal is retrospectively co-registered with the individual time stamped CT 
images, resulting in a 4DCT image set. The 4DCT data can be binned either according to 
the amplitude or the phase of the breathing signal [32,34,35]. Bad correlation between the 
external marker and the internal organ motions results in image artifacts. However, 4DCT 
images are still advantageous over 3DCT in terms of erroneous imaging during breathing 
[13]. 
2.4.2 Respiratory motion management 
There are several approaches to account for the breathing motion within radiotherapy 
[33,36]; motion-encompassing methods, free-breathing respiratory gated techniques, 
breath-hold techniques, respiratory synchronized techniques. A summary of the breathing 
adapted treatment techniques are listed below. The current work is based on the deep-
inspiration-breath-hold (DIBH) gating technique, which is further described in detail in 
Chapter 5.2. DIBH - LuCaRa protocol. 
2.4.2.1 Motion encompassing methods 
Tumor motion during free-breathing treatment delivery can be accounted for already in the 
treatment planning process. For the motion encompassing method, the treatment is planned 
to ensure target dose coverage of the full tumor motion encompassing volume. There are 
different concepts to obtain this volume by using free-breathing 4DCT imaging.  
Lung cancer - Breathing adapted radiotherapy 
10 
 
One approach, which is the current practice at Herlev Hospital, is to utilize the 
Maximum Intensity Projection (MIP) concept [37–40]. The GTV is delineated based on 
the MIP reconstruction, which includes the internal tumor motion at the time of 4DCT 
imaging. In the MIP image set, the maximum CT number in a given voxel is found over all 
respiratory phases in the 4DCT image set. It is recommended to visually check the MIP 
delineated GTV in each breathing phase of the 4DCT data set, especially in those cases 
where the tumor is closely situated to the diaphragm or mediastinal area where there is a 
risk of CT number overlap [37,41]. The tumor motion encompassing GTV can 
alternatively be delineated in each individual image set, and then combined into a union of 
GTVs [41].  
Another approach is to single out one breathing phase representing the phase where the 
tumor position is close to its time-average position, known as the Mid-ventilation concept 
[42]. This approach results in smaller total GTV volumes, compared to the MIP concept. 
However, CTV to PTV margins are required to include the measured breathing motion in 
the 4DCT data set. 
2.4.2.2 Respiratory gating 
Irradiation of the patient (during both imaging and treatment delivery) can be carried out in 
a specific phase of the breathing cycle, known as respiratory gating [33]. Compared to 
free-breathing conventional radiotherapy, imaging and treatment times are pro-longed. The 
advantage with gating is the decrease of the uncertainties related to the breathing motion.  
Free-breathing gating can either be carried out as expiration- or inspiration-gating 
[33,43,44]. Since the patient is longer time in the expiration phase compared to the 
inspiration phase, expiration-gating will be a faster method (with a higher duty-cycle) 
during imaging and treatment delivery. However, the larger resulting lung volume during 
inspiration-gating is more advantageous in terms of sparing dose to the healthy lung. DIBH 
is a breath-hold gating method where the patients hold their breath at a level close to their 
maximum inspiration level, and thereby increases the time in the advantageous inspiration 
phase. In addition to the increased lung volume, the diaphragm pulls the heart posteriorly 
and inferiorly away, which also may reduce the cardiac toxicity depending on the position 
of the lung tumor.  
The breathing reproducibility during treatment delivery and each treatment fraction is a 
major challenge that needs to be taken into account during radiotherapy planning and 
treatment delivery. There are several methods to approach reproducible breathing [44–46]. 
The patients can either be guided by audio- or visual-guidance, or a combination of both 
(audio-video-guidance). Alternatively, their breath can be controlled by a spirometric 
device, known as active breath control (ABC) [47]. Nevertheless, although the breathing 
pattern is optimized, there are known issues of baseline shifts [19,20,48]. Both the internal 
and external breathing pattern vary on a day-to-day basis, where the internal tumor and 
organ motions may correlate badly to the motion of the external tumor surrogate (e.g. a 
marker-box on the thorax surface) or the internal tumor surrogate (e.g. implanted gold 
markers, used to visualize the tumor in X-ray images) [19,20,24]. Respiratory correlated 
image guidance for patient setup prior to treatment delivery is therefore necessary to 
minimize the tumor position uncertainties [20,46]. 
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An alternative to the breath-hold approach that mitigates the breathing motion is the use 
of an abdominal compression devise [49]. A plate is pressed against the abdomen that 
reduces the diaphragmatic motion. This method is primarily used for liver patients and 
lung cancer patients with tumors situated close to the diaphragm with large tumor 
displacement during breathing. However, it is not all patients that benefit from the 
abdominal compression. In some cases the compression induce unwanted effects, such as 
displacement of tumor, or induces irregular breathing motion due to discomfort or anxiety 
[49,50].  
2.4.2.3 Real-time tumor tracking 
For a more efficient treatment, with a duty cycle of 100%, real-time tumor tracking is an 
alternative to gating. The radiation beams dynamically follow the tumor position which 
compensate for the tumor motion [51]. This approach is more complex than the gating 
procedures described earlier. Compared to DIBH, the advantage of increased lung volume 
is omitted. For real-time tumor tracking, detection of the tumor position is the most 
important challenge. Available systems are based on different techniques [33]; (1.) Direct 
tumor imaging using radiographic/fluoroscopic images during treatment. (2.) Tracking on 
internal implanted tumor surrogate fiducial markers. (3.) Tumor position prediction based 
on tracking of external breathing markers. The tracking techniques are not commercially 
available for conventional linear accelerators. However, there are other treatment units 
specially designed to carry out real-time tumor tracking, such as the Vero SBRT system 
[52,53] and CyberKnife [54]. Research has been carried out on a linear accelerator system, 
using the dynamic multi leaf collimator (dMLC) to track the tumor motion [55–59].  
In real-time tumor tracking there is a need for tumor position prediction to account for 
latency in the system. Better target localization and tracking latency would improve the 
synchronization of the dMLC tracking with the tumor motion [56,57]. Real-time tumor 
tracking has the potential to decrease the tumor position uncertainties during both imaging 
and treatment and still deliver an efficient treatment. Efficiency of IMRT delivery has 
found to be dependent on if the tumor motion was tracked in the direction of the MLC leaf 
travel or perpendicular to the leaf travel [58]. Implantation of fiducial markers as an 
internal tumor surrogate can lead to pneumothorax, limiting the clinical feasibility of real-
time internal tumor tracking. Markerless soft-tissue tracking is a solution for this. This 
feature is currently not clinically available, but thorough investigations are carried out 
[60,61]. 
2.5 Image guided pre-treatment verification 
In order to account for external and internal daily variations pre-treatment image guided 
verification is required [20,46,62]. Setup uncertainties can be minimized if patient fixation 
equipment are used, e.g. a standard fixation board or a patient specific vacuum cushion 
[23]. Pre-treatment verification can be carried out by registering the planning CT with a 
corresponding setup image. 2-dimensional (2D) digitally reconstructed radiographs (DRR) 
from the planning CT can be registered either by 2D orthogonal kilovoltage (kV) X-ray 
images acquired by a CBCT system, or 2D megavoltage (MV) image acquired by an 
electronic portal image device (EPID) system, both attached at the treatment unit. A major 
disadvantage with DRRs, 2D kV, and MV images is that they only provide bony anatomy 
Lung cancer - Interfractional adapted radiotherapy 
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positional information. 3D CBCT imaging provides additional soft-tissue visualization 
with anatomical positional information of tumor and OARs, as well as anatomical changes 
in the thorax area, such as atelectasis (collapse or closure of the lung), pneumonitis 
(inflammation of lung tissue), and pleural effusion (water in lungs) [26]. Direct match on 
the lung tumor itself (i.e. soft-tissue tumor registration) compared to bony match on the 
spine has the potential to minimize the required setup margins in the thorax area 
[21,63,64]. The CBCT images are either manually or automatically registered to the 
reference CT images. Manual registration is a complex and time consuming task and can 
be subject to inter-observer variability, contrary to automatic registration [65,66]. 
Differences between three types of automatic CBCT image–based setup protocols in 
combination with FB and DIBH are described in Paper II (Chapter 9), where the primary 
objective was to identify which automatic CBCT match method that resulted in the 
smallest PTV. The study provides clinical guidance on what automatic CBCT match 
protocol to use for DIBH or FB setup verification, and it specifically addresses how match 
results depend on the breathing techniques. The three investigated automatic CBCT match 
methods focused on: (1.) the bony anatomy of the spine, (2.) the soft-tissue of the primary 
gross tumor volume (GTV-T), and (3.) the soft-tissue of the total tumor volume (GTV-
Total), including malignant lymph nodes (GTV-N).  
2.6 Interfractional adapted radiotherapy 
As described in Chapter 2.5. Image guided pre-treatment verification, daily pre-treatment 
imaging can be carried out to correct for day-to-day variations. However, major anatomical 
changes such as change of tumor size as a response to the treatment, or creation or ablation 
of atelectasis, pneumonitis or pleural effusion over the course of treatment are hard to 
correct for without affecting the target dose coverage or the spearing of dose to the OARs. 
In adaptive radiotherapy (ART), the treatment plan is adjusted during the course of 
treatment to minimize the divergence from the planned treatment. ART is a modern, 
workload heavy approach to end up with the most optimal treatment, that has the potential 
to account for major anatomical changes not accounted for by applied margins or daily 
setup verification [36,67]. To adapt a treatment plan, the patient is re-CT scanned and re-
planned, where new anatomical structure delineations are required on each new image set. 
The delineation process is a time consuming task for clinicians, and a major contributor of 
systematic errors in radiotherapy [28,68]. To save time on the delineation process and to 
streamline the outcome, deformable image registration (DIR) is a promising tool in 
assisting with the delineation process. DIR deforms the reference contours from the 
planning CT into the anatomy of a re-CT or CBCT image. The deformed structure set on 
the new image set is subsequently visually checked by a clinician and modified until 
satisfaction before the start of the treatment planning process. More detailed information 
about image deformations are described in the next section, Chapter 3. Image registrations 
and deformations. 
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(A). Planning CT  (B). Final CT 
Figure 3. Example of tumor shrinkage observed between the planning CT (A) and the CT 
acquired at the last treatment session (B). The GTV and the body contour is colored red and 
green, respectively. 
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3 Image registrations and 
deformations 
3.1 Introduction 
Image registration is the process of determining the geometrical transformation that aligns 
the points of an image with corresponding points in a reference coordinate frame, i.e. a 
reference image. When a shape of an object is changed non-rigidly, either temporarily or 
permanent, it is deformed. To correlate the anatomical information from the various 
images, deformed image registration is a valuable tool.  
Image registration adds values to medical images by enabling: 
 Monitoring anatomical motion or changes of an individual patient (intra-patient 
variations). 
 Registration of information from different imaging modalities (like CT, PET, 
Magnetic Resonance Imaging (MRI), etc.). 
 Comparing one patient anatomy with others (inter-patient variation, atlas-based 
segmentation [69]). 
 Comparing a groups’ anatomy with others, in order to quantify the biological 
variability for population studies. 
Within the field of modern radiotherapy, image registrations and segmentations are 
important parts of the treatment. Firstly, in order to diagnose cancer diseases and to make 
accurate medical statements, the patients are imaged by a combination of various imaging 
modalities. Since there is not only one imaging device able to perform all imaging 
techniques at once, it is necessary to fuse (register) the acquired 3D images with each other 
to correlate the anatomical information in the various sets of images. Unless the image 
acquisitions are done with the same resolution, within a short period of time or using the 
same setup, anatomical changes such as baseline shifts, volume change, and change of 
breathing patterns, etc. may affect the image correlations. Thus, image registrations are 
required. Secondly, to ensure a god treatment reproducibility during the course of 
radiotherapy, everyday-pre-treatment imaging is acquired and registered to the planning 
CT image used for treatment planning. Furthermore, during an ART approach (described 
earlier in Chapter 2.6. Interfractional adapted radiotherapy), anatomical structure de-
lineations are required for the image sets acquired over the course of treatment to be able 
to adapt the treatment plan. Manual delineation of the target and OARs is a time 
consuming process prone to intra- and inter-observer variations [28,68]. DIR and 
automated segmentation methods are promising tools in reducing the delineation workload 
and streamline the delineation outcome, minimizing the delineation uncertainties [70]. 
However, the transformed delineations are still required to be reviewed and modified by a 
clinician subsequently. 
Image registrations and deformations - Elements of image registration 
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Original Re-CT Difference image 
Figure 4. An example of anatomy change in a neck nodal region during radiotherapy. (A) The 
transversal slice of the original CT image. (B) The same slice of the re-CT image acquired 37 
days after the start of radiotherapy. (C) The difference image of (A) and (B). There is clearly 
a visible shrinkage of the anatomy. Source: Wang et al. [71]. 
3.2 Elements of image registration 
The basic idea of image registration is to find a transformed version of the image that 
becomes similar to the reference image.  There are four elements essential in the image 
registration process [72]: (1.) ‘The geometrical transformation’ that rigidly or deformable 
transforms the image. (2.) ‘The similarity measure’ that describes the goodness of the 
registration. (3.) ‘The optimization algorithm’ that determines the parameters used to 
maximize the similarity measure. (4.) ‘The regularization term’ that secures that only 
reasonable transformations are carried out.  
For pre-treatment verification using a standard treatment couch it is sufficient to 
consider translational differences to correlate the patient position to the planned treatment. 
However, if using a six degree-of-freedom (DOF) treatment couch, rotations could be 
included in the correlation.  
3.3 Deformable image registration algorithms  
Deformable (non-rigid) image registration algorithms can be categorized into either 
‘feature-based’ or ‘grayscale based’ classes [70,71].  
3.3.1 Feature based 
Feature-based algorithms match contours, fiducial markers, or anatomical landmark points 
or lines in the image with the corresponding features of the reference image. These features 
needs to be defined prior to registration for the algorithm to work, which can be a time 
consuming process, especially if it is delineated manually.  
3.3.2 Grayscale based  
In contrast, grayscale-based algorithms use the intensities in the images to register the 
images, voxel-by-voxel. Due to the consistency in CT pixel intensities it is often 
advantageous to use a grayscale image-based algorithm for radiotherapy applications, 
although these often work slower [71]. Mutual information is a commonly used similarity 
A B C 
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measure used for grayscale feature based image registrations [70]. Non-linear registrations 
are frequently based on B-spline or Demon based registrations. A modified Demon’s 
algorithm is used in the current work (Paper I, Chapter 8), therefore are the basics of this 
algorithm described in more details below.  
3.3.2.1 Demon’s algorithm 
Demon’s algorithm is one of the most acknowledged image deformation algorithm used 
clinically [70,71,73–75]. The first version of the algorithm was completely grayscale 
based, and was originally introduced by Thirion [74,75]. Initially it used the gradient 
information in the images for registration. Demons algorithm is based on a diffusion 
model, letting one image diffuse through the interfaces of the other images. The diffusion 
is steered by demons, hence the name, which are local forces guiding the voxels of the 
image to be registered to the reference image, i.e. the “static” image. An important 
parameter of the algorithm, describing the extremity of the deformation, is the ratio of the 
external to internal force strength, and the regularization of it. The external forces search 
for similar features in the images to register and the internal forces regulate the resulting 
transformation. The optical flow formula (eq. 3.1.) can be used to estimate the demons 
forces. The estimated displacement ?⃗?  in three dimensions (ux, uy, uz) required for a given 
point P in a static image S, with intensity s, to match the corresponding point in the 
deformed image M, with intensity m, is given by: 
 
 2
2
sms
ssm
u
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(3.1) 
∇⃗ s is the gradient of the static image, i.e. the derivate. The (m-s) term is the external 
force of the interaction between the static and the deformed image. The deformation field 
is regularized by a Gaussian filter with a normal distribution. 
The Demon’s algorithm has been modified and further developed to be a faster and 
more accurate image registration algorithm [70,71,73].  
There are two major restrictions of the Demon’s algorithm [74]. Firstly, the original 
positioning of the two objects to be registered is crucial for the success of the method. 
Secondly, the intensities of the two images must be similar. A general solution to this for 
inter-modality registrations is to make the intensities of the two images similar prior to 
registration, by for an example atlas-based segmentation. 
Image registrations and deformations - Validation measures 
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Original CT scan, with manually delineated 
structures. 
 
 
Deformed image (re-CT registered to the 
original CT scan), including the DVF (light 
grey lines) and the propagated deformed 
structures overlaid on the original structures.  
 
Re-CT scan, with manually delineated 
structures. 
Figure 5. Creation of a deformed image and corresponding deformed structures of a thorax region. 
The propagated deformed structures are produced by applying the deformation vector field (DVF) 
(illustrated by the light gray lines in the right figure) to the manually delineated structures on the 
re-CT scan. GTV, CTV, and PTV are colored red, pink and blue, respectively. 
3.4 Validation measures  
An important aspect of developing medical image analysis algorithms is demonstrating 
that the algorithms actually work. This is done by comparing the transformed image with a 
pre-defined ground truth image. One approach is demonstrated in Figure 5, where the 
manually delineated structures regarded as “the ground truth” were created by an 
experienced radiation oncologist. The transformed image can alternatively be compared 
with an estimate of a population-based ground truth image.  
Image transformations can be evaluated for accuracy, efficiency, or reliability by 
various methods. Simple volume analysis is the most widely reported method [76]. Other 
common volume analysis methods are listed below. 
3.4.1 Center of Mass 
Center of Mass (COM) is a measure for describing the displacement of the center position 
of the segmented volume investigated [70,76]. The COM analysis is effective to use for 
small spherical volumes, but can be limited for larger complexly shaped volumes, as it is 
possible for two volumes under comparison to have identical COM, but a very different 
volume measurement (Figure 6).  
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A B C 
Figure 6. COM examples. (A.) The two volumes of different size and 
shape have clear COM displacement. (B.) The same two volumes, but 
now with identical COM. (C.) A single curved shaped volume with 
the COM located outside of the volume. Source: Hanna et al. [76]. 
3.4.2 Overlap methods 
Overlap methods are a bit more complex than just simple volume analysis, and are popular 
metrics for evaluating transformations of larger complexly shaped volumes. The 
percentage of overlap of two volumes as a fraction of their total volume is estimated 
[70,76]. The most common quantitative measures used for comparison of two samples are 
the ‘Conformity Index’ (CI) (also known as the Jaccard coefficient, or Minkowski Index) 
and the ‘Dice Similarity Coefficient’ (DSC). CI is the ratio of intersection of two volumes 
and the union of the two volumes (eq. 3.2). The DSC is closely related to CI, and will give 
a slightly different value compared to the CI for the same volume comparisons (eq. 3.3) 
[72,76,77]. 
Overlapping evaluation methods can also be used for applications other than for image 
analysis. In the current work (Paper III, Chapter 10) new overlapping concepts according 
to Van Esch et al. [78] were applied in order to evaluate the quality of the treatment plans 
in terms of target dose coverage and spread of high dose to OARs. The CI95, the ‘lesion 
coverage fraction’ (LCF), and the ‘normal tissue overdosage fraction’ (NTOF) were 
calculated for the 95% isodose. In brief, the CI95 was defined as the 95% isodose volume 
relative to the size of PTV. The LCF95 was defined as the fraction of PTV that was covered 
by the 95% isodose volume, i.e. it is a measure for target underdosage. The NTOF95 was 
defined in a similar way as the fraction of the 95% isodose volume that was outside the 
PTV. Thus, NTOF is a method to quantify the relative amount of high dose (i.e. in our case 
dose over 95% of the prescribed dose) delivered outside of the PTV. CI95 assesses only the 
relative size of the isodose volume without respect to target location. The LCF and NTOF 
allows for more detailed quality quantification. 
Ideal overlap is characterized by a CI, DSC, and LCF close to unity, and a NTOF 
approaching zero.  
Image registrations and deformations - Validation measures 
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 Figure 7. Graphical representation of the 
concepts of true (T) and false (F) positives (P) 
and negatives (N). The “ground truth” manually 
delineated structure is colored blue, and the 
propagated to-be-evaluated volume is yellow. 
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3.4.3 Sensitivity and specificity 
ROC-analysis is an additional method to evaluate image registrations [72]. All pixels in the 
3D image can be classified according to Figure 7, where the background is classified as the 
true negative (TN) values. False negative (FN) and false positive (FP) refer to registration 
errors made by the automated algorithm compared to the ground truth image. By using 
information from the TP, true negative (TN), FP, and FN, a Receiver Operator Curve 
(ROC) plot can be made where the true positive rate (sensitivity) is plotted against the false 
positive rate (specificity). The sensitivity is defined by (TP/[TP+FN]), and the specificity 
by (TN/[TN+FP]). If the registration corresponds perfectly with the ground truth, they will 
both have the maximum value of 1. The area under the curve of the ROC plot should be as 
close to 1 as possible to have a good registration result. ROC curves can be very practical 
to use if transformation results from various image registration algorithms shall be 
analyzed against each other. 
true 
negative 
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Figure 8. ROC curve. Source: MedCalc Software [79]. 
3.5 Summarization 
Image deformations can be a very handy tool within the field of medical physics. The 
image quality of moving objects such as the heart, lung tumors, prostate, cervix, bladder, 
liver etc., can be improved by utilizing image deformations for motion corrections in 4D 
imaging [73]. Moreover, image deformation techniques enables fast structure propagation 
of delineated structures from a reference image to images acquired at a later time, or at 
another imaging modality. This feature can save a lot of time in the delineation process for 
the clinicians. By utilizing automatic structure propagation, the inter-observer variability is 
minimized. Furthermore, there is ongoing research on DIR based ART workflows [80]. 
DVFs obtained between the planning CT and the daily CBCT images, acquired for pre-
treatment setup verification, are utilized to propagate the CT Hounsfield unit (HU) values 
onto the CBCT images, allowing for calculating the “dose of the day” on the CBCT image. 
These calculations can subsequently be re-mapped onto the planning CT to eventually 
evaluate the actually delivered dose to the patient compared to the planned treatment.  
DVFs can additionally be utilized to adapt the MLC aperture to account for tumor 
deformations in real-time [81]. 
New and improved deformation algorithms, both rigid and non-rigid, are constantly 
developed. Image registrations are however very sensitive for image artifacts. Special 
notice should therefore be taken to image artifacts in the images prior to image 
registrations. Figure 9 demonstrates two patient examples of image registrations where the 
resulted deformed registration is incorrect due to image artifacts in the registered images.  
Image registrations and deformations - Summarization 
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Figure 9. Two examples of erroneous CBCT image registrations (red arrows) due to image 
artifacts in the registered images (not presented, see example in Paper I, Chapter 8). The DVF is 
presented as light gray lines in the left figure. 
Investigation of the performance of a DIR software based on a modified Demon’s 
algorithm for contour propagation is described in Paper I (Chapter 8). DIR was carried out 
between the planning CT and the re-CTs and daily CBCTs acquired over the course of 
treatment to obtain the DVFs used for contour propagation. The images were acquired for 
both FB and DIBH for three lung cancer patients. 
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4 Dosimetry 
4.1 Interactions of ionizing radiation with matter 
To measure absorbed dose in a point, an infinitesimal volume, dv, is considered. The SI 
unit for absorbed dose is Gy (J/kg), which is defined as the energy imparted, dε, by 
ionizing radiation in an infinitesimal volume, where, dm, is the mass in the volume (eq. 
4.1) [82]. 
dm
d
D

  (4.1) 
The fluence of the primary photon beam, N0, passing through a media of a certain 
thickness, x, is attenuated exponentially through indirect interactions with certain 
probability (μ) (eq. 4.2). 
  xeNxN  0  (4.2) 
The dose is not deposited by the photon radiation directly, but indirectly by the 
secondary charged particles generated by photon interactions in the media. The energy 
deposition in tissue from photon irradiation occurs thereby in two steps [82,83]: 
 The kinetic energy of the primary photon radiation is transferred to charged 
particles in the media. The photons interact with the media through three 
processes yielding secondary charged particles by ‘Photoelectric absorption’, 
‘Compton scattering’, and ‘Pair-production’. For the megavoltage photon beams 
used in radiotherapy, Compton scattering is the predominant process. The 
amount of kinetic energy per unit mass transferred to electrons is defined as the 
KERMA. 
 The secondary charged particles deposit their energy in the media through 
ionization and excitation along their particle track by elastic and inelastic 
scattering processes. The most likely scattering process is with small angles and 
small energy transfers, due to the Rutherford scattering cross section (dσ/dΩ 
~1/(sin
4
(θ/2)) and the energy transfer cross section (dσ/dT ~1/T2). Since the 
incident charged particles only transfer a fraction of their kinetic energy, it is 
convenient to think of it as the particle loses its energy gradually, known as the 
Continuous Slowing Down Approximation (CSDA). The CSDA range is very 
close to the average path length of the charged particle for low-Z materials. The 
mass stopping power, dT/ρdx, is a measure for the energy loss per unit path 
length, dx, by a charged particle of certain energy, T, in a media of mass density, 
ρ. The mass stopping power consists of two parts, the mass collision and 
radiative stopping power. Since the radiative contribution is not deposited 
locally, only the collision part (SCol) is considered for the absorbed dose in the 
infinitesimal volume. The amount of kinetic energy released locally is known as 
collision KERMA (KCol). 
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24 
 
The kinetic energy transferred from the photon beam to the secondary charged particles 
in the media does not lead to full energy absorption at the same location. This is due to the 
relatively long range of the secondary electrons generated in the media. Just below the 
surface of the media, there exists no charged particle equilibrium (CPE). Therefore, the 
absorbed dose starts to build up through the depth (Figure 10). As the depth increases, CPE 
is eventually reached, approximately at the depth equal to the maximum range of the 
secondary electrons (CPE condition is described in Figure 11). Due to the convergence of 
the beam and the photon fluence attenuation in the media, the production of secondary 
electrons decreases accordingly, resulting in transient CPE in the region where the 
absorbed dose, D, is proportional to KCol. The dose curve reaches a maximum (dmax) at the 
depth where the rising slope due to buildup of charged particles is balanced by the 
descending slope due to attenuation of the indirectly ionizing radiation [82]. 
 
 
 
 
Figure 10. Collision KERMA and absorbed 
dose as a function of depth in a medium irr-
adiated by a high energy photon beam. 
Redesigned illustration from Podgorsak [84]. 
 Figure 11. CPE condition for an external source. 
If the minimum distance separating the 
boundaries of the larger volume (V) and the 
smaller internal volume (v) is greater than the 
maximum range of charged particles present, 
CPE exist in v. Source: Attix [82]. 
For mono-energetic photons with the energy, E, the absorbed dose is related to KCol 
under CPE condition in the media for external beams according to:    
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Where Ψ is the photon energy fluence, (μen/ρ) is the mass-energy absorption coefficient 
of the media, and ΦPhotons is the photon fluence. Correspondingly, during equilibrium in 
terms of secondary electrons, the dose is given according to: 
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Where (SCol/ρ) is the unrestricted mass collision stopping power and 
eΦ is the electron 
fluence in the media. 
For shallower depths < dmax the transport of charged particles must be explicitly taken 
into account. Lateral CPE is additionally dependent on if the field size is large enough to 
establish CPE in all directions. This is an issue for narrow field sizes less than the range of 
the secondary charged particles. Since the change of density affects the range of the 
secondary charged particle, this will be a greater issue for low density lung-tissue, where 
the range of electrons is approximately four times greater than in water. Additionally, this 
effect increases the penumbra width in low density media.  
4.2 Inhomogeneity corrections 
Input data for the treatment planning systems (TPSs) are obtained in water [85,86]. 
However the human body is heterogeneous and consists of various materials and cavities 
of different radiological properties, such as soft-tissue, lung-tissue, bone-tissue, air 
cavities, metal prosthesis, etc. (Figure 12). Due to the dependence of interaction 
probabilities in the media, the presence of heterogeneities influences the dose deposition in 
the patient. Thus, inhomogeneity corrections are required for more correct dose 
calculations in heterogeneous geometries.  
 
  
 
Figure 12. Examples of heterogeneous patient anatomies containing soft-tissue, lung-tissue, bone-
tissue, air cavities, and fluid. (A) A coronal slice of the middle part of the body. The arrow indicates 
air in the intestine. (B) A transversal slice of the thorax. The arrow indicates a lung tumor located in 
center of the patient’s right lung. (C) A transversal slice of the abdomen. The upper arrow indicates 
fluid in the stomach. The fluid is illustrated by the straight surface since the patient is lying down 
during imaging. The lower arrow indicates air in the colon. 
Different inhomogeneity correction methods differ mainly in the way how they account 
for the scattered photon contribution, primary electrons, and in the sampling of anatomical 
3D density information (Table 2) [83,87]. MC algorithms that use photon interaction 
probabilities and model the electron scatter in heterogeneous geometries belong to a 
calculation approach explicitly accounting for density inhomogeneities and correctly 
calculates absorbed dose in regions with non-existing CPE conditions (Table 2). Other 
methods are often based on approximations to account for density related fluence and 
 A B 
C 
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particle range changes in order to save calculation time. For correct inhomogeneity 
corrections in patients, all assumptions are required to be accounted for, where both 
changes in density and atomic number composition need to be considered. 
Table 2. Categorization of different inhomogeneity correction algorithms 
according to the level of anatomy sampled (1D or 3D) and the inclusion or 
exclusion of electron transport. Source: Papanikolaou [83]. 
 Local energy deposition Non-local energy deposition 
 Category 1 Category 3 
1 D 
1. Linear attenuation 
2. Effective attenuation  
3. Ratio of TAR (RTAR) 
4. Power law (Batho)  
5. Equivalent path length (EPL) 
1. Convolution  (pencil beam, PB) 
2. Fast Fourier Techniques (FFT) 
 Category 2 Category 4 
3D 
1. Equivalent TAR (ETAR) 
2. Differential SAR (DSAR) 
3. Delta volume (DVOL) 
4. Beam subtraction method 
1. Superposition / Convolution 
(Collapsed Cone Convolution, CCC) 
2. Monte Carlo (MC) 
3. Differential TAR (dTAR) 
4.3 Modern TPS algorithms 
Modern commercial TPSs are based on advanced algorithms that decompose the radiation 
beam into primary and scatter components and calculate them independently. 
Superposition and convolution principles are used to calculate the dose distribution based 
on MC simulated dose spread kernels and the energy deposited at each point in the 
volume. Hence, they account for changes in scattering, caused by variations in beam shape, 
intensity, patient geometry and tissue inhomogeneities. However, approximations are 
employed, not comparable to MC simulations.  
Throughout this thesis the Varian Eclipse (Varian Medical systems, Palo Alto, CA, 
USA) TPS was used for treatment planning, where the AAA was utilized [88]. Additional 
MC simulations were carried out in Paper III (Chapter 10). The superposition AAA dose 
calculation algorithm and the basics of MC simulations are therefore described in more 
details below. 
4.3.1 Anisotropic-Analytical-Algorithm  
The AAA algorithm has previously been described extensively [88–92]. The AAA 
algorithm is a three source pencil-beam convolution-superposition model, where the 
primary and secondary photons and the contamination electrons are individually calculated 
for each beamlet. The dose contributions from all sources are subsequently superpositioned 
to the final dose distribution, where the heterogeneity correction only is carried out during 
the superposition phase by a modified Batho heterogeneity correction [88]. The most 
important approximation of AAA is that the energy deposition is divided into two 
components, the first component models the photon interactions along the fanline, and the 
second component models the scatter perpendicular to the fanline as a sum of six radial 
exponential functions for a discrete number of angular sectors [88–90]. Thus, the two 
component approximation does not take the divergent scatter of heterogeneities from upper 
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levels correctly into account. The depth and lateral components are anisotropically scaled 
independently according to the electron density distribution of the medium. Additionally, 
the approximation of using a discrete number of angular sections for the radial exponential 
functions cause smoothing of the calculated dose distribution near heterogeneous 
interfaces [88,89]. 
4.3.2 Monte Carlo simulations 
The initial MC simulation of the photon generating process in the accelerator head is an 
advantage over other dose calculation algorithms. Each photon history is subsequently 
simulated until the kinetic energy of the generated secondary charged particles is released, 
typically down to a cut-off energy of about 10 keV. For sufficient statistics, a large number 
of photon interactions are required to be simulated due to the long mean free path length of 
photons resulting in few interactions in the patient body. This results in long calculation 
times, which is the major reason why MC simulations are not frequently used in clinical 
environments. However, increased computer powers and variance reduction techniques 
may speed up the MC calculation processes enough to make them clinically acceptable for 
routine use [83]. More detailed information about the MC simulations carried out in this 
thesis is described in Paper III, 10.2.6, Monte Carlo simulations. 
4.3.2.1 Dose-to-water conversion 
Generally for most TPSs, the calculated absorbed dose is reported as dose-to-water (Dw) 
[93]. MC simulations report the absorbed dose as dose-to-medium (Dm), where the 
patient-specific electron density information obtained from each patient’s CT image set, 
and media dependent interaction cross sections are used to calculate the absorbed dose. In 
order to compare MC doses with TPS computed dose distributions, Dm needs to be 
converted into Dw. The conversion procedure is described by Siebers et al. [94]. In short, 
they propose an analytical method based on Bragg-Gray cavity theory, in which they use 
the Spencer-Attix mass restricted collision stopping power ratios (SPRs) as conversion 
factors. They calculated the ratio of tabulated stopping power for water and the 
investigated medium for a nominal energy. A better approach is to use MC computed SPRs 
for the beam in question. The dose-to-water conversion method employed in Paper III 
 is a conversion approach in between, where MC computed SPRs for a reference beam of 
the linear accelerator in question is used according to eq. 4.5. 
 mQSPRDD wmmw ,  (4.5) 
Where Q is the beam quality, and m is the medium. 
4.4 Scintillator dosimetry 
The dosimetry in this thesis is carried out with fiber-coupled organic plastic scintillators 
(PSDs). The advantages of using PSD for complex and dynamic radiotherapy dosimetry in 
megavoltage photon beams have previously been presented in studies based on 
homogeneous setups in either water or solid water phantoms [95–98]. Benchmarking 
against MC simulations have shown good agreement with measurements [97]. 
Additionally, a recent study by Francescon et al. even concluded the Exradin W1 PSD 
(Standard Imaging, Middleton, WI, USA) to be the only detector of those investigated that 
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could reproduce the Monte Carlo simulated data in water with high accuracy [99]. PSDs 
are particularly well suited for complex dose verifications due to their water-equivalency, 
and small size for high spatial resolution and minimum perturbation of the radiation fields. 
Alanine and thermoluminescent dosimeters (TLDs) are also highly water equivalent, but 
they do not provide real-time output, which is a significant drawback in studies involving 
many treatments and complex phantom setups. 
4.4.1 Calibration procedure 
One drawback with PSD dosimetry is the fact that the signal is affected by produced 
Cerenkov light, and fluorescence light in the fiber during irradiation, known as the stem-
effect. The amount of stem-effect is due to how much of the fiber that is irradiated. This 
needs to be corrected for during the calibration process. The obtained signal is therefore 
required to be corrected in order to acquire the absorbed dose delivered in the scintillator. 
The study by Guillot et al. [100] describes several different methods to remove the stem-
effect. The stem-effect removal approach used in this thesis is referred to as the Method C, 
in their study. The essential of the method is described in more detail in this section. 
Chromatic removal of the unwanted signal is possible since the spectra of the Cerenkov 
and fluorescence light is different from the scintillator signal. The calibration procedure 
was conducted in a Solid Water (Gammex Inc., Middletron, WI, USA) calibration 
phantom according to Figure 13. 
Configuration 1
111 BbAaD   
  
Configuration 2
222 BbAaD   
Figure 13. Schematic illustration of the calibration phantom used for chromatic removal calibration. 
A is the signal in the green channel and B is the signal in the blue channel. The absorbed 
dose D in the scintillator would be given by the relation D = a · A + b · B. The unknown 
constants a and b are calculated by calibrating the scintillator at known delivered dose for 
two different irradiation conditions: (i) an irradiation with a small amount of the fiber in 
the radiation field (Configuration 1, left in Figure 13), to minimize the generation of 
Cerenkov light and fiber fluorescence; (ii) an irradiation involving as much fiber in the 
radiation field as possible to maximize the stem effect (Configuration 2, right in Figure 
13). a is defined as the gain factor. The ratio −b/a is defined as the Cerenkov Light Ratio 
(CLR), or stem-signal ratio.  
4.4.1.1 Specific calibration procedure 
The reference dose (100 MU, 10x10 cm
2
 field at a source-surface distance of 90 cm, and 
depth of 11.5 cm) was measured by a Farmer ionization chamber, type 30011 (PTW, 
Freiburg, Germany) in the Solid Water phantom, at configuration 1. The depth of 11.5 cm 
agreed with the center position in the Poly(methyl methacrylate) (PMMA) phantom used 
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for scintillator dosimetry in heterogeneous setups (described in Chapter 6, Phantom 
details). Irradiation was delivered by a Varian Clinac iX 2300 linear accelerator (Varian 
Medical Systems), with a beam energy of 6 MV at a dose rate of 600 MU/min. The 
calibration dose was normalized to the corresponding calculated dose in Eclipse to 
eliminate the daily output variation of the linear accelerator. To determine the dosimetric 
correction factor between the Solid Water phantom and the in-house developed PMMA 
phantom, corresponding measurements were carried out in the PMMA phantom (using the 
most homogeneous setup, where all body cylinders were filled with PMMA). The mean 
and one standard deviation (1 SD) of the dosimetric correction factor between the solid 
water calibration phantom and the PMMA phantom measured with the ionization chamber 
was 0.9983 (0.0013). 
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5 Clinical methods 
This section gives an overall description on the methods used in the clinical studies not 
described in the papers. More detailed method descriptions are presented in each 
manuscript (Paper I-III). 
5.1 Pre-clinical DIBH pilot study 
Before initialization of the clinical DIBH-LuCaRa (Lung Cancer Radiotherapy) protocol, 
there existed preconceptions about the impracticability to perform DIBH for locally 
advanced lung cancer patients due to their comorbidities, such as chronic obstructive 
pulmonary disease (COPD) or poor pulmonary functionality, etc. For that reason a pre-
clinical pilot study was carried out for locally advanced lung cancer patients to assess how 
long time these patients could hold their breath (Figure 14). Forty-eight patients planned 
for curative radiotherapy at Herlev Hospital in 2011 were enrolled in the pilot study.  
 
Figure 14. Duration of breath-hold times for 48 
locally advanced lung cancer patients, reproduced 
in 3 breath-hold sessions for each patient. On each 
box, the central dark gray mark represents the 
median value. The edges of each box are the 25th 
and the 75th percentiles, the whiskers correspond to 
approximately ± 2.7 SD of the data, and outliers are 
plotted as crosses individually. 
It was found that the patients in median could hold their breath for longer than 20 
seconds. Breath-hold during 20 seconds is the required time frame for breast cancer 
patients to be offered DIBH treatment at Herlev Hospital [101]. Thus, the same 
requirement was applied for the locally advanced lung cancer patients enrolled in the 
clinical DIBH-LuCaRa study.  
5.2 DIBH - LuCaRa protocol 
A total of 23 locally advanced lung cancer patients were enrolled to the IRB approved 
DIBH-LuCaRa protocol by the Department of Oncology at Herlev Hospital between 
December 2012 and July 2014. The patient characteristics are summarized in Table 3. 
Every patient received verbal and detailed written information about the DIBH-LuCaRa 
protocol, and gave informed consent to the work before inclusion. For more details about 
the clinical protocol see Appendix C: Clinical protocol (in Danish).  
Clinical methods - DIBH - LuCaRa protocol 
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PS, Performance Status; TNM, Tumor-Node-Metastasis staging; Loc., Location; M, Male; 
F, Female; L/R-UL, Left/Right-Upper Lobe; L/R-LL, Left/Right-Lower Lobe; RML, Right 
Middle Lobe; Y, Yes; N, No; NaN, Not-a-Number; SCLC, Small Cell Lung Cancer; 
LCNEC, Large-Cell Neuroendocrine Carcinoma; fx, fraction.  
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5.3 Respiratory coaching 
Prior to imaging for treatment planning, all patients were introduced during a 30 minute 
training session to the DIBH procedure by a radiotherapist (RTT). The Varian real-time 
position management (RPM) system, version 1.7 (Varian Medical Systems), integrated 
with the CT and CBCT imaging systems, and the linear accelerator, was utilized to 
monitor the patients’ respiration [32]. Infrared cameras were fixed at the end of the CT-
couch and on the wall in the treatment room, facing the treatment-couch (Figure 15F). 
These were used for tracking the respiratory motion by the vertical displacement of a 
marker box with infrared reflective markers placed at the lower chest or upper abdomen of 
the patients (Figure 15 (B, D, E)). 
   
  
Figure 15. (A.) Operator during the training session. (B.) Computer goggles are used for visual 
guidance. The marker box is positioned on the thorax. (C.) The view of the operator.  (D.) The 
marker box. (E.) Patient setup in an individualized fixation at the CT scanner, with the marker box 
positioned on the thorax. (F.) The RPM camera located at the end of the CT couch.  
The goal with the training session was to establish stable reproducible breathing 
amplitude and to evaluate the patients’ breath-hold capacity. The intended gating window 
A 
F 
E D 
C B 
Clinical methods - Respiratory coaching 
34 
 
(i.e. the upper and lower gating thresholds) and the patients’ amplitude level were 
individually decided for each patient. During the training sessions, the patients were 
verbally guided by the operator when to hold the breath (Figure 15 (A, C)). To achieve a 
reproducible inspiration level, they were additionally visually guided by using video 
goggles (Figure 15B) [101]. The patients were required to hold their breath at least 20 
seconds at a reproducible patient-specific amplitude level and a gating window of 2-3 mm 
width to be enrolled in the DIBH-LuCaRa protocol. The operator guided the patients 
explicitly to fall down to their baseline between the deep breath-holds, since otherwise the 
relative breath-hold level was affected (For examples of baseline shifts see the section 
below). 
5.3.1 Example of breathing curves 
Four patient examples illustrate the importance of correct patient guidance to achieve an 
optimal DIBH treatment.  
 
Figure 16. Two different examples of breathing curves for patient 13 to acquire a CBCT image. 
Yellow line is the initial baseline. The blue dashed line illustrates the baseline shift relative to the 
initial baseline (yellow line). The red lines define the gating window. The green color illustrate 
when the beam-on for image acquisition was active. (A.) A correctly carried out session with 2 
breath-holds required to acquire the image at fraction (fx) 27. (B.) An example of severe baseline 
shift (increasing the amplitude by 12 mm, i.e. 95% amplitude increment). This was not accounted 
for by a re-initialization of the tracking software by the operator. Additionally, there were clearly 
observed increased fluctuations within the gating window compared to (A.) (even going below the 
gating window). 
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Figure 17. A correctly (green) and 
erroneously (violet, Figure 16B) 
acquired DIBH CBCT image for 
patient 13 at fx 33 overlaid on each 
other. The arrow indicates the 
tumor location. The color shifts are 
measures on how much the anatomy 
is shifted in the patient. The anterior 
surface shift (violet) corresponds to 
the baseline shift in Figure 16B. 
 
 
Figure 18. Four different examples of breathing curves for patient 1 to acquire a CBCT image. 
Additional figure explanations are described in Figure 16.  (A.) A correctly carried out session with 
6 small breath-holds (about 20-25 seconds long) were required to acquire the image at fx 2. (B.) At 
fx 17, only 2 longer breath-holds (about 30 seconds long) were required. (C.) At fx 7, the tracking 
was not re-initialized after moving the couch for patient positioning. The couch displacement 
affected the baseline, which decreased the breathing amplitude by about 5 mm. (D.) The operator 
forgot to guide the patient to fall down to the initial baseline after each deep breath-hold. Thus, the 
baseline was changed and the amplitude was decreased after each breath-hold. Observe that the 
gating window at fx 33 is wider (4.8 mm) than for the other fractions (2.5 mm) in this figure. This is 
due to a plan adaption with a re-CT scan at fx 22, where a new reference breathing curve was 
obtained which was more comfortable for the patient. Please note that this patient had a tendency to 
peak before falling into the gating window. This tendency was reduced after adjusting to a wider 
gating window (D).   
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Figure 19. Four different examples of breathing curves for patient 5 to acquire a CBCT image.  
Additional figure explanations are described in Figure 16. Compared to Patient 1 and similar to 
patient 6, this patient was able to hold the breath approximately 60-70 sec, resulting in fewer times 
of breath-hold per image acquisition and faster total image acquisition time. (A.) A correctly carried 
out session with 2 breath-holds required to acquire the image at fx 2. (B.) At fx 7, only 1 long 
breath-hold (about 70 seconds) was required. The operator missed however to re-initiate the 
tracking before imaging, resulting in a baseline shift and increased amplitude of 2.5 mm. The 
fluctuation increased at the end of the breath-hold (even going above the gating window). This may 
be due to difficulties for the patient to hold the breath such long time (C.) At fx 12, although the 
patient was able to hold the breath during the whole image acquisition, there was observed some 
difficulties to fall down to the baseline subsequently after the long breath-hold. (D.) Similar to fx 7, 
the baseline was shifted, resulting in increased amplitude of 5 mm at fx 17.  
 
Figure 20. Three different examples of breathing curves for patient 6 to acquire a CBCT image. 
Additional figure explanations are described in Figure 16. The patient was able to hold the breath 
long enough to acquire a CBCT image during only 1 breath-hold. After approximately 30 seconds 
of the breath-hold, these three examples clearly illustrate patient induced compensations for 
insufficient capacity to hold the breath stable within the gating window. 
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5.4 Treatment 
5.4.1 Imaging 
Dual-CT scanning was carried out using a 16 slice Philips Brilliance CT Big Bore scanner, 
version 3.5.17001 (Philips Medical Systems, Cleveland, OH, USA). A 4-dimensional CT 
(4DCT) was acquired in FB and a normal CT in DIBH. The patients were positioned in 
treatment position by a patient-specific fixation used throughout the course of treatment for 
good patient position reproducibility. Intra-venous (IV) contrast was administrated during 
both 4DCT and DIBH CT imaging, for better contrast of nodal anatomy in the 
mediastinum. Information about the administration of the IV contrast is described in Paper 
II, 9.8.3. Details about the IV contrast administration. Each image set included the entire 
lung volume, starting from the top of the sixth cervical vertebrae. From the FB 4DCT an 
un-tagged image reconstruction and a maximum intensity projection (MIP) image set were 
obtained. The un-tagged 4DCT reconstruction was routinely utilized for free-breathing 
treatment planning, due to its more correct HU representation, compared to the MIP 
reconstruction. 
PET CT imaging was routinely carried out for all patients using a GEMINI TF 16 slice 
Big Bore PET/CT, version 2.3 (Philips Medical Systems) in order to diminish the 
delineation uncertainties. The patients were positioned in treatment position. 
5.4.2 Delineation 
Delineations of anatomical structures were performed according to standard protocol by 
only one experienced oncologist on all image sets for that patient [21]. Contouring of the 
GTVs were performed in collaboration with an experienced radiologist using information 
from the co-registered MIP and PET/CT images. The delineated GTV was subsequently 
verified and corrected in all breathing phases. Residual structures such as the CTV, PTV, 
spine, heart, esophagus, lung, healthy lung (subtracting the GTV from the total lung 
volume) were additionally delineated solely by the oncologist, whereas CT radiographers 
semi-automatically delineated the body contour. 
5.4.3 Treatment planning 
All treatment plans were created using the AAA dose calculation algorithm in Eclipse by 
one treatment planner experienced in lung cancer, in order to avoid inter-observer 
variability in the treatment planning process. All treatment plans were designed and 
optimized for PTV dose coverage and dose reduction to the OARs according to an 
established dose constraint protocol (Table 1). Only 6 MV photon beams were considered, 
since higher energy photon beams can compromise target coverage due to more 
pronounced lateral charged particle disequilibrium [83,102–104]. The treatment planner 
aimed to construct clinical acceptable VMAT plans for all image sets in FB and DIBH. For 
the cases where this was not achievable, comparative IMRT plans in terms of target dose 
coverage and preservation of the dose constraints were produced. The VMAT treatment 
plans were created by partial dual-arcs avoiding initial entrance dose through the healthy 
lung, medulla and the heart. The IMRT treatment plans were designed in a similar way, 
consisting of a 5- or 6-field beam arrangement. The beam and arc arrangements between 
FB and DIBH were for the most parts the same for the same patient. However, some 
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adjustments of beam angle, field weights and apertures were made to achieve clinically 
acceptable plans. 
5.4.4 Treatment delivery 
Daily pre-treatment setup verification was carried out by 2D kV orthogonal x-ray images, 
and weekly 3D CBCT images. The patients were routinely treated in free-breathing where 
the setup was based on bony match. According to the DIBH-LuCaRa protocol, each patient 
was weekly additionally CBCT imaged in DIBH pre- and post-treatment. The patients 
were furthermore CT imaged in FB and DIBH in the middle of their course of treatment 
and at their last treatment day (Figure 21). 
 
Figure 21. Schematic illustration over when extra CBCT images pre- and post-treatment (red 
cross) and re-CTs (green CT) acquired according to the DIBH-LuCaRa protocol over the course 
of treatment. 
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6 Phantom details 
Within the field of radiotherapy, it is important to assure the prescribed dose is delivered to 
the treatment volume to achieve optimal clinical output. In order to do so, firstly, the 
output of the accelerator output needs to be thoroughly quality assured on a regular basis. 
Secondly, the dosimetry is required to be ensured in the patients. The major concern with 
treatment planning is the dose calculation issues present due to lack of CPE and incorrect 
scatter calculations [88–91,93]. In order to have control on what absorbed dose that is 
delivered, systematic dosimetry is required in heterogeneous patient-like geometries. For 
this reason, a thoracic-like PMMA phantom was designed. Phantom inserts of various 
materials were able to be located at different positions in the phantom in order to simulate 
various homogeneous and heterogeneous setups (Figure 22).  
 
   
Figure 22. (a) A heterogeneous setup where the two lateral body cylinders are filled with balsa 
wood inserts. (b) A homogeneous setup, where the whole phantom are filled with PMMA inserts. 
(c) The heterogeneous setup described in (a) viewed from the side, where the lateral body cylinder 
containing the lung insert is longitudinal shifted from the central position in the phantom. (d) Balsa 
wood lung insert with associated tumors, ranging from 1-8 cm in diameter.  
For lung cancer treatments, tumor volume changes during radiotherapy are well known 
[27,36,105–107]. The dosimetric challenges increase when tumor and field sizes decrease. 
The philosophy of radiotherapy is to deliver the same prescribed dose to the tumor volume, 
irrespective of the size of the tumor. In order to investigate this further, tumor inserts 
embedded in low-density medium was used in the phantom to simulate different tumor 
sizes. All tumor inserts were designed to suit BCF-60 scintillators from Saint-Gobain 
(Ceramics & Plastics Inc.) with an outer diameter of 2.2 mm and scintillator length of 2 
mm, described by Beierholm et al. [97].  
6.1 Design 
The phantom design is illustrated in Appendix A: Phantom design. In short, the essential 
parts are the following: The body of the phantom is 34 cm in width, 23 cm in height, and 
40 cm in length, mimicking the size of a thorax, containing three hollow cylinders with the 
length of 50 cm, and an outer diameter of 10 cm. These cylinders, with an inner diameter 
of 9 cm, can be filled with different inserts of various materials to simulate different 
homogeneous and heterogeneous geometries. The various inserts were made of delrin, 
balsa wood, and PMMA representing bone, lung and soft tissue, respectively. The lung 
a c d 
b 
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inserts were 15 cm long and with a diameter of 9 cm, mimicking a human lung in size. 
PMMA spheres of various sizes (1, 1.5, 2, 3, 5, 8 cm in diameter) embedded in low-density 
balsa wood were available to simulate tumors in lung (Figure 22d). In the lower part of the 
body, two smaller cylindrical holes, of a diameter of 2 cm and 3 cm (which also can be 
altered to 2 cm), are positioned at different distances from the phantom center, i.e. 6.5 cm 
and 9.5 cm, respectively. These holes can, one at a time, be filled with a delrin rod to 
simulate the spinal column at different diameters and position from the center of the 
phantom. Paper IV found good agreement between human tissue and the phantom 
materials in terms of Hounsfield unit representation of the various materials [108]. 
6.1.1 Motion simulation 
The phantom can be equipped with an optional motorized linear stage moving one of the 
body cylinders in a one dimensional movement. In order to track the motion of the body 
cylinder, a motion measurement device can be attached to the phantom setup (For more 
phantom details about the linear stage and the motion measurement device see section 14.5 
and 14.6 in Appendix A: Phantom design). The linear stage is the A-LST0250B with a 
built-in controller from Zaber Technologies Inc. (Vancouver, Canada). The linear stage 
can either be programmed in a simple mode in the freely available Zaber Console software, 
or more advanced programmed in LabView (National Instruments, Austin, TX, USA), 
using a freely available Zaber add-on. The linear stage has a moving range of 254 mm, 
controlled by a 2-phase stepper motor with unidirectional accuracy of 63 μm. The 
maximum force the linear stage exerts in the direction of travel is 350 N for the lowest 
speed (0.0047 mm/s), which is adequate to move the body cylinders accurately. Motion 
simulations were not carried out in the current thesis. However, the thoracic-like phantom 
was designed in order to enable future investigations on the dosimetric impact of breathing 
induced tumor motion. 
6.2 Chemical composition analyses 
In order to perform MC simulations of the dosimetry in the phantom, it is essential to know 
the chemical composition of the materials. The balsa wood and delrin materials were 
therefore analyzed for their chemical composition by BELAB AB (Norrköping, Sweden) 
and ALS Scandinavia AB (Luleå Sweden). The results and uncertainty data are presented 
in Appendix B: Chemical analysis. They are shortly presented in this section. It should be 
kept in mind that the uncertainty of the chemical analysis could be quite high for some of 
the analyses. For further analytical uncertainty details see Chapter 15.5 CHNO analysis, 
uncertainty data.  
In order to correlate the HU with the electron density of the image, the electron density 
relative to water is required, where the electron density of water is 3.343∙1023 e-/cm3 = 
0.555∙NA e
-
/cm
3
, where NA is the Avogadro’s constant. The electron density, ρe, of a 
medium can be calculated according to (eq. 6.1). 
  i
i
i
ime
A
Z
w  (6.1) 
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Where ρm is the medium density and wi is the fraction by weight of the chemical 
element i in a compound or mixture, and (Z/A)i is the corresponding atomic number to 
atomic weight ratio of the chemical element i. 
6.2.1 Balsa wood 
The mass density of balsa wood was 0.1 g / cm
3
. The chemical composition of balsa wood 
was found to be complex, including 5.4% humidity, and different trace elements (≤ 1%), 
such as nitrogen, calcium, potassium, and magnesium, etc. The rest (94.6%), consisted of 
carbon (46.6%), hydrogen (5.7%), and oxygen (41.4%). About 1.7% of the balsa sample 
was ash, which was not analyzed. If excluding the ash and the humidity, the relative 
electron density of balsa wood was 0.095. If including the 5.4% humidity as water (H2O), 
the relative electron density of balsa wood was 0.100. 
6.2.2 Delrin 
The mass density of delrin was 1.4 g /cm
3
. The chemical composition of delrin was found 
to be similar to the nominal chemical formulation of the copolymer Polyoxymethylene 
(POM-C), (CH2O)n, where n is the amount of monomers in the molecular chain. 
According to the chemical analyze, the delrin material consisted of carbon (40.7%), 
hydrogen (6.9%), oxygen (52.3%), and nitrogen (< 0.1%). The relative electron density of 
the nominal POM-C composition was 1.362, while it was 1.347 for the chemical delrin 
composition analyzed.  
6.2.3 PMMA 
The mass density of PMMA was 1.18 g/cm
3
. The nominal chemical composition of 
PMMA is (C5O2H8)n, resulting in a relative electron density of 1.147. 
6.2.4 Solid Water 
The calibration phantom used for finding stem-effect coefficients for the scintillator 
measurements was carried out in a Solid Water phantom (Gammex Inc.). The mass density 
of Solid Water is 1.02 g/cm
3
. The chemical composition was carbon (67.2%), hydrogen 
(8.1%), nitrogen (2.4%), oxygen (19.9%), calcium (2.3%), and chloride (0.1%). This 
chemical composition resulted in a relative electron density of 1.014. 
 
 43 
 
7 Conclusions 
7.1 Summary 
The manuscripts in the current thesis addresses some of the uncertainties present during 
radiotherapy of lung cancer patients. Breathing motion and the heterogeneity of the patient 
geometry in the thorax region are two major contributors to uncertainties affecting the 
treatment outcome for this group of patients. Twenty-three lung cancer patients were 
enrolled in a clinical protocol to investigate the clinical benefit to treat them in DIBH, 
compare to FB. Furthermore, a specially designed thoracic-like phantom was utilized for 
scintillator dosimetry to assess known calculation issues in heterogeneous and homo-
geneous setups relevant for lung cancer radiotherapy. 
The findings, and their implications within the field of radiotherapy of lung cancer, are 
further discussed in the following sections. 
7.1.1 Deformable image registration and structure propagations 
Paper I specifically investigates the performance of a deformable image registration 
software based on a modified Demon’s algorithm for contour propagation on both FB and 
DIBH CT and CBCT images acquired over the course of treatment for three lung cancer 
cases. Geometrical similarities were found between the propagated structures and the 
manually delineated structures, considered as the ground truth, with a slightly favor of FB 
imaging. This result was somewhat surprising as it is commonly believed that the image 
registration would be better for DIBH images since the image artifact are removed and the 
positional displacement of the anatomy is mitigated by gating. The study illustrates the 
difficulties of deformable image registration for large anatomical changes over time, 
apparent image artifacts, and low tissue contrast in the images, irrespectively of FB and 
DIBH. Unrealistic deformation vector fields were sometimes created during deformable 
image registration. Care should thus be taken if applying the deformation vector fields for 
any application, such as structure propagation, dose accumulation, or 4D reconstructions, 
since this could result in erroneous interpretations.  
7.1.2 CBCT image-based setup verifications and resulting PTV sizes 
Paper II provides clinically relevant guidance on what automatic CBCT setup verification 
protocol to use in combination with DIBH and FB for locally advanced NSCLC patients to 
achieve the smallest PTV. Three different match methods were evaluated; match on the 
soft-tissue of the GTV-T, or GTV-Total, or bony match on the spine. Both intra- and 
interfractional motion data were evaluated and used for CTV to PTV margin calculations. 
DIBH was found to be superior over FB regarding the size of PTV and lung sparing, where 
match on the GTV-T was the most optimal and feasible method. The study was based on 
weekly acquired CBCT images. Daily imaging would yield an even better and more 
thorough investigation on interfractional variations. Due to the extra dose this would yield 
to the patients, this was not an option in the current study. However, since the study was a 
population based study, enough residual information was extracted to draw our 
conclusions. Not all patients were able to comply with the DIBH technique throughout 
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their course of treatment. For that reason, it is recommended to have a FB backup 
treatment plan if implementing DIBH as a routine treatment. Large positional uncertainties 
in the longitudinal direction for the DIBH images, compared to the FB images, were found 
during matching on the bony structure. These are likely related to the fact that some 
patients tended to arch their back to compensate for their insufficient capacity to hold their 
breath within the patient-specific pre-defined gating window. This study indicates that 
precautions are required to minimize this arching issue. In clinical practice, it should be 
noted that the presented margin of the spine in the longitudinal direction is not clinically 
relevant to apply in the treatment planning process since the spinal cord runs in that 
direction. The magnitude of the margin presented was used as a quantitative measure 
including both the systematic and random error components, to evaluate the match method. 
In order to evaluate anatomical changes over time, weekly CBCT imaging could be used. 
However, to be able to assess at what occasion the anatomical change has occurred daily 
CBCT imaging is required. This anatomical information would not be available if only 2D 
orthogonal x-ray images for daily positioning and weekly CBCT images for soft-tissue 
verification was acquired. Nevertheless, the major reason to implement a daily image 
protocol is the online correction of the soft-tissue tumor position prior to treatment, i.e. to 
reduce baseline shifts related to tumor shift relative to the spine and/or external markers. 
This is especially important for DIBH treatments since external and internal motion are not 
correctly correlated. In many clinics it is common that it is the clinicians and physicists 
that review each setup image post treatment. A daily CBCT image based setup protocol 
would then be a very workload heavy process in the clinic. One approach to deal with this 
is to let the radiation therapists become more involved in the evaluation process of the 
images. If they find a systematic anatomical change affecting the treatment, then the 
clinicians and/or physicists are contacted to decide how to deal with that information. The 
extra cost for the clinic needs to be weighted against the clinical benefit for the patient, 
prior implementation of a daily image setup verification protocol.  
7.1.3 Dosimetric clinical impact of DIBH 
Paper III specifically addressed target dose coverage and organ sparing in DIBH, 
compared to FB, by using detailed MC simulations for locally advanced NSCLC patients 
treated with complex IMRT and VMAT treatment plans. Many commercial dose 
calculation algorithms have issues to correctly account for changes of lateral electron 
scatter, especially in heterogeneous situations. The largest inaccuracies are usually noticed 
in the transition between materials of different densities. Lateral charged particle 
disequilibrium will be emphasized during DIBH, since the lung density decreases. The 
range of secondary electrons will increase resulting in larger volume of disequilibrium and 
a broader penumbra at field boundaries, affecting the treatment calculation. MC 
simulations, on the other hand, are able to accurately predict the delivered dose in 
heterogeneous patient geometries. Although the treatment planning was carried out using 
AAA, the MC simulations supported organ sparing in DIBH, where DIBH was 
advantageous over FB. Additionally, MC simulations resulted in inferior target dose 
coverage compared to AAA, with similar deviations between MC and AAA for both FB 
and DIBH. The unsatisfactory target dose coverage was therefore concluded to be related 
to the treatment planning algorithm, rather than the treatment technique. Compared to FB 
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treatment, DIBH is a more resource intensive treatment technique. It would therefore be 
advantageous if it was possible to identify those patients with potential benefit from DIBH-
based treatment. If implementing DIBH as a routine treatment, it is however recommended 
to carry out dual-treatment planning, in both FB and DIBH, as a treatment backup if the 
patients’ health gets worse during the course of treatment, where they can no longer 
proceed with DIBH. The treatment planning may be improved if using a fully integrated 
MC optimization and dose calculation system. Care should however then be taken if 
clinically implemented, because all clinical radiation response data are based on old, less 
accurate dose calculation algorithms. 
7.1.4 Dose calculation issues in heterogeneous setups 
Paper IV and Paper V assess dose calculation issues of a commercial AAA dose 
calculation algorithm in heterogeneous patient-relevant geometries. In order to obtain 
accurate measurements of absorbed dose, a well-defined thoracic-like phantom was 
designed for point dose dosimetry by fiber-coupled organic PSDs. PSDs are well suited for 
complex dose verification in megavoltage photon beams due to their water-equivalency, 
and small size for high spatial resolution and minimum perturbation of the radiation fields. 
Previous studies have found good agreement with high accuracy between PSD 
measurements and MC simulations in homogeneous water setups. Due to these features, 
and the provided real-time output, PSDs were used for the heterogeneous dosimetry to 
assess potential dose calculation issues in heterogeneous setups, relevant for lung cancer 
radiotherapy. Clinical relevant treatment plans of different complexities were measured 
and compared to AAA calculations. In the simplest homogeneous setups, dose similarities 
were found between TPS calculations and measurements. Nevertheless, for more complex 
cases, large dose deviations were observed. A systematic tumor-size dependency was 
identified, where the largest dose deviations were observed for the smallest tumor sizes, 
independently of treatment technique. Additionally, conventional field techniques resulted 
in higher dose deviations compared to more complex treatment techniques, such as IMRT 
and VMAT. These observations could potentially be related to the fact that the more 
complex treatment plans (IMRT and VMAT) have several beam entries around the body of 
the phantom, and not just directly through the low-density material of the phantom, like the 
simple conventional beam configurations investigated. Thus, the larger dose deviation for 
the simplest field techniques could potentially be due to lack of sufficient spread of lateral 
radiation, required in order to obtain charged particle equilibrium. The observed dose 
deviations, and considerable tumor-size dependency may originate from imperfections in 
the AAA algorithm in heterogeneous setups. The effect is large enough to have 
implications for lung cancer treatment planning. Consolidating MC simulations will be of 
great value for further establishment of the observed dose deviations. 
 
7.2 Main conclusions 
This thesis concludes that the clinical gain of DIBH is not always beneficial over FB 
treatments, in terms of better image deformation for structure propagation, and reducing 
setup uncertainties. DIBH was however advantageous, in terms of reducing the dose to 
OARs during treatment planning, and reducing the resulting size of PTV-Total. There were 
identified severe tumor-size dependent dose deviations that were large enough to 
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potentially have implications for lung cancer radiotherapy treatment planning. The 
constructed thoracic-like phantom and the in-house scintillator system provide a promising 
tool for evaluation of dose calculations in heterogeneous geometries irradiated by clinically 
relevant treatment plans.   
1. Geometrical similarities were found between propagated and manually delineated 
structures, with a slightly favor of FB imaging. There were identified difficulties 
to perform deformable image registration for large anatomical changes over time, 
apparent image artifacts, and low tissue contrast in the images, irrespectively of 
FB and DIBH. Care should therefore be taken if applying the resulting 
deformation vector fields for any application. 
2. Compared to FB, larger setup uncertainties were introduced during DIBH, 
especially in the longitudinal direction. Precautions must therefore be applied 
during DIBH for the patients that tend to arch their back to compensate for their 
insufficient breath-hold level. DIBH was, however, found to be superior to FB 
for all match methods investigated in terms of smallest resulting PTV-Totals. 
Overall, soft-tissue auto-match was superior to bony registration, independently 
of FB and DIBH. The soft-tissue match on PTV-Total was more feasible than the 
match on PTV-T and PTV-N separately. For the soft-tissue match on PTV-Total, 
the resulting PTV-Total volume was in average reduced by approximately 13% 
for DIBH, compared to FB. The corresponding reduction for bony registrations 
was about 8%. If including the intra-fractional motion in the margin calculations, 
the PTV reductions were decreased. 
3. Although the treatment plans were carried out by a simplified dose calculation 
algorithm (AAA), MC simulations confirmed that DIBH was advantageous over 
FB, in terms of reducing undesired dose to the OARs, and maintaining the target 
dose coverage between FB and DIBH. The lung volume increased in median by 
86.8% in DIBH, while the size of GTV decreased by 14.8%. However, MC 
simulations additionally revealed severe under- and over-dosage of the target 
dose coverage, irrespectively of FB or DIBH treatment plans. This issue was 
therefore concluded to be related to the treatment planning algorithm, rather than 
the treatment technique.  
4. A well-defined thoracic-like phantom was designed for scintillator dosimetry. 
Several homogeneous and heterogeneous setups relevant for lung cancer radio-
therapy could be applied. The phantom made of PMMA can be filled with inserts 
of different materials, including simulated lung tumors made of PMMA spheres 
(ranging from 1-8 cm in diameter) embedded in low-density balsa wood to 
simulate lung-tissue. Delrin was used to simulate bone-tissue. PMMA, 
balsawood, and delrin were found to be HU-equivalent to human tissue. 
Chemical analyses were carried out to establish the anatomical composition of 
the phantom materials to enable MC simulation.  
5. Calculation issues were identified with the thoracic-like phantom. Conventional 
field techniques resulted in higher dose deviations compared to more complex 
treatment techniques, such as IMRT and VMAT. A systematic tumor-size depen-
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dency was found, which was emphasized for small tumors ≤ 2 cm in diameter. 
The identified tumor-size effect was large enough to potentially have im-
plications for lung cancer radiotherapy treatment planning. The scintillator 
system and the heterogeneous phantom provide a promising tool for critical 
evaluation of complex radiotherapy calculations and dose delivery. 
7.3 Future perspectives 
The trend within modern radiotherapy is to make the treatments more individualized to 
increase the clinical outcome (Paper I, Paper II, and Paper III). With individualized 
margins and treatment plans the hope is to increase the chance of local tumor control, 
while minimizing the treatment toxicity. There are several aspects of uncertainties that 
contribute to the clinical output, such as target definition, setup verification, and treatment 
planning. When implementing a new treatment, such as DIBH, it is imperative to have a 
thorough clinical follow-up. This is the only way to assure that the risk of relapse or 
radiation-induced toxicity is not increased by individualizing the treatment. It would be of 
great interest to investigate the clinical impact of treating in FB and DIBH over the course 
of treatment. Assessment of implications for an adaptive approach, due to anatomical shifts 
and deformations, and changes of breathing pattern can then be evaluated for the two 
breathing methods. It would also be of interest to investigate the clinical feasibility of other 
image deformation algorithms in order to assess their clinical use for lung cancer 
radiotherapy applications.   
As evident from the phantom studies (Paper IV and Paper V), no MC simulations have 
been conducted to benchmark our dosimetric findings. Detailed MC simulations together 
with independent dose measurements by other studies should be carried out to establish the 
implications for treatment planning of lung cancer. Other phantom inserts could be 
developed, for other types of dosimetry, such as alanine, gel, and film, etc. In the current 
thesis, measurements were carried out in static setups, without any movement of the target. 
It would be of great interest to carry out dosimetry in setups where breathing motion is 
simulated, in order to correlate the dynamic treatment output of the accelerator to the 
dynamic internal motions of the patients. For this purpose, the phantom is equipped with 
an optional motorized linear stage which could be programmed to simulate patient-like 
breathing motion in one dimension. It would additionally be interesting to incorporate the 
breathing motion into the MC simulations, in order to accurately assess the dosimetric 
impact of motion. 
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8 Paper I 
Deformable image registration for geometrical evaluation of DIBH radiotherapy 
treatment of lung cancer patients 
Paper I was presented at the  XVII International Conference on the Use of Computers in 
Radiation Therapy 2013 (ICCR2013), 6-9 May, 2013 in Melbourne, Australia. The work is 
published in the Journal of Physics: Conference Series 489 (2014) 012077. A commercial 
deformable image registration algorithm is investigated for three lung cancer cases. 
Analyzed images were acquired during both FB and DIBH breathing. 
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Deformable image registration for geometrical 
evaluation of DIBH radiotherapy treatment of lung 
cancer patients 
W Ottosson
1,2
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2
, S Borissova
2
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1Center for Nuclear Technologies, Technical University of Denmark, DTU Risø Campus, 
DK-4000 Roskilde, Denmark 
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Abstract.  
Background and Purpose: Respiration and anatomical variation during radiotherapy (RT) 
of lung cancer yield dosimetric uncertainties of the delivered dose, possibly affecting the 
clinical outcome if not corrected for. Adaptive radiotherapy (ART), based on deformable 
image registration (DIR) and Deep-Inspiration-Breath-Hold (DIBH) gating can 
potentially improve the accuracy of RT. The objective was to investigate the performance 
of contour propagation on repeated CT and Cone Beam CT (CBCT) images in DIBH 
compared to images acquired in free-breathing (FB), using a recently released DIR 
software.  
Material and Methods: Three locally advanced non-small cell lung cancer patients were 
included, each with a planning-, midterm- and final CT (pCT, mCT, fCT) and 7 CBCTs 
acquired weekly and on the same day as the mCT and fCT. All imaging were performed 
in both FB and DIBH, using Varian RPM system for respiratory tracking. Delineations of 
anatomical structures were performed on each image set. The CT images were 
retrospective rigidly and deformable registered to all obtained images using the Varian 
Smart Adapt v. 11.0. The registered images were analysed for volume change and Dice 
Similarity Coefficient (DSC).  
Results: Geometrical similarities were found between propagated and manually 
delineated structures, with a slightly favour of FB imaging. Special notice should be 
taken to registrations where image artifacts or low tissue contrast are present.  
Conclusions: This study does not support the hypothesis that DIBH images perform 
better image registration than FB images. However DIR is a feasible tool for ART of lung 
cancer. 
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8.1 Introduction 
Anatomical changes and variations due to respiration influence the accuracy of imaging, 
treatment planning and treatment delivery, and may affect the outcome of the planned 
treatment if not corrected for [62]. In ART, the treatment plan is adjusted during the course 
of treatment to minimize the divergence from the planned treatment, in terms of target dose 
coverage and spearing of dose to adjacent healthy organs at risk. Thus, ART has the 
potential to account for major anatomical changes not accounted for by applied margins 
[36]. Conventionally, lung cancer patients are treated in FB. However, breathing adapted 
radiotherapy (BART) by means of DIBH may suppress the geometric and dosimetric 
uncertainties related to respiration. Furthermore BART makes it possible to safely reduce 
the margins to the targets, yielding a reduction of irradiated volume [109,110]. The 
advantages of BART and ART illustrates that more individualized treatments are called for 
to improve the quality of RT. ART is, however, a time consuming process since 
anatomical structure delineations are needed on each new image set. DIR may be a 
promising tool in assisting with the delineation process, by deforming the reference 
contours from the planning CT into the anatomy of a second CT or CBCT. Our hypothesis 
is that image registrations performed based on DIBH images will result in improved image 
registrations, with enhanced correlation of volumes and higher scoring of DSC, since they 
often have visually better image quality compared to images in FB. The objective of this 
study was to investigate the performance of contour propagation on repeated CT and 
CBCT images of the thorax over the course of lung cancer treatment, imaged in DIBH, 
compared to conventional FB, using a recently released DIR software, based on a modified 
demons algorithm [71]. 
8.2 Material and methods 
8.2.1 Patient data 
Three locally advanced non-small cell lung cancer patients treated in 33 fractions (fx) 
using volumetric modulated arc therapy with a prescribed dose of 66 Gy (2 Gy/fx, 5 
fx/week) at Herlev Hospital, between December 2012 and May 2013, were included in this 
study. They were treated on Varian Clinac iX 2300 linear accelerators [21,85] (Varian 
Medical Systems, Palo Alto, CA) equipped with On-Board Imagers (OBI) capable of 
performing FB and DIBH CBCT, using version 1.4 of the OBI software.  
8.2.2 Image acquisition 
Each patient was dual-CT scanned (acquiring a 4DCT in FB and a DIBH CT) before the 
start of, in the middle of, and after completion of the course of treatment, (pCT, mCT, fCT, 
respectively). All imaging were performed in treatment position [21]. They were scanned 
in a 16 slice Philips Brilliance CT Big Bore, version 3.5.17001 (Philips Medical Systems, 
Cleveland, OH) integrated with a Varian real-time position management (RPM) system, 
version 1.7 (Varian Medical Systems), for monitoring the patients’ respiration during CT 
scanning. Intra venous (IV) contrast was administered to the patients during both 4DCT 
and DIBH imaging, for better contrast of nodal anatomy in the mediastinum. During DIBH 
imaging, the patients were audio-visually guided to hold their breath within a predefined 
amplitude level and gating window of 2-3 mm width. Additionally, all patients had 6-7 
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dual-CBCTs (in FB and DIBH) acquired on the treatment unit using the OBI. The CBCTs 
were acquired weekly and on the same day as the mCT and fCT. The Varian RPM system 
was once more used for monitoring the respiration to acquire DIBH gated imaging. 
8.2.3 Definition of target and organs at risk 
Delineations of anatomical structures for each patient were performed according to 
standard protocol by only one experienced oncologist (JLA or SB) on all image sets for 
that patient [21]. Delineations were carried out in the treatment planning system Eclipse v. 
10 (Varian Medical Systems). Contouring of FB and DIBH Gross Tumor Volumes (GTVs) 
were performed by the oncologist in collaboration with an experienced radiologist. 
Residual FB and DIBH structures such as Clinical Target Volume (CTV), Planning Target 
Volume (PTV), medulla, heart, esophagus, lung and body were additionally delineated by 
the oncologist. The heart, esophagus, and lung were not delineated in the CBCT images, 
since they extended the CBCT scanning range.  
8.2.4 Deformable registration and contour propagation 
All CT images were retrospective pre-aligned by semi-automatic rigid registration and 
subsequently automatic deformed registered to all obtained images (both CBCT and 
secondary CT images) using Smart Adapt v. 11.0 (Varian Medical Systems). This resulted 
in 54 rigid and 54 deformable registrations per patient (corresponding numbers were 48 for 
the one patient with only 6 CBCT scans), which in total resulted in 312 registrations for all 
patients. The rigid pre-alignment increased the accuracy of the subsequent DIR, and 
prevented large unrealistic deformations [71]. The initial rigid registrations were based on 
the bony anatomy of the columna (50-3000 Hounsfield units), where the rest of the settings 
were predefined from the manufacturer. The rigid registration was done in three steps, each 
step with a higher image resolution, which improved the efficiency of the algorithm. The 
default DIR algorithm used in Smart Adapt was derived from a modified demons 
algorithm [71] based on a diffusion model. In the algorithm additional interaction forces 
(demons) are added to the original demons algorithm [75] and the voxel resolution of the 
images gradually increases during the optimization process. The floating image is warped 
to form a deformed image that match the reference image as closely as possible voxel-by-
voxel [71,75]. The driving forces are based on the intensity differences between the two 
images, as well as the gradient of the image object. A symmetric force is also built into the 
solver to fulfill the consistency requirement for DIR, i.e. the transformation that maps the 
reference image to the floating image should be consistent with the inverse transformation 
that maps the floating image to the reference image. The DIR in this study was restricted to 
the field of view of the smallest image (typically the CBCT scan), resulting in a volume of 
interest (VOI) which was further analyzed. All structures extending the VOI (typically the 
heart, esophagus, medulla, and body) were cropped to be comprised by the VOI, such that 
a common ground for comparison was created. For each DIR, the contours on the floating 
CT image were propagated onto the resulting deformed image (dCT) using the obtained 
image transformation.   
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8.2.5 Geometrical comparison 
Rigidly and deformed registered structure volumes (VRIG,DIR) were analyzed relative to the 
corresponding structure volumes (VREF) on the reference image for volume change and 
DSC, where DSC was calculated according to eq. 8.1 [77]. 
REFDIRRIG,
REFDIRRIG,
VV
VV
2


DSC  (8.1) 
For statistical analysis MATLAB Statistics Toolbox version 8.3 (R2013b) (The 
MathWorks, Natick, MA) was used. Paired t-tests to evaluate the median DSC measures of 
the various structures were performed, where differences were considered significant for p 
< 0.05. 
8.3 Results/Discussion 
Figure 23 (open triangles) illustrates that the manually delineated reference CT and CBCT 
GTVs overall are decreasing over the course of treatment. The DIBH volumes (upward 
pointing triangles) are in general smaller compared to FB (downward pointing triangles) 
which may be due to the lesser image artifacts (e.g. motion blurring) in the DIBH images 
resulting in smaller targets. The dCT GTVs do not correlate well with the manually 
delineated reference CBCT (Figure 23 (a)) or CT (Figure 23 (b)) volumes. If a perfect 
volume correlation was achieved between the dCT structures and the reference volumes, 
the filled triangles (Figure 23) would follow the corresponding curves with open markers 
(Figure 23 (a)) or be the same volume as the open markers (Figure 23 (b)). The dCTs of 
the pCT at fx 2 and 7 of patient 1 correlate well with the reference CBCTs, but for the 
remaining fractions the dCT of the mCT and fCT have better correlation with the reference 
CBCTs. This illustrates the difficulty to perform DIR registration when the anatomy 
changes over time. In this case, the patient would benefit from ART. It is clearly seen in 
Figure 23 (a), at fx 15-20 for patient 2, that appearing image ring artifacts (figure 2) in the 
reference CBCT image affect the DIR process, and thus the propagation of structures. The 
effect was equally seen for DIBH and FB images, and for all CT-CBCT registrations at fx 
15-20 for patient 2. The CT-CBCT and CT-CT registrations of patient 3 (Figure 23) 
systematically underestimate the GTVs, both for FB and DIBH images. This may be due to 
DIR issues in regions with low level of tissue contrast (since the demons algorithm uses 
intensity values for registration) as the tumor for this patient was closely situated to the 
mediastinum. 
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Figure 23. (a) Absolute volume per each fraction of the dCT GTVs (filled triangles) in relation to the 
manually delineated reference CBCT GTVs (open triangles) along with the manually delineated 
GTVs of pCT, mCT and fCT (x and circles) utilized when performing CT-CBCT DIR. Upward 
pointing triangles correspond to DIBH, and downward pointing triangles represent FB. In the pCT 
column it is the pCT that is deformed to match the CBCTs and similar for the columns labeled mCT 
and fCT. (b) Corresponding absolute volume of dCT GTVs (filled triangles) in relation to manually 
delineated reference CT GTVs (open triangles) when performing CT-CT DIR between the pCT, 
mCT and fCT. In the pCT column it is the mCT and fCT that is deformed to match the pCT and 
similar for the columns labeled mCT and fCT. 
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(a) 
 
(b) 
 
Figure 24. (a) The reference CBCT (fx 15) of patient 2 with manually delineated CBCT structures. 
(b) The same CBCT (fx 15) overlaid with the dCT structures, i.e. the propagated deformed pCT 
structures. The red, pink, blue and the outer light green delineations represent GTV, CTV, PTV and 
body contour, respectively. Colors are available in the online version. 
No significant difference among DSC measures of the various structures were observed 
between DIBH and FB CT-CBCT and CT-CT image registrations over the course of 
treatment (Table 4). However, the FB images had slightly higher DSC median value 
compared to DIBH images (both for CT-CBCT registrations and CT-CT registrations). 
This observation conflicts with our hypothesis that DIBH imaging resulting in visually less 
image artifacts compared to FB imaging, yielding better image registration. The applied 
DIR improved the median DSC measure, compared to rigid registrations, except for some 
CT-CBCT registrations (indicated by bold font), though still within one standard deviation, 
and no significant difference was observed.  
Table 4. Median DSC measures (one standard deviation) of the propagated deformed structures and 
rigidly registered structures for all patients during CT-CBCT and CT-CT registration. Bold values 
indicate that rigidly registered structures have a higher DSC score compared to the propagated 
structures of the dCT. 
Structures 
CT-CBCT  CT-CT 
FB DIBH  FB DIBH 
RIG
a 
DIR
b 
RIG
a 
DIR
b 
 RIG
a 
DIR
b 
RIG
a 
DIR
b 
GTV 0.74(0.10) 0.78(0.13) 0.73(0.13) 0.74(0.15)  0.76(0.13) 0.84(0.16) 0.75(0.13) 0.83(0.20) 
CTV 0.80(0.07) 0.81(0.09) 0.79(0.10) 0.78(0.11)  0.82(0.09) 0.88(0.12) 0.79(0.11) 0.86(0.17) 
PTV 0.83(0.07) 0.84(0.07) 0.82(0.08) 0.81(0.08)  0.86(0.07) 0.89(0.09) 0.83(0.10) 0.87(0.14) 
Body 0.98(0.01) 0.98(0.01) 0.97(0.01) 0.98(0.04)  0.97(0.01) 0.99(0.01) 0.97(0.01) 0.99(0.01) 
Medulla 0.75(0.10) 0.72(0.13) 0.77(0.05) 0.74(0.14)  0.74(0.05) 0.76(0.05) 0.75(0.08) 0.78(0.07) 
Esophagus NaN
c 
NaN
c 
NaN
c 
NaN
c 
 0.58(0.10) 0.73(0.08) 0.59(0.09) 0.70(0.08) 
Heart NaN
c
 NaN
c
 NaN
c
 NaN
c
  0.85(0.05) 0.90(0.06) 0.87(0.13) 0.93(0.08) 
Total lung NaN
c
 NaN
c
 NaN
c
 NaN
c
  0.89(0.01) 0.95(0.01) 0.93(0.04) 0.97(0.02) 
a.Rigid image registration  
b.Deformable image registration 
c.Not available number 
8.4 Conclusion 
This study does not support the hypothesis that DIBH images result in better image 
registrations (both rigid and deformed) when using a modified demons type algorithm for 
deformable image registration. Large variation was observed for organs without sharp 
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contrast boundaries (including tumors close to mediastinum, atelectasis and thorax wall). 
Notice should also be taken to image artifacts and bad image quality that can affect the 
outcome of DIR (e.g. fx 15-20 for patient 2, Figure 24). Our observations indicate that 
ART planning may be necessary during the course of treatment for optimal lung cancer 
RT, since the pCT not always can be registered correctly to subsequent CBCT and CT 
images over the course of treatment due to large and rapid volume changes (e.g. fx 12 for 
patient 1, Figure 23 (a)). Based on this small patient dataset, it turned out that DIR 
sometime resulted in a worse median DSC measure compared to conventional rigid 
registration, though still within one standard deviation. The median DSC of the DIR for 
these three patients was however mostly higher compared to rigid registrations. Unrealistic 
deformation vector fields were also sometimes created during DIR. These unrealistic 
deformation vector fields should carefully be employed if used for other applications, e.g. 
such as dose deformation. DIR analysis provides a feasible and promising tool for 
indicating if adaptive re-planning is necessary based on geometrical variations throughout 
the course of lung cancer treatment, with slightly better correlation for FB than DIBH 
imaging.  
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9 Paper II  
The advantage of Deep-Inspiration Breath-Hold and soft-tissue auto-match for cone-
beam CT setup methods in locally advanced lung cancer radiotherapy 
Paper II is submitted to the scientific journal Radiotherapy & Oncology, and is under 
review process at the moment. Three different automatic CBCT setup methods in 
combination with DIBH and FB were investigated, in terms of obtaining the smallest PTV. 
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Abstract  
Background and Purpose: Three automatic cone-beam computed tomography (CBCT) 
match methods in combination with deep-inspiration breath-hold (DIBH) and free-
breathing (FB) were investigated, in terms of obtaining the smallest planning target 
volume (PTV). 
Material and Methods: CBCT images were acquired pre- and post-treatment in FB and 
DIBH, for 17 locally advanced lung cancer patients. Bony match on the spine, and soft-
tissue matches on the primary gross tumor volume (GTV-T), and the total tumor volume 
(GTV-Total), including malignant lymph nodes (GTV-N), were retrospectively analyzed. 
All automatic matches were compared with manual ground truth matches. Translational 
residuals of GTV-T, GTV-N and spine were assessed and setup margins and resulting 
PTVs were calculated. 
Results: For the soft-tissue matches PTV-Total was in average reduced by approximately 
13% for DIBH compared to FB. The corresponding reduction for bony registrations was 
about 8%. The smallest residual misalignments of the spine were observed for FB, 
independently of match method. 
Conclusions: Although DIBH was superior to FB for all match methods in terms of 
smallest PTV-Totals, more setup uncertainties were introduced. Soft-tissue auto-match 
was superior to bony registration, independently of FB and DIBH. Precautions must be 
applied during DIBH for the patients that tend to arch their back to compensate for their 
insufficient breath-hold level. 
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9.1 Introduction 
In radiotherapy, margins are traditionally applied to the clinical target volume (CTV) and 
the organs at risk (OAR)s to account for different systematic and random sources of errors 
related to organ motion, patient positioning and target delineation [16]. Large margins 
limit the deliverable dose to the planning target volume (PTV) due to the dose constraints 
of the adjacent OARs. Smaller PTVs will spare the adjacent healthy tissue from 
unnecessary dose, and/or enable delivery of a higher dose to the target yielding a positive 
effect on the treatment outcome. There are two major aspects that affect the size of the 
PTV: Inter-fractional motion, and patient instability (intra-fractional motion). Pre-
treatment verification by means of image guidance is a way to quantify and correct for 
setup errors [62–64]. Three dimensional (3D) cone-beam computed tomography (CBCT) is 
suitable for soft-tissue visualization and registration [62]. This image modality provides 
information about anatomical positions of tumor and OARs, as well as anatomical changes 
in the thorax area, such as atelectasis (collapse or closure of the lung), pneumonitis 
(inflammation of lung tissue), and pleural effusion (water in lungs) [26]. Direct match on 
the lung tumor itself (i.e. soft-tissue tumor registration) compared to bony match on the 
spine has the potential to minimize the required setup margins in the thorax area 
[21,63,64]. The CBCT images are either manually or automatically registered to the 
reference CT images. Manual registration is a complex and time consuming task and can 
be subject to inter-observer variability, contrary to automatic registration [65,66]. 
Respiratory motion is a challenge, influencing both imaging and treatment delivery 
[29,30]. Breathing adapted radiotherapy by means of deep-inspiration breath-hold (DIBH) 
may suppress the influence of respiration on geometric and dosimetric uncertainties, 
leading to reduced internal target motion and smaller PTVs [29,109–111].  
This work studies CBCT setup verification of locally advanced lung cancer patients 
performing free-breathing (FB) and DIBH breathing techniques, with the primary objective 
to identify which automatic CBCT match method that results in the smallest PTV. The 
study provides clinical guidance on what automatic CBCT match protocol to use for DIBH 
or FB setup verification, and it specifically addresses how match results depend on the 
breathing techniques. The three investigated automatic CBCT match methods focused on: 
(a.) the bony anatomy of the spine, (b.) the soft-tissue of the primary gross tumor volume 
(GTV-T), and (c.) the soft-tissue of the total tumor volume (GTV-Total), including 
malignant lymph nodes (GTV-N).  
9.2 Material and methods 
Technical study details are provided in the supplementary material to this paper. 
9.2.1 Patient data 
Seventeen locally advanced non-small-cell lung cancer (NSCLC) patients scheduled for 
curative radiotherapy at Herlev Hospital, between December 2012 and July 2014, were 
enrolled (supplementary Table 10). The patients were treated with volumetric modulated 
arc therapy (VMAT) or intensity-modulated radiotherapy (IMRT) in 30-33 fractions (fx), 
receiving a total dose of 60-66 Gy (2 Gy/fx, 5 fx/week).  
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9.2.2 Image acquisition 
All images were acquired in treatment position. Weekly CBCT images in FB and DIBH 
was acquired, both pre- and post-treatment, resulting in four CBCTs per weekly image 
session. Furthermore each patient was dual-CT scanned in a 16 slice Philips Brilliance CT 
Big Bore scanner, version 3.5.17001 (Philips Medical Systems, Cleveland, OH) (acquiring 
a 4DCT in FB and a normal CT in DIBH) before the start of, in the middle of, and after 
completion of the course of treatment. Intra-venous contrast was administered to the 
patients during both 4DCT and DIBH CT imaging, for better contrast of nodal anatomy in 
the mediastinum. Each patient was additionally scanned in a GEMINI TF 16 slice Big 
Bore PET/CT, version 2.3 (Philips Medical Systems) before the start of the course of 
treatment in order to diminish the delineation uncertainties in the planning CT. Delineation 
details can be found elsewhere [21,112]. 
The CT and CBCT systems were integrated with the Varian real-time position 
management (RPM) system, version 1.7 (Varian Medical Systems), for monitoring the 
patients’ respiration during imaging. The patients were audio-visually guided during DIBH 
imaging using video goggles, where the patients held their breath within a patient-specific 
predefined amplitude level and a gating window of 2-3 mm width. All FB and DIBH 
CBCTs were acquired during the same treatment session.  
9.2.3 Image registrations and residual setup deviations 
All CBCT images were retrospectively registered to reference CTs in Offline Review v. 10 
(Varian Medical Systems) by one observer solely (FR) to avoid inter-observer variations. 
The un-tagged reconstruction of a 4DCT scan in FB was used as reference CT for the FB 
CBCTs [21] and a DIBH CT scan was used as reference CT for the DIBH CBCTs. Only 
translational corrections were allowed in the vertical (VRT), longitudinal (LNG) and 
lateral (LAT) directions. Most of the automatic match settings were predefined by Varian 
[65]. 
Three match volumes of interest (VOIs) were used: (a.) The bony anatomy of the spine, 
where the planning risk volume (PRV) of the spinal cord plus an isotropic margin of 2.5 
cm operated as the matching VOI for the bony match method. The PRV of the spinal cord 
was defined as an 0.5 cm isotropic expansion of the spinal cord. The Hounsfield unit (HU) 
interval within the VOI was set to [50; 3000] HU. (b.) The soft-tissue of the GTV-T (or 
GTV-T/IM for the FB imaging, which included the internal margin (IM) from the 4DCT 
reference scan according to the Maximum Intensity Projection (MIP) concept [21] plus an 
isotropic margin of 1 cm operated as the matching VOI for the primary tumor soft-tissue 
match method. The HU-interval was set to [-150; 150] HU. (c.) The soft-tissue of the 
GTV-Total, including the malignant lymph nodes, plus 1 cm isotropic margin operated as 
the matching VOI for the total tumor soft-tissue match method. The HU-interval was the 
same as in method (b.). All match VOIs are depicted in Figure 25. 
The CBCTs were firstly aligned by automatic rigid registrations to the reference CT 
images. Each match was subsequently manually verified and readjusted to the best possible 
alignment, which were considered as the ground truth. Hereby the inter-fractional residual 
setup deviation of the bony anatomy of the spine, the primary tumor and the malignant 
lymph nodes were assessed as the differences between the automatic and manual regi-
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strations. The patient stability (intra-fractional motion) was similarly quantified by the 
geometrical shifts between the manual matches of the pre- and post-treatment CBCTs for 
the spine, the primary tumor and the malignant lymph nodes.  
The residual misalignments of the spine and GTV-T were obtained for all the automatic 
CBCTs registrations. The residual misalignments of GTV-N were, however, only obtained 
for the 7 patients with separately delineated GTV-Ns. Since the lymph nodes are not easily 
visible in the CBCTs, the main bronchi area was used as a lymph node match surrogate to 
get an estimation of the GTV-N residual misalignments. The main bronchi area, (including 
the trachea, carina and the bronchus) is a stable anatomical surrogate structure closely 
situated to the involved lymph node stations which were centrally positioned in this study 
(supplementary Table 10). To quantify the overall magnitudes of the translational shifts, 
the 3D-vectors of the residual deviations were calculated. Statistical tests were considered 
significant for p ≤ 0.05.  
9.2.4 Error definition and margin calculations 
The anatomical misalignments for the different automatic match methods investigated 
were expressed in terms of the overall group mean (GM), and systematic (Σ) and random 
(σ) errors [15]. CTV to PTV margins were calculated according to the Van Herk formalism 
[15,16], and the PRV margins of the spine were calculated according to the McKenzie’s 
formalism [18]. 
Since most tumors were located close to the mediastinum (Figure 25, supplementary 
Table 10), margins were calculated using two different penumbra factors (σP) in order to 
quantify the effect of different penumbra widths on the CTV to PTV margin. σP = 0.64 cm 
describes the width of the penumbra in lung tissue, and σP = 0.32 cm in water, i.e. soft-
tissue, modeled by a cumulative Gaussian [17]. Margins were calculated both including 
and excluding the intra-fractional motion. 
The calculated CTV to PTV margins for the tumor and lymph nodes were applied to 
each patient’s CTV-T and CTV-N in the treatment planning system (TPS) Eclipse v. 10 
(Varian Medical Systems). The sizes of the CTVs and PTVs in FB and DIBH were 
extracted from the TPS for evaluation. 
9.3 Results 
Details for intra- and inter-fractional misalignments, GMs, systematic and random error 
components are found in the supplementary Table 11.  
9.3.1 Analysis of intra-fractional motion 
For the intra-fractional motion, FB was found to be in favor over DIBH for all anatomical 
structures (Table 6, supplementary Figure 26). The significant differences in SDs between 
FB and DIBH were most noticeable in the LNG direction (supplementary Table 11). 
Compared with the GTV-T and GTV-N, larger maximum intra-fractional 3D-vectors were 
observed for the spine, which for DIBH, mainly was due to the misalignments in the LNG 
direction (Table 7, supplementary Table 11).  
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9.3.2 Analysis of inter-fractional motion 
As expected, the smallest residual misalignments (≤ 2 mm) and the smallest 3D-vector of 
the spine were observed in FB after automatic bony registration (Table 5, supplementary 
Figure 26 - Figure 29). Largest inter-fractional misalignments of the spine were observed 
during DIBH independently of match method, especially in the LNG direction. 
For the lymph nodes, the smallest 3D-vectors were found for soft-tissue auto-match on 
the GTV-Total, regardless of FB or DIBH. No significant difference between the FB and 
DIBH 3D-vectors was observed for lymph nodes.  
For the primary tumor, DIBH 3D-vector was superior to FB for the both automatic soft-
tissue registrations, especially in the LNG direction (supplementary Table 11). The soft-
tissue match on the GTV-T was favorable over match on GTV-Total, irrespectively of FB 
or DIBH. The largest 3D-vectors of GTV-T and GTV-N were found for the bony 
registration on the spine, regardless of FB or DIBH, where FB was favorable over DIBH. 
No significant differences of the residual misalignments were found for any of the 
investigated structures if performing soft-tissue match on GTV-T or GTV-Total. 
9.3.3 Analysis of CTV to PTV margins 
Only minor, non-significant differences in the calculated CTV to PTV margins were found 
using the penumbra factor for lung tissue (σp = 0.64 cm) instead of using the penumbra 
factor for water (σp = 0.32 cm). CTV to PTV margins (Table 6) and PTVs (Table 9) are 
therefore only presented for lung tissue.  
All margins increased when including the intra-fractional motions in the margin 
calculations (Table 6). The largest margin increases (1.1-2.2) mm were observed in the 
LNG direction during DIBH. Corresponding margin increments in FB were smaller (0.2-
1.3 mm). 
Compared to soft-tissue GTV-T registration, the disadvantage of the bony registration 
method were the larger misalignments of the tumor (especially in the LNG direction, and 
in DIBH), resulting in (when including the intra-fractional motion) an extra margin of 1.6-
2.8 mm in FB and 2.0-3.4 mm in DIBH (Table 6). The margin differences for the GTV-N, 
if performing bony registration or soft-tissue registration on GTV-Total were not that 
large, ranging between -0.3-0.7 mm (FB) and -0.3-1.4 mm (DIBH), where the largest 
differences were observed in the LNG and LAT direction during DIBH. Bony registration 
yielded the smallest margin for the spine, compared to any soft-tissue registration method.  
Although DIBH resulted in the overall largest margins, the resulting PTV-Total sizes 
were for most cases found to be smaller for DIBH compared to FB, regardless of what 
match method carried out (Table 9). The CTVs for DIBH were on average 14.2%, 9.0%, 
and 13.1% smaller than the corresponding values for FB, respectively (Table 8). These 
differences are mainly due to the two different treatment planning concepts applied (using 
the MIP concept for the 4DCT image). The largest reduction of PTV-Total were detected 
for both soft-tissue auto-match methods (about a 13% overall volume reduction if 
excluding intra-fractional motion and about 9% reduction if including it) (Table 9). The 
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equivalent numbers for bony auto-match on the spine were an 8% overall volume 
reduction if excluding the intra-fractional motion and about 7% reduction if included.  
9.4 Discussion 
The margins in Table 6 should be considered as a lower limit for safe radiotherapy since 
they exclude rotational errors, shape variations, and delineation uncertainties [16]. The 
potential registration biases due to repeated breath-holds during DIBH are expected to be 
small since no significant image artifacts during DIBH CBCT imaging were observed. The 
observed misalignments on GTV-T and GTV-N after bony registration are mainly in the 
VRT and LNG direction (Table 7), and may be due to the moving pattern of the tumor 
relative to the bony structure of the spine. Consequently, this relative tumor motion may 
also be the reason why the 3D-vectors of the spine are the largest after soft-tissue auto-
match on the GTV-T.  
9.4.1 Comparison with other studies 
In the present study, 88% of the patients had mediastinal involvement. Several studies on 
patients with small primary tumors detached from the mediastinal areas referred to lung 
stereotactic body radiotherapy (SBRT), have demonstrated the advantage of soft-tissue 
registrations [63,66]. The current study suggests that also locally advanced lung cancer 
patients with mediastinal involvement benefit from soft-tissue registration on the tumor, 
regardless of FB or DIBH. This conclusion is supported by investigations of setup 
verifications in conventionally fractionated FB lung radiotherapy [22,64,65].  
In the present study, the mean 3D-vector of the primary tumor after automatic bony 
registration was 3.2 mm ± 1.6 mm (1 SD) in FB and 4.1 mm ± 2.5 mm (1SD) in DIBH 
(Table 5). The result for FB is comparable with the study by Grams et al. [65] which 
reported a mean difference in the corresponding 3D-vector of 3.5 mm ± 1.8 mm (1 SD). 
They used a similar match VOI as in our study. However, only 2 patients out of 11 had 
mediastinal involvements. Other studies, where the patient populations did not include any 
[63,66] or very few [64] patients with mediastinal involvement, larger corresponding 3D-
vectors were reported. This difference is likely due to the fact that the locally advanced 
tumors are more attached to the mediastinal area and close to the spine, and therefore less 
influenced by irregular breathing patterns. Yeung et al. [64] stated they could reduce the 
setup margin of the primary tumor by more than 1 cm by using tumor match instead of 
bony match. This is however not supported by our study, where only a reduction of 1.6-3.4 
mm was found for the GTV-T. This may be because their patient population only included 
3 patients out of 13 with mediastinal involvement. In accordance with [22,63–66], we 
found that it is not advisable to use the bony anatomy structure as a target surrogate. The 
PRV margins of the spinal cord during soft-tissue registrations in FB (about 3-5 mm 
(Table 6)) were comparable with spinal cord margins reported in [18,22,113]. Moreover, 
the residual GTV-N deviations and associated 3D-vector in FB and DIBH were found to 
be similar for the bony and soft-tissue match methods (Table 5), which agrees with [22]. In 
agreement of the results of Rahma et al. [22,113], the CTV to PTV margins of GTV-T 
were reduced regardless of what soft-tissue auto-match methods carried out, in comparison 
to bony registration on the spine. 
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9.4.2 Compensation of insufficient breath-hold level 
Shallower breath-holds during DIBH, may result in patients arching with their back to 
compensate for their insufficient compliance to reach the breath-hold amplitude level. This 
was in some extent observed in the current study, since larger intra-fractional SDs and 
misalignments (> 5 mm) for the spine were observed in the LNG direction during DIBH, 
compared to FB (Table 7 and supplementary Table 11). The intra-fractional motions of 
GTV-T and GTV-N were, however, not affected that much by this, where maximum 
residual shifts of 5 mm in the LNG direction were observed for GTV-T, and 4 mm for 
GTV-N (supplementary Table 11). Since the DIBH CBCT imaging often extends over 
several deep-inspiration breath-holds. This may cause tiredness of the patients, yielding 
even more arching of their backs.  
9.5 Conclusion 
This study demonstrates the advantage of combining DIBH with soft-tissue CBCT auto-
match setup verifications for locally advanced lung cancer patients to obtain the smallest 
treatment volumes. DIBH in combination with a soft-tissue auto-match procedure reduced 
the size of the total PTV between 9-13% on average compared to FB, depending on 
whether the intra-fractional motion was included or not. When included, the gain of DIBH 
was reduced. Bony registration resulted in about 1-5% on average larger PTV-Totals, 
compared to the soft-tissue registrations. Soft-tissue auto-match on GTV-T was found to 
be clinically most practical, since the target verification procedure is faster (compared to 
verification of GTV-Total), and more accurate (compared to bony registration). We advise 
against performing soft-tissue registration on GTV-Total if the GTV-T and GTV-N are not 
closely located within an image slice. If there exists several involved lymph nodes, and 
they are located far away from each other, there may be difficulties to verify the correct 
lymph node positions, and there is a risk that they may change their relative localization 
during DIBH. Thus, decision should be taken already at the stage of treatment planning, as 
to which part of the tumor volume to prioritize during verification, and thereby what setup 
margins to apply on the targets and OARs.  
Although DIBH yields the smallest PTVs for all match methods investigated, the 
treatment technique introduces more setup uncertainties (especially in the LNG direction), 
resulting in larger CTV to PTV margins compared to FB. We believe this is because some 
patients tend to arch with their back to compensate for their insufficient compliance to 
reach the breath-hold amplitude level. Our recommendations are therefore not to push the 
patients to hold their breath at their maximum amplitude peak of breath-hold. 
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9.6 Figures 
 
Figure 25. The different match VOIs presented on the DIBH CT image of patient 12. The white 
lines represent the match VOIs when performing (A) automatic bony match on the spine, (B) 
automatic soft-tissue match on GTV-T, and (C) automatic soft-tissue match on GTV-Total. The 
volume within the VOIs utilized for the registrations are colored red (i.e. pixels with an intensity 
range of [50; 3000] HU for bony match (A), and [-150; 150] HU for soft-tissue match (B and C)). 
Color version of figure is available online. 
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9.7 Tables 
Table 5. Median and maximum residual 3D-vectors for the three different match 
methods investigated for the spine, GTVT-T and GTV-N in FB and DIBH. Italic style 
indicates that one breathing technique is statistically significant (p ≤ 0.05) superior to 
the other breathing technique in terms of the smallest mean. Corresponding significance 
in median value and variance for the 3D-vectors are indicated by underline and bold 
styles, respectively. P-values are presented in the supplementary Figure 26 - Figure 29. 
(See the supplementary Table 11 for more detailed data on the intra- and inter-fractional 
motion in each direction). 
 
Manual match on 
Spine [mm] 
 
Manual match on 
GTV-T[mm] 
 
 
Manual match on 
GTV-N [mm] 
 Intra-fractional motion 
 FB  DIBH  FB  DIBH  FB  DIBH 
Manual match on Spine, GTV-T, and GTV-N, respectively 
3D-vector (SD) 1.4 (1.0)  1.7 (2.3)  1.9 (1.0)  2.8 (1.3)  2.0 (0.8)  2.8 (1.3) 
|Max 3D-shift| 7.1  12.9  5.4  5.7  4.5  6.0 
 Inter-fractional motion 
 FB  DIBH  FB  DIBH  FB  DIBH 
Auto-match on Spine 
3D-vector (SD) 1.0 (0.7)  1.0 (2.2)  3.2 (1.6)  4.1 (2.5)  3.0 (1.9)  3.4 (2.4) 
|Max 3D-shift| 2.2  9.3  8.5  16.2  10.3  14.4 
Auto-match on GTV-T 
3D-vector (SD) 2.8 (1.7)  4.1 (2.2)  1.4 (1.2)  1.4 (0.9)  2.8 (1.2)  3.0 (1.2) 
|Max 3D-shift| 7.4  9.9  8.2  3.6  5.4  6.2 
Auto-match on GTV-Total 
3D-vector (SD) 2.5 (1.4)  3.5 (2.1)  1.9 (0.9)  1.6 (0.7)  2.5 (1.1)  2.5 (1.1) 
|Max 3D-shift| 7.3  10.1  5.4  3.2  5.1  6.0 
FB, free-breathing; DIBH, deep-inspiration breath-hold; SD, standard deviation.  
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Table 6. Margins (including or excluding the intra-fractional motion) for the three different 
match methods investigated for the spine, GTVT-T and GTV-N in FB and DIBH. (See the 
supplementary Table 11 for more detailed data on the overall group means (GMs), the 
systematic (Σ) and the random (σ) error components used for the margin calculations). 
 Margin of Spine [mm]  Margin of GTV-T[mm]  Margin of GTV-N [mm] 
 FB  DIBH  FB  DIBH  FB  DIBH 
 VRT LNG LAT  VRT LNG LAT  VRT LNG LAT  VRT LNG LAT  VRT LNG LAT  VRT LNG LAT 
Auto-match on Spine 
Margin
a
 1.5 1.1 1.4  1.5 5.2 1.4  7.8 10.9 8.3  8.9 10.3 7.7  6.6 7.5 7.0  7.0 9.0 7.1 
Total margin
b
 2.7 1.9 2.1  2.9 7.2 2.5  8.3 11.7 8.6  9.7 11.4 8.3  7.1 8.3 7.8  7.8 10.7 7.7 
Auto-match on GTV-T 
Margin
a
 4.3 4.9 5.2  5.5 7.4 5.4  6.0 7.8 6.2  6.3 6.2 5.1  7.5 6.3 7.5  8.0 8.1 6.6 
Total margin
b
 4.8 5.2 5.5  6.1 8.9 5.9  6.7 8.9 6.6  7.5 8.0 6.3  7.9 7.3 8.1  8.6 9.9 7.3 
Auto-match on GTV-Total 
Margin
a
 3.3 4.8 4.0  4.0 5.6 4.2  6.6 7.3 5.9  5.4 6.3 5.3  6.4 7.9 6.1  7.4 7.1 5.8 
Total margin
b
 4.0 5.0 4.3  4.7 7.5 4.8  7.3 8.6 6.4  6.9 8.1 6.4  6.9 8.6 7.1  8.1 9.3 6.6 
FB, free-breathing; DIBH, deep-inspiration breath-hold; VRT, vertical; LNG, longitudinal; 
LAT, lateral. a. The calculated margins excluding the intra-fractional motion. The PRV margin 
of the spine is calculated according to [18], and the CTV to PTV margins for GTV-T and GTV-
N are calculated according to [15,16], using the penumbra factor σp = 0.64 cm. 
b. The calculated 
margins including the contribution from intra-fractional motion. 
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Table 8. The mean volume of the CTVs and the overall mean of the percentage deviations 
between FB and DIBH. Bold values indicate that the overall mean of the percentage 
deviations are statistically significantly (p ≤ 0.05) negative, i.e. DIBH yields statistically 
significantly smaller CTV volumes compared to FB in average.  
Mean volume  CTV-T (min; max)
 
 CTV-N (min; max)  CTV-Total (min; max) 
FBa [cm3]   303 (47; 800)  80 (12; 216)   337 (109; 800) 
DIBHa [cm3]   269 (32; 737)  68 (7; 188)   298 (89; 734) 
Dev.b [%]   - 14.2 (-34.0; -1.3)  - 9.0 (-38.2; 55.4)   - 13.1 (-30.2; -1.3) 
a. The mean volume of the CTV-T, CTV-N and CTV-Total, extracted from the treatment 
planning system Eclipse. b. The overall mean of the percentage deviations between FB and 
DIBH. Negative values indicate that DIBH CTVs are smaller than FB CTVs. 
 
 
Table 9. The mean of the resulting PTVs in FB and DIBH, including or excluding intra-
fractional motion. Additionally, the overall mean of the percentage deviations between FB and 
DIBH PTVs, and the percentage fraction of DIBH PTVs that were smaller than the FB PTVs 
for each match methods are presented. Bold values indicate that the overall mean of the 
percentage deviations are statistically significantly (p ≤ 0.05) negative, i.e. DIBH yields 
statistically significantly smaller PTV volumes compared to FB in average. The data presented 
for auto-match on GTV-Total are the results for the 7 patients with separately delineated lymph 
nodes. 
 Auto-match on Spine  Auto-match on GTV-T  Auto-match on GTV-Total 
 PTV-T PTV-N PTV-Total  PTV-T PTV-N PTV-Total  PTV-T PTV-N PTV-Total 
Mean volume Excluding intra-fractional motion 
FB [cm
3
]  614   216  697   524  212  605   279  200  459 
 min; max 148;1546 46;531 284;1546  116;1335 45;536 233;1335  115;456 41;499 240;856 
DIBH [cm
3
]  567  197  643   451  198  530   222  177  392 
  min; max 120;1482 35;492 258;1482  80;1188 36;498 199;1188  76;387 31;451 224;763 
Dev.
a
 [%]  - 9.2  -4.8  - 8.3   - 15.8  -3.9  - 12.8   - 21.6  - 8.0  - 13.6 
  min; max -26.3;-0.4 -23.5;34.8 -22.9;-0.4  -34.5;5.4 -20.8;34.1 -31.2;5.4  -37.1;-2.1 -25.8;33.1 -27.4;0.0 
DIBH < FB
b
 [%]  100  85.7  100.0   93.8  71.4  93.8   100  85.7  100 
Mean volume Including intra-fractional motion 
FB [cm
3
]  645  223  728   558  221  644   296  221  493 
 min; max 160;1612 48;548 302;1612  129;1428 47;546 247;1428  124;480 47;543 258;909 
DIBH [cm
3
]  591  226  678   505  217  590   253  204  443 
  min; max 123;1538 42;550 277;1538  96;1344 41;543 233;1344  92;441 37;508 258;849 
Dev.
a
 [%]  - 10.1  6.9  - 7.3   - 11.2  2.2  -8.6   - 15.5  -4.5  - 9.7 
  min; max -26.0;-1.2 -11.6;53.1 -23.8;-0.5  -32.5;3.0 -12.7;47.0 -32.5;3.0  -29.8;-2.4 -22.0;37.5 -21.6;0.0 
DIBH < FB
b
 [%]  100  42.9  100   93.8  71.4  93.8   100  85.7  100 
a. The overall mean of the percentage deviations between FB and DIBH. Negative values 
indicate that DIBH PTVs are smaller than FB PTVs. b. The percentage fraction of DIBH PTVs 
that are smaller compared to FB PTVs. 
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9.8 Supplementary material 
9.8.1 Treatment delivery 
The treatments were delivered in FB using Varian Clinac iX 2300 linear accelerators 
[21,85] (Varian Medical Systems, Palo Alto, CA) equipped with On-Board Imagers (OBI) 
capable of performing FB and DIBH CBCT, using version 1.5 of the OBI software. The 
Varian low-dose thorax CBCT scanning protocol was utilized.  
9.8.2 Ethical considerations  
The clinical protocol was approved by the Copenhagen Regional Committee on Health 
Research Ethics (protocol no. H-4-2012-066) and the Danish Data Protection Agency (ID. 
nr: 2007-58-0015 / HEH.750.24-61). Every patient gave informed consent to the work 
before inclusion.  
9.8.3 Details about the IV contrast administration 
The CT injection system was Stelland from MEDRAD. 
The IV-contrast we used was Iomeron 300mg I/ml from BRACCO Imaging SpA 
For a normal patient, we administered: 50 ml IV for the DIBH scan and 100 ml IV for 
the 4DCT scan. If the patient weighted < 50 kg, we administered: 35ml IV for the DIBH 
scan, and 70 ml for the 4DCT scan.   
We used a delay time of:  
 60 s for the DIBH scan  
 30 s for the 4DCT scan 
We used a contrast flow of: 
 3 ml/s for the DIBH scan 
 2 ml/s for the 4DCT scan 
9.8.4 Exclusion/inclusion of CBCT images 
FB and DIBH CBCTs were only included in the study if they were acquired during the 
same treatment session. Thus, additional pre-treatment FB CBCTs acquired other days 
during the course of treatment were not included. CBCTs revealing large anatomical 
changes such as creation or disappearance of atelectasis, tumor deformation, shrinkage, 
and displacement, as well as puncture of the vacuum pillow used for patient fixation, were 
not included in the analysis. If a patient was re-scanned during the course of treatment only 
the CBCTs acquired after the re-scans were included in the study to minimize the biases 
caused by anatomical changes. A total of 166 pre-treatment CBCTs (83 in FB and 83 in 
DIBH), and 164 post-treatment CBCTs (82 in FB and 82 in DIBH) were acquired and 
analyzed. However, 119 CBCTs were excluded due to following reasons: anatomical 
changes (80), poor image quality (3), incompliance with the image protocol (24), 
automatic match difficulties because of target shrinkage (4), and pneumonia (8). A total of 
400 pre-treatment (200 in FB and 200 in DIBH) and 394 post-treatment (197 in FB and 
197 in DIBH) automatic registrations on the spine, GTV-T and GTV-Total, and an equal 
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number of manual verifications on the spine, GTV-T and GTV-N were performed. This 
resulted in 1012 pre-treatment (506 in FB and 506 in DIBH) and 394 post-treatment shift 
events for evaluating the three different match methods and the intra-fractional motion. 
9.8.5 Details about the image registration 
The automatic rigid registration process was performed in three steps, each step with a 
higher image resolution, improving the efficiency of the algorithm [65]. The registrations 
were restricted to the field of view of the CBCT scans. Parts of the spinal cord, tumor 
volume, and malignant lymph nodes reaching beyond this volume of interest were ignored. 
For visual geometrical verification of the primary tumor and the involved lymph nodes, the 
pre-defined “lung” HU-window level was used for both the reference CTs and CBCTs. 
Equivalently, the “abdomen” HU-window level was used for verification of the bony 
registration. 
Although, most of the automatic match settings were predefined by Varian, the 
observer was allowed to choose what volume of interest (VOI) and which Hounsfield units 
(HU) within the VOI to use when performing the automatic registrations. For the bony 
match on the spine, the HU-interval within the VOI was set to [50; 3000] HU. This interval 
covers not only the cortical bone with high HU-values, but also the soft bone with lower 
HU-values, around 50 HU. The reason for the 2.5 cm margin around the spinal cord PRV 
was to include the major part of the vertebra in the bony registration. 
For the soft-tissue matches on GTV-T and GTV-Total, the HU-interval was set to [-
150; 150] HU to include the major part of the soft-tissue tumor and lymph nodes. The 
added margin of 1 cm around the GTV-T and GTV-T/IM has been found to yield stable 
match results according to Rahma et al. [22,113]. 
9.8.6 The reason why to choose the Un-tagged reconstruction instead of the average 
(AVG) reconstruction after a 4DCT scan 
For a Philips CT scanner, the un-tagged volume will utilize all of the sinogram data to 
reconstruct the data volume. There is no binning operation. This differs from the AVG 
dataset in two ways. The ‘data averaging’ is performed in sinogram space by back-
projecting all of the raw data. Furthermore, the AVG volume is an average of the bins that 
were reconstructed and therefore based on the width and spacing of bins which may not 
include all of the data collected. Whereas, the un-tagged volume is always a true 
representation of the time averaged data that was acquired.  
9.8.7 Details about the error definition and margin calculations 
The anatomical misalignments were expressed in terms of the overall group mean (GM), 
systematic (Σ) and random (σ) errors, according to van Herk [15]. In the absence of 
significant biases, the GM will be close to zero. The systematic error (Σ) is a measure of 
the reproducibility of the setup among patients, and is defined as the standard deviation of 
the GM. The random error (σ) is a measure for the reproducibility of setup between 
fractions and is defined as the root mean square of the standard deviations of intra-patient 
shifts. Treatment execution (random) variations lead to a blurring of the dose distribution, 
while treatment preparation (systematic) deviations lead to a displacement of the dose 
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distribution with respect to the CTV [16]. Based on these data, the CTV to PTV margins 
were calculated according to the Van Herk formalism [15,16]: 
pp  
22
PTV 5.2Margin  
(9. 1) 
where the parameter β=1.64 assures delivery of 95% of the prescribed dose to 90% of 
the patient population [17]. 
Since the spinal cord is a serial OAR, and the treatments were delivered as three 
dimensional IMRT or RA plans, the PRV margins for the spinal cord were calculated 
according to McKenzie’s formula [18], using the systematic and random components, 
according to: 
 5.05.2Margin OAR  (9. 2) 
To take into account the intra-fractional motion in the margin calculations, all the 
systematic and all random components were added in quadrature, according to [15,16]:   
2
Intra
2
Inter   
(9. 3) 
2
Intra
2
Inter    
(9. 4) 
9.8.8 Statistical analysis 
For statistical analysis MATLAB including the Statistics Toolbox version 8.3 (R2013b) 
(The MathWorks, Natick, MA) was utilized. To evaluate the data several statistical tests 
were carried out, where the results were considered statistically significant for p ≤ 0.05. 
Two-sampled paired t-tests and F-tests were performed to compare the means and the 
variances of the FB and DIBH data sets. Additionally two-sided Wilcoxon signed rank test 
were applied to test the medians of the data sets. To compare the match methods against 
each other in terms of which ones that resulted in the smallest PTVs, balanced one-way 
ANOVA tests were carried out.  
9.8.9 Confounding factors 
Potential confounding factors in this study are mainly due to the nature of CBCT imaging. 
Firstly, the FB CBCT imaging often extends over several respiratory cycles. However, we 
expect the potential bias to be very small since the FB CBCT images are registered to the 
time weighted un-tagged reconstruction of a 4DCT scan, which mimics a slow image 
acquisition, similar to the CBCT. Secondly, the CBCT image extension is spatially limited 
in the LNG direction. This is more of a problem for locally advanced lung cancer patients 
than for SBRT patients due to the larger tumor volumes that have the potential to reach 
beyond this limitation. One solution can be to acquire several CBCTs to cover the whole 
thorax area, which subsequently could be stitched together to create a long enough 3D 
image covering the whole thorax area. However this feature is not provided by the 
manufacturer of the utilized CBCT imaging device at this time. Another confounding 
factor involving the DIBH imaging is that in most cases it took several DIBH before a 
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whole CBCT scan was acquired (supplementary Table 12). The beam-off and hold of the 
CBCT scan acquisition when the patients breathing curve went outside the gating window 
were controlled manually by the operating radiotherapists (RTT)s. Nonfulfillment of the 
manually hold of the CBCT acquisition at the time when the breathing curve fails to be 
within the gating window could yield some motion artifacts during DIBH CBCT imaging. 
If the CBCT acquisition control unit could receive beam-on information from the 
respiratory monitoring system, just like the treatment unit, this issue would be minimized. 
The potential biases are nevertheless expected to be small since no significant image 
artifacts due to repeated breath-holds during DIBH CBCT imaging were observed in our 
study.  
9.8.10 Clinical practicality 
DIBH is more resource intensive for the staff than FB treatment, since each patient needs 
to be guided throughout all imaging and treatment delivery during the course of treatment. 
Although DIBH yields the smallest PTVs, the treatment technique introduces more setup 
uncertainties, resulting in larger CTV to PTV margins compared to FB. The cost of larger 
uncertainties and the heavier workload for the staff must be weighted against the 
dosimetric gain for each patient; in terms of saving adjacent healthy OARs and/or enabling 
possible dose escalation.  
Setup verification using GTV-T and GTV-N can be a problem if they are not visible in 
the same image slices, and the observer needs to scroll between slices in different 
directions to verify their positions. It is achievable, but very time consuming. Due to the 
limited time slot on the treatment unit, we advise against performing soft-tissue registration 
on GTV-Total if the GTV-T and GTV-N are not closely located within an image slice. 
Soft-tissue auto-match on GTV-T is the preferred match method since the target 
verification procedure is faster (compared to verification of GTV-Total) and more accurate 
(compared to the bony registration). Thus, larger CTV to PTV margins should be applied 
to the CTV-N to ensure the dose coverage and larger PRV margin of the spinal cord to 
ensure no overdosage of the spinal cord. An additional verification problem may arise if 
the patient has several involved lymph nodes, and they are located far away from each 
other. In that case it is difficult to verify the correct lymph node positions. There is also a 
risk that they may change their relative localization during DIBH. A decision should be 
taken already at the stage of treatment planning, as to which part of the tumor volume to 
prioritize during verification, and thereby what setup margins to apply.  
Due to the large number of fractions in conventionally fractionated radiotherapy, the 
cost of daily CBCTs must be weighed against the benefit of increased targeting accuracy 
and detection of anatomical abnormalities affecting the treatment outcome. Daily CBCT 
minimizes the risk of missing anatomical changes that might appear and disappear during 
the course of treatment. These anatomical changes may not just affect the dose distribution, 
but could also cause tumor displacement or obscure the visibility of the tumor. Møller et al. 
[26] discovered that for the 163 lung cancer patients analyzed in their study, an adaptive 
strategy was indicated for 12% as a result of atelectasis, pneumonitis or pleural effusion. 
This is further supported by our study, where 20% of the totally 449 acquired CBCTs 
contained anatomical changes, tumor shrinkage or pneumonia. 
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9.8.11 Future perspectives 
In the future, the treatment process is required to be more individually optimized for each 
patient to obtain the highest treatment outcome possible. Evaluation of both FB and DIBH 
CT images in order to assess the tumor motion and the potential gain with DIBH prior to 
treatment planning, together with different margins, can be carried out in order to decide 
the setup and treatment strategy for the individual patient. The next step could be to 
evaluate on the treatment plan, instead of volume sizes, by producing many treatment plans 
for the different treatment strategies (e.g. FB or DIBH treatment plans, match on the tumor 
or the spine for setup verification, etc.). However, these individualized treatment planning 
processes are very workload heavy. Nevertheless, if the processes of target and OARs 
delineation and treatment planning are more automatized, it may be clinically feasible to 
implement a more individualized treatment. These features are currently not fully 
integrated in most commercial TPSs, but thorough investigations are carried out [70,114–
116]. 
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9.9 Supplementary figures 
 
Figure 26. The intra-fractional residual deviations for FB and DIBH in the VRT, LNG, and LAT 
directions and the corresponding 3D-vector. The first, second and third line of subplots represent the 
translational shifts between CBCTBefore and CBCTAfter after manual match on the spine, GTV-T, and 
GTV-N (or lymph node surrogates when the lymph nodes were not visible), respectively. The 
student’s t-test, the Wilcoxon signed rank test and the F-test when investigating the statistically 
significant differences in mean, median and variance between DIBH and FB are represented by pt, 
pw and pv, respectively. On each box, the central light gray mark represents the median value. The 
edges of each box are the 25th and the 75th percentiles, the whiskers correspond to approximately ± 
2.7 SD of the data, and outliers are plotted as crosses individually. 
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Figure 27. The inter-fractional residual deviations after auto match on the spine for FB and DIBH in 
the VRT, LNG, and LAT directions, including the corresponding 3D-vectors. The first, second and 
third line of subplots represent the translational shifts when performing manual match on the spine, 
GTV-T, and GTV-N (or lymph node surrogates when the lymph nodes were not visible), 
respectively. Additional figure explanations are described in supplementary Figure 26.  
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Figure 28. The interfractional residual deviations after auto match on the GTV-T for FB and DIBH 
in the VRT, LNG, and LAT directions, including the corresponding 3D-vectors. The first, second 
and third line of subplots represent the translational shifts when performing manual match on the 
spine, GTV-T, and GTV-N (or lymph node surrogates when the lymph nodes were not visible), 
respectively. Additional figure explanations are described in supplementary Figure 26.  
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Figure 29. The inter-fractional residual deviations after auto match on the GTV-Total for FB and 
DIBH in the VRT, LNG, and LAT directions, including the corresponding 3D-vectors. The first, 
second and third line of subplots represent the translational shifts when performing manual match on 
the spine, GTV-T, and GTV-N (or lymph node surrogates when the lymph nodes were not visible), 
respectively. Additional figure explanations are described in supplementary Figure 26.  
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9.10 Supplementary tables 
 
Table 10. Summary of patient characteristics. 
Patient characteristics 
Number of patients (%) 
or median (min;max) 
Median Age 62 (48;75) 
Gender  
 Male 13 (76%) 
 Female 4 (24%) 
Performance Status  
 0 16 (94%) 
 1 1 (6%) 
Differentiating grade  
 Adenocarcinoma 9 (53%) 
 Planocellular carcinoma 7 (41%) 
 Larce cell neuroendocrine carcinoma 1 (6%) 
T-stage  
 1 1 (6%) 
 2 4 (24%) 
 3 6 (35%) 
 4 6 (35%) 
N-stage  
 0 2 (12%) 
 1 3 (18%) 
 2 8 (47%) 
 3 4 (24%) 
M-stage  
 0 17 (100%) 
Tumor Location  
 Upper lobe 13 (76%) 
 Middle/lower lobe 4 (24%) 
Primary tumor site  
 Central 10 (59%) 
 Peripheral 2 (12%) 
 Chest wall 4 (24%) 
 Central/Chest wall 1 (6%) 
Mediastinal involvement  
 Tumor 1 (6%) 
 Lymph node 5 (29%) 
 Tumor and lymph node 9 (53%) 
 No involvement 2 (12%) 
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Table 11. The intra- and inter-fractional motion of the spine, GTVT-T and GTV-N for FB and 
DIBH. Bold style indicates that one breathing technique is statistically significant (p ≤ 0.05) 
superior to the other breathing technique in terms of the smallest mean, median or standard 
deviation (SD). Corresponding significance in mean, median and variance for the 3D-vectors 
are indicated by italic, underline and bold styles, respectively.  
 Manual match on Spine [mm]  Manual match on GTV-T[mm]  Manual match on GTV-N [mm] 
 FB  DIBH  FB  DIBH  FB  DIBH 
 VRT LNG LAT  VRT LNG LAT  VRT LNG LAT  VRT LNG LAT  VRT LNG LAT  VRT LNG LAT 
Intra-fractional motion - Manual match on Spine, GTV-T, GTV-N, respectively 
Mean 0.0 -0.2 0.2  -0.2 -0.6 0.0  0.2 -0.4 0.2  0.7 -0.3 0.0  0.6 -0.8 0.1  0.7 -0.6 0.0 
Median 0.0 0.0 0.0  0.0 0.0 0.0  0.0 -1.0 0.0  1.0 0.0 0.0  0.0 -1.0 0.0  1.0 -1.0 0.0 
SD 1.2 0.8 0.9  1.6 2.5 1.3  1.4 1.6 1.0  1.7 2.2 1.3  1.1 1.2 1.0  1.6 2.3 1.2 
|Max shift| 7.0 3.0 2.0  8.0 12.0 4.0  4.0 5.0 3.0  4.0 5.0 4.0  4.0 3.0 2.0  4.0 4.0 4.0 
3D-vector (SD) 1.4 (1.0)  1.7 (2.3)  1.9 (1.0)  2.8 (1.3)  2.0 (0.8)  2.8 (1.3) 
 |Max 3D-shift|  7.1    12.9    5.4    5.7    4.5    6.0  
GM -0.1 -0.1 0.1  -0.2 -0.4 0.0  0.3 0.0 0.2  0.7 -0.3 0.0  0.7 -0.6 0.1  0.7 -1.0 0.1 
ΣIntra
a 0.8 0.5 0.5  0.7 1.6 0.6  0.7 1.4 0.6  0.9 1.2 0.8  0.6 0.7 0.5  0.5 1.6 0.7 
σIntra
b 1.0 0.8 0.9  1.5 1.8 1.2  1.3 1.3 1.1  1.5 1.8 1.1  1.1 1.1 0.9  1.9 1.8 1.0 
Inter-fractional motion - Auto match on Spine 
Mean 0.1 -0.3 -0.2  0.2 -0.8 -0.1  -0.2 0.8 -0.6  -0.4 0.2 -0.7  -1.0 1.7 -0.1  -1.7 -0.4 -0.6 
Median 0.0 0.0 0.0  0.0 0.0 0.0  0.0 1.0 0.0  0.0 0.0 -1.0  -1.0 2.0 0.0  -1.0 0.0 0.0 
SD 0.6 0.7 0.6  0.8 2.6 0.6  1.8 2.3 1.9  2.6 3.8 1.8  1.9 2.0 1.5  2.2 3.0 1.5 
|Max shift| 2.0 2.0 2.0  3.0 9.0 2.0  4.0 8.0 7.0  6.0 15.0 5.0  9.0 7.0 4.0  8.0 12.0 4.0 
3D-vector (SD) 1.0 (0.7)  1.0 (2.2)  3.2 (1.6)  4.1 (2.5)  3.0 (1.9)  3.4 (2.4) 
 |Max 3D-shift|  2.2    9.3    8.5    16.2    10.3    14.4  
GM 0.2 -0.4 -0.1  0.3 -0.8 -0.1  -0.1 0.3 -0.6  -0.5 0.0 -0.7  -1.1 1.5 -0.2  -1.7 -0.2 -0.5 
ΣInter
a 0.5 0.3 0.4  0.5 1.7 0.5  1.6 2.7 1.7  1.9 2.1 1.5  1.0 1.4 1.2  1.1 1.8 1.3 
σInter
b 0.5 0.7 0.6  0.8 2.1 0.5  1.1 1.5 1.1  1.7 3.2 0.9  1.7 1.5 1.3  2.1 2.5 0.9 
Marginc 1.5 1.1 1.4  1.5 5.2 1.4  7.8 10.9 8.3  8.9 10.3 7.7  6.6 7.5 7.0  7.0 9.0 7.1 
Total margind 2.7 1.9 2.1  2.9 7.2 2.5  8.3 11.7 8.6  9.7 11.4 8.3  7.1 8.3 7.8  7.8 10.7 7.7 
Inter-fractional motion - Auto match on GTV-T 
Mean 0.3 -1.1 0.7  0.5 -0.8 0.6  0.1 -0.1 0.3  -0.1 0.2 0.0  -0.1 1.6 -0.2  -0.2 1.4 0.3 
Median 0.0 -1.0 0.0  1.0 -1.0 0.0  0.0 0.0 0.0  0.0 0.0 0.0  0.0 1.5 0.0  0.0 2.0 0.5 
SD 1.7 2.0 2.1  2.6 3.3 2.3  1.1 1.6 1.1  1.1 1.2 0.9  1.8 1.4 1.5  2.1 2.1 1.4 
|Max shift| 5.0 6.0 6.0  9.0 9.0 6.0  3.0 7.0 4.0  3.0 3.0 2.0  4.0 4.0 4.0  5.0 6.0 3.0 
3D-vector (SD) 2.8 (1.7)  4.1 (2.2)  1.4 (1.2)  1.4 (0.9)  2.8 (1.2)  3.0 (1.2) 
 |Max 3D-shift|  7.4    9.9    8.2    3.6    5.4    6.2  
GM 0.3 -0.9 0.6  0.5 -0.5 0.7  0.0 -0.3 0.1  -0.2 0.2 0.0  -0.3 1.5 -0.3  -0.2 1.7 0.4 
ΣInter
a 1.5 1.7 1.9  1.9 2.5 2.0  0.8 1.5 0.9  1.0 0.9 0.5  1.4 0.9 1.4  1.5 1.5 1.1 
σInter
b 1.3 1.4 1.0  1.7 2.3 1.0  0.9 1.2 0.9  1.0 1.0 0.9  1.3 1.3 1.2  1.6 1.6 1.1 
Marginc 4.3 4.9 5.2  5.5 7.4 5.4  6.0 7.8 6.2  6.3 6.2 5.1  7.5 6.3 7.5  8.0 8.1 6.6 
Total margind 4.8 5.2 5.5  6.1 8.9 5.9  6.7 8.9 6.6  7.5 8.0 6.3  7.9 7.3 8.1  8.6 9.9 7.3 
Inter-fractional motion - Auto match on GTV-Total 
Mean 0.8 -0.8 -0.1  1.6 0.5 0.7  -0.1 -0.3 0.2  0.1 -0.2 -0.3  -0.2 1.1 -0.2  -0.2 0.9 0.1 
Median 1.0 -0.5 0.0  1.0 0.0 0.0  0.0 0.0 0.0  0.0 0.0 0.0  0.0 1.0 0.0  0.0 1.0 0.0 
SD 1.4 2.0 1.6  2.2 2.6 1.8  1.4 1.5 0.9  0.9 1.3 0.8  1.3 1.6 1.3  1.8 1.8 1.1 
|Max shift| 6.0 6.0 4.0  7.0 6.0 6.0  3.0 4.0 3.0  2.0 3.0 2.0  3.0 4.0 3.0  4.0 6.0 2.0 
3D-vector (SD) 2.5 (1.4)  3.5 (2.1)  1.9 (0.9)  1.6 (0.7)  2.5 (1.1)  2.5 (1.1) 
 |Max 3D-shift|  7.3    10.1    5.4    3.2    5.1    6.0  
GM 0.6 -1.0 0.0  1.6 0.4 0.6  0.0 -0.6 0.3  0.0 -0.5 -0.3  -0.4 0.7 -0.1  -0.2 0.9 0.2 
ΣInter
a 1.1 1.6 1.2  1.2 1.8 1.4  1.1 1.3 0.8  0.6 1.0 0.6  1.0 1.6 0.9  1.4 1.2 0.8 
σInter
b 1.1 1.4 1.9  1.9 2.2 1.3  1.1 1.2 0.8  0.8 1.1 0.6  1.0 1.1 1.0  1.2 1.6 0.7 
Marginc 3.3 4.8 4.0  4.0 5.6 4.2  6.6 7.3 5.9  5.4 6.3 5.3  6.4 7.9 6.1  7.4 7.1 5.8 
Total margind 4.0 5.0 4.3  4.7 7.5 4.8  7.3 8.6 6.4  6.9 8.1 6.4  6.9 8.6 7.1  8.1 9.3 6.6 
FB, free-breathing; DIBH, deep-inspiration breath-hold; SD, standard deviation; GM, the 
overall group mean; VRT, vertical; LNG, longitudinal; LAT, lateral. a. The systematic error 
component. b. The random error component. c. The calculated margins excluding the intra-
fractional motion. The PRV margin of the spine is calculated according to [18], and the CTV to 
PTV margins for GTV-T and GTV-N are calculated according to [15,16], using the penumbra 
factor σp = 0.64 cm. 
d. The calculated margins including the contribution from intra-fractional 
motion. 
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Table 12. Time measurements for the different treatment processes. For DIBH, please note 
the extra DIBH training session (scheduled for 1 h prior the planning CT scan). For the FB 
4DCT imaging please note the prolonged processes of CT reconstruction, import and 
fusion, and GTV delineation. 
 FB [minutes] DIBH [minutes] 
Process Median SD Min Max Median SD Min Max 
DIBH training session NaN NaN NaN NaN 51 9.6 38 66 
CT scan 10 4.2 4 19 10 4.1 4 24 
CT reconstruction 20 14.7 7 63 5 4.2 2 18 
CT import and PET fusion a 49 16.9 20 90 NaN NaN NaN NaN 
Delineation GTV 20 10.3 5 64 9 4.8 2 29 
Delineation CTV/PTV 5 5.3 1 27 4 3.2 1 18 
Delineation OARs 13 3.4 8 22 15 4.2 7 24 
Delineation Total 48 15.3 26 106 36 9.8 23 69 
Treatment planning 60 23.6 25 120 60 21.3 25 100 
CBCT imaging session b 5 1.9 2 13 5 2.2 1 13 
DIBH CBCT acquisition c  NaN NaN NaN NaN 2.1 1.4 1.1 11.5 
Number of breath-holds, [#] NaN NaN NaN NaN 2 1.6 1 11 
First DIBH CBCT session NaN NaN NaN NaN 11 3.8 5 18 
a.Estimated time for the corresponding DIBH import and PET fusion process is 10 
minutes. b. The time to initiate, acquire and save the CBCT images. The presented data do 
not include the duration data for the first DIBH CBCT acquired, because that session is 
prolonged due to set-up of reference breath-hold levels. That data is instead presented 
under “First DIBH CBCT session”. c. The total beam-on time was about 1 min for both FB 
and DIBH CBCTs since the same image protocol was applied. The pro-longed time to 
acquire the DIBH CBCT images was due to the number of breath-holds that were required 
to complete a full CBCT scan. 
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10 Paper III 
Monte Carlo calculations support organ sparing in Deep-Inspiration Breath-Hold 
intensity-modulated radiotherapy for locally advanced lung cancer  
Paper III is submitted to the scientific journal Radiotherapy & Oncology, and is under 
review process at the moment. MC simulations were carried out to assess the potential 
dosimetric benefits of DIBH compared to FB for volumetric-modulated-arc-therapy 
(VMAT) and IMRT for locally advanced lung cancer. Comparison against a commercial, 
less accurate, dose calculation algorithm (AAA) was carried out. 
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Abstract 
Background and Purpose: Studies indicate that deep-inspiration-breath-hold (DIBH) is 
advantageous over free-breathing (FB) for locally advanced lung cancer radiotherapy. 
However, these studies were based on simplified dose calculation algorithms, potentially 
critical due to the heterogeneous nature of the lung region. Using detailed Monte Carlo 
(MC) simulations, a comparative study of DIBH vs. FB was therefore designed. 
Material and Methods: Eighteen locally advanced lung cancer patients underwent FB and 
DIBH CT imaging and treatment planning with the Anisotropic-Analytical-Algorithm 
(AAA) for intensity-modulated radiotherapy or volumetric-modulated-arc-therapy using 
66 Gy in 33 fractions.  All plans were re-calculated with MC. 
Results: Relative to FB, the total lung volume increased 86.8% in DIBH, while the gross 
tumor volume decreased 14.8%. MC revealed equally under- and over-dosage of the 
target for FB and DIBH, compared to AAA. For the organs-at-risk (OARs), DIBH 
reduced the mean heart dose by 25.5% (AAA) vs. 12.6% (MC), the total lung 
V5Gy/V20Gy by 9.0/20.0% (AAA) vs. 11.6/19.9% (MC). 
Conclusions: The MC simulations revealed (i) that DIBH compared with FB can 
significantly reduce the dose to the OARs even if the treatment planning is carried out 
with AAA, and (ii) that AAA-based treatment plans resulted in inferior target dose 
coverage. Target dose deviations were similar for FB and DIBH. Therefore, issue (ii) 
relates to the treatment planning algorithm rather than treatment technique. 
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10.1 Introduction 
Respiratory motion is a challenge during radiotherapy of non-small-cell lung cancer 
(NSCLC) patients. Deep-inspiration-breath-hold (DIBH) is a method to diminish the un-
certainty of breathing motion during radiotherapy for both lung, breast and Hodgkin 
lymphoma [101,102,110,117]. During DIBH, the lung is inflated, and the density of the 
lung parenchyma decreases, while the heart moves toward the back of the thorax, where 
the shape of the heart is affected of the inflated lungs. For some DIBH cases, the gross 
tumor volume (GTV) can be displaced away from the  radiosensitive spinal cord [110]. 
DIBH is a treatment method which may enable use of smaller treatment fields due to less 
tumor motion, consequently reducing dose to the adjacent healthy tissues and organs at 
risk (OARs). 
Lung cancer GTVs are often situated in a region of large tissue heterogeneity where the 
accuracy of the dose calculation algorithm is critical to a precise evaluation of target dose 
coverage. Monte Carlo (MC) dose simulations are able to simulate all ionization 
interactions present in a patient. The disadvantage with MC is the large computation time 
because of the many interaction histories required. Most commercial dose calculation 
algorithms utilize approximations to limit the computation time. Many commercial 
algorithms have issues to correctly account for changes of lateral electron scatter [88–90]. 
The dose calculation accuracy is thereby affected negatively, and not comparable with MC 
in heterogeneous geometries. The largest inaccuracies are usually noticed in the transition 
between materials of different densities. Lateral charged particle disequilibrium will be 
emphasized during DIBH, since the lung density decreases. The range of secondary 
electrons will increase resulting in a larger volume of disequilibrium and a broader 
penumbra at field boundaries [102,103]. 
The clinical benefit of DIBH for lung cancer patients have previously been evaluated in 
studies based on simple field technique and simplified calculation algorithms [118–122]. 
Due to the high amount of heterogeneities present in the lung region, there are limitations 
to these studies. Still, there are some studies presenting MC simulations [91,102–
104,123,124] and measurement data [88,92] for lung treatments. Most of these studies inv-
estigate conventional treatment techniques with static fields, and did not investigate the 
potential benefits of DIBH. However, the MC study by Wang et al. [123] presented a 
dosimetric evaluation for 5 lung cancer patients treated with intensity modulated 
radiotherapy (IMRT), where one patient was treated with end-inspiration gating. They did 
however not assess the potential benefit of DIBH for this more complex treatment 
technique. This current study, including 18 patients, is the first DIBH MC study designed 
to obtain accurate assessment of the potential benefits of DIBH compared to free-breathing 
(FB) for volumetric-modulated-arc-therapy (VMAT) and IMRT for locally advanced lung 
cancer. For this purpose, VMAT and IMRT treatment plans produced in a convolution-
superposition based treatment planning system (TPS) were re-calculated using MC, 
comparing DIBH with FB. 
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10.2 Material and methods 
10.2.1 Patient data 
Eighteen locally advanced NSCLC patients scheduled for curative radiotherapy at Herlev 
Hospital, between December 2012 and July 2014, were enrolled. The patients were treated 
in FB with VMAT or IMRT in 33 fractions (fx), receiving a total dose of 66 Gy (2 Gy/fx, 5 
fx/week). The treatments were delivered using Varian Clinac iX 2300 linear accelerators 
[21,85] (Varian Medical Systems, Palo Alto, CA) equipped with On-Board Imagers (OBI) 
capable of performing FB and DIBH CBCT, using version 1.5 of the OBI software. Table 
13 summarizes the patient characteristics. 
10.2.2 Ethical considerations  
The clinical protocol was approved by the Copenhagen Regional Committee on Health 
Research Ethics (protocol no. H-4-2012-066) and the Danish Data Protection Agency (ID. 
nr: 2007-58-0015 / HEH.750.24-61). Every patient gave informed consent prior to 
inclusion. 
10.2.3 Image acquisition 
Prior to planning imaging, all patients were introduced during a 30 minute training session 
to the DIBH procedure by a radiotherapist (RTT). The Varian real-time position 
management (RPM) system, version 1.7 (Varian Medical Systems), integrated with the CT 
imaging system, was utilized to monitor the patients’ respiration [32]. The patients were 
audio-visually guided during DIBH by using video goggles to achieve a reproducible 
inspiration level. During the training session, they were required to hold their breath at 
least 20 seconds at a reproducible patient-specific amplitude level and a gating window of 
2-3 mm width. 
All images were acquired in treatment position. The CT image protocol and details 
about the delineation of anatomical structures have previously been described by Ottosson 
et al. [21,112]. In brief, each patient was dual-CT scanned in a 16 slice Philips Brilliance 
CT Big Bore scanner, version 3.5.17001 (Philips Medical Systems, Cleveland, OH) 
(acquiring a 4-dimensional CT (4DCT) in FB and a normal CT in DIBH). Intra-venous 
contrast was administered to the patients during both 4DCT and DIBH CT imaging, for 
better contrast of nodal anatomy in the mediastinum. Each image set included the entire 
lung volume, starting from the top of the sixth cervical vertebrae. From the FB 4DCT an 
untagged image reconstruction and a maximum intensity projection (MIP) image set were 
obtained [21]. Each patient was additionally scanned in a GEMINI TF 16 slice Big Bore 
PET/CT, version 2.3 (Philips Medical Systems) in order to diminish the delineation un-
certainties in the CT. 
10.2.4 Definition of target and organs at risk 
The image sets were imported and co-registered in the Eclipse TPS, version 10 (Varian 
Medical Systems). Delineations of anatomical structures were performed according to 
standard protocol by only one experienced oncologist (JLA or SB) on all image sets for 
that patient [21]. Contouring of the GTVs was performed in collaboration with an 
experienced radiologist using information from the co-registered MIP and PET/CT images. 
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The delineated GTV was subsequently verified and corrected in all breathing phases. 
Residual structures such as the clinical target volume (CTV), the planning target volume 
(PTV), medulla, heart, esophagus, lung, healthy lung (the opposing lung from where the 
primary tumor is located) were additionally delineated solely by the oncologist, whereas 
CT radiographers semi-automatically delineated the body contour. 
10.2.5 Treatment planning process 
All treatment plans were created using the Anisotropic-Analytical-Algorithm (AAA) dose 
calculation algorithm in Eclipse by one treatment planner (CL), experienced in lung 
cancer, in order to avoid inter-observer variability in the treatment planning process. Due 
to an inferior Hounsfield unit (HU) representation, the FB treatment planning was carried 
out using the untagged CT reconstruction instead of the MIP image set, which solely was 
utilized for enhanced target delineation. All treatment plans were designed and optimized 
for PTV dose coverage and dose reduction to the OARs according to an established dose 
constraint protocol, as follow; The medulla was not allowed to receive more than 45 Gy 
(V45Gy = 0%). An absorbed dose of 5 Gy was delivered to less than 60% of the total lung 
volume (V5Gy (Total lung) ≤ 60%), and to less than 40% of the healthy lung volume (V5Gy (Healthy 
lung) ≤ 40%). Concurrently, 20 Gy was delivered to less than 35% of the total lung volume 
(V20Gy ≤ 35%), or if that was not possible, the mean dose of the total lung volume was not 
to exceed 20 Gy (MLD ≤ 20 Gy). In a similar way, 50 Gy was delivered to a maximum of 
20% of the heart volume (V50Gy ≤ 20%), and the mean dose of the heart volume was to be 
less than 46 Gy (MHD ≤ 46 Gy). For the esophagus, 55 Gy was delivered to no more than 
30% of the volume (V55Gy ≤ 30%), with a maximum dose of 66 Gy (V66Gy = 0%), and the 
mean dose of the esophagus was to be no more than 34 Gy. In addition to the dose 
constraints for the OARs there were requirements on the target dose coverage, in order to 
achieve a clinically acceptable treatment plan. At least 95% of the prescribed dose was to 
be delivered to 98% of the PTV (D98% ≥ 95%). It is often difficult to comply with the dose 
coverage constraint because of the heterogeneities in the lung region. Therefore, if the soft-
tissue tumor was embedded in lung-tissue, it was acceptable that 98% of the PTV only was 
covered by 90% of the prescription dose. An overdosage of up to 107% was allowed to 2% 
of the PTV (D2% ≤ 107%), but the maximum absorbed dose was to be less than 110% (Dmax 
≤ 110%). GTV and CTV dose constraints are additionally implemented, where at least 
95% of the prescribed dose was to cover 99% of the GTV and CTV, (D99% ≥ 95%). 
In this study only 6 MV photon beams were considered, since higher energy photon 
beams can compromise target coverage due to more pronounced lateral charged particle 
disequilibrium [83,102–104]. The treatment planner aimed to construct clinically 
acceptable VMAT plans for all image sets in FB and DIBH. However for three image sets 
(both FB and DIBH for one patient, and only FB for another patient) it was not achievable 
and comparative IMRT plans in terms of target dose coverage and preservation of the dose 
constraints were produced. The VMAT treatment plans were created by partial dual-arcs 
avoiding initial entrance dose through the healthy lung, medulla and the heart. The IMRT 
treatment plans were designed in a similar way, consisting of a 5- or 6-field beam arrange-
ment. The beam and arc arrangements between FB and DIBH were for the most parts the 
same for the same patient. However, some adjustments of beam angle, field weights and 
apertures were made to achieve clinically acceptable plans. 
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The measurement-based AAA dose calculation algorithm, utilized in this study for the 
commercial TPS, has previously been described extensively [88–92]. The AAA algorithm 
is a three source pencil-beam convolution-superposition model, where the primary and 
secondary photons and the contamination electrons are individually calculated for each 
beamlet. The dose contributions from all sources are subsequently superpositioned to the 
final dose distribution, where the heterogeneity correction only is carried during the super-
position phase by a modified Batho heterogeneity correction [88]. The most important 
approximation of AAA is that the energy deposition is divided into two components, the 
first component models the photon interactions along the fanline, and the second 
component models the scatter perpendicular to the fanline as a sum of six radial 
exponential functions for a discrete number of angular sectors [88–90]. Thus, the two 
component approximation does not take the divergent scatter of heterogeneities from upper 
levels correctly into account. The depth and lateral components are anisotropically scaled 
independently according to the electron density distribution of the medium. Additionally, 
the approximation of using a discrete number of angular sections for the radial exponential 
functions cause smoothing of the calculated dose distribution near heterogeneous 
interfaces [88,89]. 
10.2.6 Monte Carlo simulations 
All treatment plans were subsequently re-calculated using MC, with preserved monitor 
units and beam configurations, as were used for the commercial AAA algorithm. The MC 
simulations can provide dose distributions where heterogeneities are more correctly 
accounted for since the anatomy, including the electron density information, is obtained 
from each patient’s CT image set. 
The building and commissioning of a Varian 2300 iX linear accelerator (Varian 
Medical Systems, Palo Alto, CA, USA) model, as well as the procedure of MC simulation 
have previously been described by Ottosson et al. [104]. In short, EGSnrc was used as the 
engine for BEAMnrc, which was utilized to build and commission the MC model [125–
127]. The model was tuned to correlate with reference measurements carried out in a 
homogenous water phantom [104]. The MC simulations of absorbed dose to the patients 
were carried out by the use of DOSXYZnrc. Voxalized MC phantoms were created via the 
CTC-ask conversion algorithm using each patient’s planning CT and DICOM structure set 
as input [128]. The voxel sizes were expanded to match the CT scan grid. Backscatter 
corrections were simulated for each field using the formalism described by Popescu et 
al.[129]. This correction has further been verified by Sibolt et al. [130]. A set of in-house 
MATLAB scripts were used to generate input files from each patient’s DICOM RP files. 
These generated input files together with the voxalized phantom and the BEAMnrc-
simulated phase space files were used to simulate the absorbed dose to each patient in 
DOSXYZnrc. The selected number of simulated histories (2×10
8
 - 4×10
8
 histories) resulted 
in an estimated statistical uncertainty of about 1% (ranging between 0.57% and 1.23%) in 
the high dose area. All absorbed doses were reported as dose-to-water, to mimic the 
reported absorbed doses in the TPS. The procedure described by Siebers et al. [94] to 
convert MC simulated dose-to-media into dose-to-water was employed. The resulting 3D 
dose distributions were converted into DICOM RD files using CERR [131] and 
subsequently imported into the Eclipse TPS to generate dose volume histograms (DVHs).  
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10.2.7 Data analysis 
Dose characteristics and volume data for the GTV, CTV, PTV, total lung, healthy lung, 
medulla, and esophagus were extracted for FB and DIBH treatment plans calculated with 
AAA and MC. The conformity index (CI), the lesion coverage fraction (LCF), and the 
normal tissue overdosage fraction (NTOF) were additionally calculated for the 95% 
isodose according to Van Esch et al. [78]. These indexes can be utilized to evaluate the 
quality of the treatment plan in terms of target dose coverage and spread of high dose to 
adjacent healthy tissue. In brief, the CI95 is defined as the 95% isodose volume relative to 
the size of PTV. The LCF95 measures the fraction of PTV that is covered by the 95% 
isodose volume, i.e. a measure for target underdosage. The NTOF95 measures in a similar 
way the fraction of the 95% isodose volume that is outside the PTV. Thus, NTOF is a 
method to quantify the relative amount of high dose (i.e. in our case dose over 95% of the 
prescribed dose) delivered outside of the PTV. Ideal target coverage is characterized by a 
CI and LCF close to unity, and a NTOF approaching zero. CI assesses only the relative 
size of the isodose volume without respect to target location. The LCF and NTOF allows 
for more detailed quality quantification. Patient-specific paired percentage differences 
between FB and DIBH for the both calculation algorithms were calculated for each patient, 
and for all investigated dose characteristics and treatment plan quality indexes. 
For statistical analysis MATLAB including the Statistics Toolbox version 8.3 (R2013b) 
(The MathWorks, Natick, MA) was utilized. Wilcoxon signed rank test for non-parametric 
paired data was carried out to compare the medians of the data sets. The results were 
considered statistically significant for p < 0.05. 
10.3 Results 
All patients complied with the gating technique and were able to hold their breath within 
their patient-specific gating window and amplitude level long enough to acquire a full 
DIBH CT image. The median and range of the gating amplitude levels, breath-hold times 
to acquire the DIBH CT images, and CT beam-on times to acquire the DIBH CT images 
were 14.3 mm (10.5; 25.3) mm, 16.4 s (13.3; 19.3) s, and 10 s (9.0; 11.9) s, which resulted 
in a median duty cycle of 61.1%. 
10.3.1 Dose volume histogram 
On the left hand side of Figure 30 each patient’s cumulative DVH simulated by MC for FB 
and DIBH is illustrated. Compared to DIBH treatment plans, a larger amount of FB 
treatment plans did not comply with the applied dose constraints indicated by the black 
markers in the figure, especially for the total lung and esophagus. 
On the right hand side of Figure 30 the median of the MC and corresponding AAA 
calculated DVHs are presented. The MC simulations reveal considerable under- and over-
dosage of the planning target volume compared to AAA. For the OARs, a larger amount of 
low dose is delivered in the MC simulated treatment plans compared to AAA, especially 
for the OARs closely situated to the low-density lung-tissue. Hence, this is not observed 
for the medulla at low doses. On the contrary, the volume of medulla receiving high dose 
is increased for the MC simulations, where the maximum dose increased by 10% in MC 
compared to AAA (Figure 30, Table 14).  
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10.3.2 Organs at risk 
The presented volume and DVH data in Table 14 are the median values and ranges or 
standard deviations (SDs) of the paired data for all 18 patients. The paired volume and 
dose constraint data of the OARs for each patient are additionally illustrated in Figure 31. 
The MC simulations imply that the doses to all the OARs are higher in reality compared 
to the doses calculated by AAA (Figure 31, Table 14), applicable for both FB and DIBH. 
Paired statistically significant differences between the AAA and MC algorithms were 
observed for all dose constraints of the OARs (Table 14). Compared to AAA, the largest 
increases in delivered mean and maximum doses were observed for the heart. The MHD 
and maximum heart doses increased in median about 31% and 17%, respectively in FB, 
and 46% and 48%, respectively in DIBH, for the MC simulated treatment plans, compared 
to AAA. 
In favor of DIBH, statistically significant differences in volume and delivered doses 
(for both AAA and MC calculations) between FB and DIBH were obtained for all OARs 
(except the healthy lung and the esophagus) (Table 14, Figure 31). In DIBH, the total lung 
volume increased substantially for all patients, by a median increment of 86.8% (37.1; 
167.5)%. This caused the MLD to reduce in median by 18.1% (4.5; 39.3)% (MC) and 
20.4% (2.9; 41.8)% (AAA). DIBH additionally reduced the total lung V20Gy in median by 
19.9% (4.7; 43.1)% (MC), which was comparable with the AAA calculations, 20.0% (4.8; 
44.3)%. For the V5Gy constraint (which is a measure for the low dose bath in a treatment 
plan) there was a larger reduction during DIBH for the MC simulations, 11.6% (-11.2; 
25.9)%, compared to the AAA calculations, 9.0% (-14.4; 26.4)%. An example of large 
increment in total lung volume is presented for patient 7 in Figure 32. Various blurry 
motion image artifacts are clearly observed in the FB image set, especially in the 
diaphragm area, while the density of the lung parenchyma has been decreased and the 
tumor edges has become clearer in the DIBH image set.  
10.3.3 Target coverage 
The paired dose constraint data of the target dose coverage for each patient is illustrated in 
Figure 33. No statistically significant difference between FB and DIBH data was found in 
terms of dose coverage constraints of GTV, CTV, and PTV (Table 14, Figure 33) (except 
for the maximum dose delivered to the PTV, where DIBH resulted in higher maximum 
dose), applicable for both AAA and MC. Similarly, no statistically significant difference 
was discovered between FB and DIBH for the treatment plan quality indexes; CI, LCF, 
and NTOF (except for the LCF (which is a measure of the target underdosage) simulated 
by MC, where DIBH resulted in about 1% lower LCF, compared to FB). 
The MC simulations indicate statistically significant under- and overdosage of the 
GTVs, CTVs, and PTVs compared to the AAA calculations (Table 14, Figure 33). This 
was additionally identified by the LCF index, where the MC simulated treatment plans in 
median were about 1% lower compared to AAA treatment plans, independent of breathing 
technique (Table 14). The NTOF index (which is a measure for high dose overdosage 
outside of the PTV) did not indicate any difference in overdosing outside of PTV, neither 
between FB and DIBH or between AAA and MC treatment plans. The maximum dose and 
D2% of the PTV simulated by MC were similar for FB and DIBH, and were in median 
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about 8% and 4% higher, compared to AAA calculations (Figure 33, Table 14). On the 
contrary, the MC simulated minimum doses of the PTV were in median 9.1% (3.2; 31.5)% 
lower in FB, and 12.0% (4.8; 18.8)% lower in DIBH, compared to AAA (Figure 33, Table 
14). The D98% was, regardless of FB or DIBH, about 3.5% lower in median for MC, 
compared to AAA calculations (Figure 33, Table 14). Similarly, the MC simulated D99% of 
the GTV and CTV were about 5% lower for AAA calculated treatment plans, 
independently of FB or DIBH (Figure 33, Table 14). 
10.4 Discussion 
Breathing adapted radiotherapy can diminish the challenge of respiratory motion in lung 
cancer radiotherapy. There exist preconceptions about the impracticability to perform 
DIBH for lung cancer patients due to comorbidities, such as chronic obstructive pulmonary 
disease (COPD) or poor pulmonary functionality. However, all 18 locally advanced 
NSCLC patients enrolled in this study complied with the gating technique, and were able 
to acquire a full DIBH CT image in one single breath-hold. 
This study confirms the dosimetric advantage of DIBH, compared to FB, for locally 
advanced lung cancer patients by MC simulations of complex IMRT and VMAT treatment 
plans. However in comparison with AAA, the MC simulations revealed considerable 
under- and overdosage of the target, and higher doses delivered to the OARs, especially a 
higher maximum dose to the medulla, heart and esophagus (Table 14). 
10.4.1 Comparison with other clinical dose calculation studies 
In agreement with the study by Giraud et al. [118], the target dose coverage was found to 
be identical between FB and DIBH. The Giraud study however, applied smaller CTV-PTV 
margins for the DIBH treatment plans, while those margins were unaltered in the current 
study. For DIBH, the increased total lung volume of about 87% in median is in accordance 
with the study by Rosenzweig et al. [119], while Josipovic et al. [122] reports an average 
lung volume increase of about 60%. All 18 DIBH treatment plans in the current study were 
well below the V20% constraint for the total lung volume and in favor of DIBH (Table 14, 
Figure 30 - Figure 31). The current study indicates a reduction of about 22% for V20% 
during DIBH compared to FB, for both AAA and MC calculations (Table 14, Figure 31). 
The study by Josipovic et al. [122] found a corresponding reduction in V20% of about 15% 
for more simple static field techniques. The study by Tahir et al. [121] evaluated moderate 
inspiration breath-hold gating against expiration gating by a spirometric system. In favor of 
inspiration, they found a reduction of only 2.5% for the V20%. Their result is due to the 
smaller lung volume obtained in moderated inspiration breath-hold, compared to DIBH. 
The MLD of the current study was reduced by 20.4% (AAA) and 18.1% (MC) for complex 
treatment plans in DIBH (Table 14). The study by Josipovic et al. [122] found that the 
MLD only was reduced about 16% for their more simple static treatment technique. In 
comparison with the current study, where the heart volume decreased about 24% during 
DIBH (Table 14), no significant reductions of the heart volume were reported by 
Marchand et al. [120]. They did however utilize a spirometric control for the DIBH 
procedure and treated with conventional static fields. Giraud et al. [118] found significant 
benefit of DIBH for the esophagus. This observation was not supported in the current 
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study, which probably was due to the more complex treatment techniques carried out, 
compared to their study. 
The major benefit with DIBH is the possibility to better spare OARs from radiation, 
compared to FB. The DIBH procedure is however a more resource intensive treatment 
technique, in terms of requirement of more personnel, longer simulation and treatment 
times, extra time slots for patient-specific training sessions, etc. It would therefore be 
advantageous if patients could be sorted prior to treatment planning, identifying those with 
potential benefit from DIBH-based treatment. Sorting criteria could include patient size 
and tumor location, tumor size and proximity to other structures, etc. However, this is out 
of the scope for this study and the subject of future investigations. Nevertheless, the study 
by Josipovic et al. [132] identified two NSCLC cases that did not benefit from DIBH, and 
they decided to treat in FB instead. The first patient had two targets situated close to each 
other, but they separated during DIBH. This resulted in increased PTV, MLD and V20%. 
The second patient’s setup verification cone beam CT revealed inter-fractional variation of 
the tumor position, despite good reproducibility of the external surrogate breathing signal. 
Thus, if clinically implementing DIBH, daily soft-tissue visualization and verification of 
the tumor position in three dimensions is recommended. Additionally, it is most likely 
necessary to perform dual-treatment planning, in both FB and DIBH, as a treatment backup 
if the patients’ health gets worse during the course of treatment, where they can no longer 
proceed with DIBH. 
10.4.2 Comparison with other Monte Carlo studies 
There are several fundamental differences on how the AAA and MC algorithms calculate 
absorbed dose in the patients. Some affecting factors of the observed differences between 
AAA and MC may be; (i) the statistical uncertainty of the MC simulations, and (ii) the 
conversion from dose-to-media to dose-to-water, (iii) both the AAA and MC models are 
based on measurements carried out using open fields in homogeneous water setups, (iv) 
the PTVs are situated in critical build-up and build-down areas where the discrepancies 
between AAA and MC are anticipated to be the largest. 
The dosimetric issues with AAA in heterogeneous volumes are clearly illustrated, 
especially for the low dose areas of the OARs and for the target dose coverage of the PTV 
(Figure 30). For the target dose coverage, the dose build-up and build-down is not 
correctly calculated by the AAA algorithm since the target is embedded in, and/or situated 
close to low-density lung-tissue. 
The optimization processes in Eclipse are carried out in several steps. The inverse 
planning module does not make use of AAA but uses its own simplified dose calculation 
algorithm, which is faster but less accurate, compared to AAA [88,133]. The final dose 
distribution is eventually calculated by a more accurate dose calculation algorithm, e.g. in 
our case AAA. The study by Mihaylov and Siebers [133] conclude that the optimization 
convergence error from the inverse optimization process could contribute with up to 5% 
dose prediction errors if changed to a fully integrated MC optimization process for head-
and-neck cases. Our posture is that this error could be even larger for lung cancer cases due 
to the low-density heterogeneous nature of the lung region. Thus, with a fully integrated 
MC optimization process the sparing of dose to the OARs could be further improved. 
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However, it is then important to decide whether or not the prescribed dose and the applied 
dose constraints should remain unaltered. There is a potential risk if implementing MC for 
clinical use since all clinical survival data and radiation response data are based on less 
correct dose calculation algorithms. In that case a thorough MC benchmarking process 
against a less accurate calculation algorithm needs to be conducted. 
It was expected that the target dose coverage for the AAA calculations should not 
deviate between FB and DIBH, since each treatment plan was designed and optimized to 
be clinically acceptable in terms of target dose coverage. Thus, did not the median PTV 
dose decrease as the lung density decreased, contradictory to the study by Aarup et al. [91]. 
Additionally, compared to FB, there was no statistically significant difference in the 
number of monitor units delivered in DIBH when an identical dose to the tumor was 
prescribed. One reason for this could be that the same maximum number of monitor units 
was utilized as a constraint during the optimization processes for both FB and DIBH 
treatment plans. Yorke et al. [102] states that there should be expected a discrepancy in 
target dose coverage between FB and DIBH for the MC simulated treatment plans because 
of the lower electron densities in the CT images for DIBH. This is not supported in the 
current study, since no statistically significant discrepancy in target dose coverage between 
FB and DIBH was observed for the MC simulated treatment plans (Table 14, Figure 30, 
Figure 33) (except for the maximum dose delivered to the PTV, and the LCF for MC). 
These findings could be related to the more correct convolution-superposition dose 
calculation algorithm, i.e. AAA, and the more complex treatment techniques, i.e. IMRT 
and VMAT, utilized in this study compared to the study by Yorke et al. [102]. The 
simplified pencil beam based algorithm used in their study to generate treatment plans did 
not take into account the changes of lateral electron scatter in media other than water. 
Moreover, the MC algorithm does not distinguish between the lung-tissue in the FB and 
DIBH images, in terms of different interaction cross-sections. 
There was however detected noticeable disagreement between MC and AAA target 
dose coverage, irrespective of breathing technique (Table 14, Figure 30, Figure 33). In 
accordance with Yorke et al. [102], the current study identified about 3.5% underdosage of 
the PTV (i.e. D98% constraint) for the MC simulated dose, where the dose was reduced near 
the lung/soft-tissue interface. In contrast, they did not identify any overdosage of the PTV, 
while the current study found about 4% higher D2% in median for MC, compared to AAA. 
Yorke et al. [102] reports no significant difference between MC and standard treatment 
planning for the lung and spinal cord. This is in accordance with the current study, except 
for the larger amount of low dose delivered to the OARs in MC compared to AAA (not 
applicable for the medulla) (Figure 30). VMAT and IMRT treatment plans are more 
conform but deliver a larger amount of low dose to the patient volume, compared to 
conventional static treatment planning [122]. Because of the use of VMAT and IMRT and 
the known calculation problem of low dose scatter in AAA, the issue of extra low dose 
delivered to the OARs is emphasized in the current study for the MC simulations. It should 
moreover be pointed out that the MC uncertainties increase for low doses. 
In addition, MC yields a broader penumbra, compared to AAA, in low-density tissue 
where the ranges of secondary electrons increase. This matter is not correctly accounted 
for in AAA, where largest discrepancies are found at the interfaces between two media of 
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various densities. This issue is therefore especially reflected in the lower dose delivered at 
the edges of the PTV situated closely to the low-density lung-tissue (Figure 30). The 
matter is additionally reflected in the relative larger volume of the OARs receiving an 
increased amount of low scattered dose, compared to the AAA calculations (Figure 30). 
This is especially emphasized for the OARs closely situated to the low-density lung-tissue 
and air-cavities of esophagus, thus not affecting the medulla. Hanley et al. [134] concluded 
that the broader penumbra had little clinical effect in DIBH, especially if several treatment 
fields are used, as for IMRT and VMAT. 
10.5 Conclusion 
Although the IMRT and VMAT treatment plans are created using a simplified 
convolution-superposition dose calculation algorithm (i.e. AAA), more accurate MC 
simulations confirms that DIBH is advantageous over FB for locally advanced NSCLC 
patients, in terms of reducing undesired dose to the OARs, and still keep the target dose 
coverage unchanged. However, the MC simulated dose distributions revealed inferior 
target dose coverage, equally in both FB and DIBH, compared to AAA calculated 
treatment plans. Consequently, this issue is related to the treatment planning algorithm 
rather than the utilized breathing technique. The treatment planning may be improved if 
using a fully integrated MC optimization and dose calculation system. Care should 
however then be taken if clinically implemented, because all clinical radiation response 
data are based on old, less accurate dose calculation algorithms. 
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10.6 Figures 
 
Figure 30. The cumulative DVHs for the PTV, total lung, healthy lung, heart, medulla, and 
esophagus. FB and DIBH are characterized by red and blue colors, respectively. To illustrate 
the spread of the DVHs for all 18 patients, the DVHs on the left hand side in the figure are only 
the MC calculated ones. Each thin line represents the MC DVH for one patient, where FB and 
DIBH DVHs are indicated by light red and light blue colors, respectively. The thick red and 
blue lines in the figure represent the median MC calculated DVHs of FB and DIBH, 
respectively. The dashed thick lines depicted in the DVHs on the right hand side in the figure 
illustrate the corresponding median of the AAA calculated cumulative DVHs. The black 
markers represent the dose constraint applied for that specific organ during treatment planning. 
Color version of figure is available online. 
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Figure 31. The FB relative to DIBH distributions of the volume and dose constraint for the organs at 
risk; medulla, heart, esophagus, healthy lung, and total lung for the MC and AAA calculated 
treatment plans. Each marker represents one patient. If the markers are situated exactly on the black 
line there is no difference between FB and DIBH doses. DIBH is in favor if the markers are situated 
below the black line. Correspondingly, FB is in favor if the markers are situated above the black 
line. A shift between the patients’ blue (MC) and red (AAA) markers indicate that there is a 
calculation difference between the two calculation algorithms. The volume and dose constraints 
were as follow; Medulla: Dmax  ≤ 45 Gy = 68.18% (relative dose); Heart: V50Gy ≤ 20% (relative 
volume); Esophagus: V55Gy ≤ 30%; Healthy lung: V5Gy  ≤ 40%;  Total lung: V5Gy  ≤ 60% and V20Gy  ≤ 
35%. Markers that are situated at doses higher than these dose constraints are not theoretically 
clinically acceptable. The MC calculations are considered as golden standard. Color version of 
figure is available online. 
 
 99 
 
  
  
  
Figure 32. Coronal (A), sagittal (B), and transversal (C) slices of the CT scan for patient 
number 7. On the left hand side is the FB image set, and on the right hand side is the DIBH 
image set. For this patient, the total lung volume increased by 167% in DIBH. 
A 
B 
C 
Paper III - Figures 
100 
 
 
Figure 33. The FB relative to DIBH distributions of the target dose coverage dose constraint of the 
GTV, CTV, and PTV for the MC and AAA calculated treatment plans. Each marker represents one 
patient. The dose constraints were as follow; GTV: D99% ≥ 95% (relative dose); CTV: D99% ≥ 95%; 
PTV: D98% ≥ 95%; D2% ≤ 107%; Dmax ≤ 110%. Markers that do not fulfill these dose constraints are 
not theoretically clinically acceptable. Additional figure explanations are described in Figure 31. 
Color version of figure is available online. 
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10.7 Tables 
Table 13. Summary of patient characteristics. 
Patient characteristics 
Number of patients (%) 
or median (min;max) 
Median Age 63 (48;75) 
Gender  
 Male 12 (67%) 
 Female 6 (33%) 
Performance Status  
 0 17 (94%) 
 1 1 (6%) 
Differentiating grade  
 Adenocarcinoma 12 (67%) 
 Planocellular carcinoma 5 (27%) 
 Large cell neuroendocrine carcinoma 1 (6%) 
T-stage  
 1 2 (11%) 
 2 2 (11%) 
 3 7 (39%) 
 4 7 (39%) 
N-stage  
 0 3 (17%) 
 1 3 (17%) 
 2 8 (44%) 
 3 4 (22%) 
M-stage  
 0 18 (100%) 
Tumor Location  
 Upper lobe/middle lobe 15 (83%) 
 Lower lobe 3 (17%) 
Primary tumor site  
 Central 9 (50%) 
 Peripheral 3 (17%) 
 Chest wall 4 (22%) 
 Central/Chest wall 2 (11%) 
Mediastinal involvement  
 Tumor 1 (6%) 
 Lymph node 5 (28%) 
 Tumor and lymph node 10 (55%) 
 No involvement 2 (11%) 
 
Paper III - Tables 
102 
 
 
Table 14. Median dose characteristics for FB and DIBH treatment plans calculated with AAA 
and MC dose calculation algorithms. Patient-specific paired percentage differences between 
FB and DIBH for the both calculation algorithms were calculated for each patient, which are 
presented as the median and standard deviation (SD). Bold style indicates statistically 
significant paired difference between FB and DIBH for the AAA and MC calculations, 
respectively. Underline style of the MC calculated median values indicate statistically 
significant paired difference between MC and corresponding AAA calculations. Statistical 
testing was performed with paired Wilcoxon signed rank tests with a two tailed significance 
level of 0.05.  
 AAA MC 
 FB DIBH %-Diff. FB DIBH %-Diff. 
Structure Median (range) Median (range) Median (SD) Median (range) Median (range) Median (SD) 
PTV  
 volume (cm
3
) 557  (185;1377) 501  (145,1349) 
 
-8.7  (5.8) 
      
 mean dose (Gy) 66.0 (66.0,66.2) 66.0 (66.0, 66.0) 0.0  (0.1) 66.0 (65.5,67.2) 65.9 (65.4,66.6) -0.1  (0.4) 
 max dose (%) 105.4 (104.1,117.1) 107.1 (104.7,110.4) 1.0  (5.2) 113.7 (112.0,125.5) 115.8 (113.1,123.3) 1.1  (3.2) 
 min dose (%) 84.6 (51.1,93.4) 85.9 (63.0,91.9) 1.7  (17.9) 76.0 (36.5,84.8) 77.2 (55.5,85.9) -1.1 (26.2) 
 D98% (%) 96.1 (88.6,97.9) 95.7 (91.6,97.8) -0.2  (1.2) 92.6 (88.5,95.1) 92.4 (89.2,93.5) -0.3  (1.0) 
 D2% (%) 102.6 (101.9,106.8) 103.0 (102.1,105.2) 0.3  (0.6) 107.3 (105.9,109.8) 107.4 (106.3,109.0) 0.4  (0.7) 
 CI 1.22  (1.05,1.58) 1.19  (1.03,1.59) -2.0  (9.5) 1.22  (1.03,1.55) 1.18  (1.00,1.57) -2.9  (10.5) 
 LCF 0.98  (0.88,1.00) 0.98  (0.91,1.00) -0.1  (1.5) 0.98  (0.90,1.00) 0.97  (0.89,0.99) -1.0  (1.8) 
 NTOF 0.18  (0.04,0.36) 0.14  (0.04,0.37) -7.2 (36.1) 0.18  (0.04,0.35) 0.14  (0.03,0.36) -4.5 (35.0) 
CTV 
 volume (cm
3
) 352  (89,1064) 334  (68,1043) 
 
-10.2  (6.8) 
      
 D99% (%) 97.8 (93.1,98.3) 97.5 (96.2,98.1) -0.2  (1.0) 92.7 (91.7,95.4) 92.7 (91.7,94.1) 0.0  (0.6) 
GTV  
 volume (cm
3
) 212  (29,806) 185  (20,791) 
 
-14.8 (9.5) 
      
 D99% (%) 98.1 (96.3,99.2) 98.1 (96.7,99.0) -0.1  (0.6) 92.9 (91.5,95.6) 92.9 (91.4,94.9) 0.0  (0.7) 
Total lung  
 volume (cm
3
) 3212  (1725,4601) 5918  (3036,8133) 86.8 (31.9) 
      
 mean dose (Gy) 14.0 (8.2,23.4) 11.6 (7.3,17.2) -20.4  (9.2) 14.7 (9.2,23.8) 12.4 (8.4,17.4) -18.1  (8.3) 
 V5Gy (%) 45.8 (31.0,64.3) 43.4 (24.5,59.7) -9.0  (10.2) 51.5 (33.1,67.0) 44.0 (27.0,61.9) -11.6 (9.3) 
 V20Gy (%) 23.5 (12.3,36.1) 18.6 (11.0,30.2) -20.0  (9.8) 24.0 (12.4,36.7) 19.1 (11.1,30.2) -19.9  (9.6) 
Healthy lung 
 V5Gy (%) 32.0 
 
(5.8,56.1) 34.3 
 
(3.2,59.2) 
 
0.1 (5.8) 36.5 (9.1,59.0) 37.4 (5.7,62.1) 0.0 (4.9) 
Medulla  
 volume (cm
3
) 17  (9,29) 22  (11,31) 
 
21.4  (34.1) 
      
 max dose (Gy) 41.0 (24.8,44.0) 39.2 (18.5,44.5) -2.4 (12.1) 45.4 (28.2,48.7) 43.0 (22.5,49.5) -3.9 (9.8) 
 mean dose (Gy) 21.4 (6.4,32.8) 18.1 (6.2,27.2) -15.9  (14.4) 21.4 (7.4,33.2) 18.3 (7.1,27.4) -16.5 (13.3) 
Heart  
 volume (cm
3
) 765  (501,1137) 563  (386,908) 
 
-23.7 (10.8) 
      
 mean dose (Gy) 3.4 (0.7,30.9) 2.6 (0.3,29.1) 25.5  (21.2) 4.4 (2.3,31.0) 3.8 (2.2,29.4) -12.6  (12.8) 
 max dose (Gy) 67.5 (4.1,71.2) 46.9 (1.0,71.8) -8.9  (67.3) 70.6 (6.9,77.3) 51.1 (4.7,75.5) -10.2  (54.6) 
Esophagus    
 volume (cm
3
) 30  (16,53) 25  (4,51) 1.9  (29.2) 
      
 mean dose (Gy) 18.1 (10.2,39.8) 19.4 (7.1,32.0) 0.0  (20.5) 18.6 (11.0,40.4) 19.8 (7.8,32.4) 0.5  (19.5) 
 max dose (Gy) 67.2 (35.0,70.4) 67.7 (32.7,71.3) -0.1  (5.5) 72.2 (39.6,75.7) 72.7 (38.8,75.9) 0.6  (6.3) 
AAA, Anisotropic-Analytical-Algorithm; MC, Monte Carlo; FB, free-breathing; DIBH, deep-
inspiration breath-hold; %-Diff., percentage difference; PTV, planning target volume;  D98% 
and D2%, percentage dose delivered to 98% and 2% of the PTV, respectively; CI, conformity 
index; LCF, lesion coverage fraction, NTOF, normal tissue overdosage fraction; CTV, clinical 
target volume; GTV, gross tumor volume; D99%, percentage dose delivered to CTV and GTV, 
respectively; V5Gy, V20Gy, V45Gy, V50Gy, V55Gy, percentage of an organ volume 
receiving at least 5Gy, 20Gy, 45Gy, 50Gy, 55Gy, respectively.  
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11 Paper IV  
Dose verification of radiotherapy for lung cancer by using plastic scintillator dosimetry 
and a heterogeneous phantom 
Paper IV was presented at the 8
th
 International Conference on 3D Radiation Dosimetry 
(IC3DDose), 4-7 September, 2014 in Ystad, Sweden. The work is published in the Journal 
of Physics: Conference Series 573 (2015) 012022. An in-house designed thorax phantom is 
used for scintillator dosimetry in homogeneous and heterogeneous setups, mimicking a 
lung cancer patient. Clinical relevant treatment plans of different complexities were 
measured and compared to calculations carried out using a commercial treatment planning 
system using the AAA algorithm.  
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Dose verification of radiotherapy for lung cancer by 
using plastic scintillator dosimetry and a heterogeneous 
phantom 
W Ottosson
1,2
, CF Behrens
2
, and CE Andersen
1
 
1Center for Nuclear Technologies, Technical University of Denmark, DTU Risø Campus, 
DK-4000 Roskilde, Denmark 
2Department of Oncology, Radiotherapy Research Unit, Herlev Hospital, University of 
Copenhagen, DK-2730 Herlev, Denmark 
E-mail: wiot@dtu.dk 
Abstract Bone, air passages, cavities, and lung are elements present in patients, but 
challenging to properly correct for in treatment planning dose calculations. Plastic 
scintillator detectors (PSDs) have proven to be well suited for dosimetry in non-reference 
conditions such as small fields. The objective of this study was to investigate the 
performance of a commercial treatment planning system (TPS) using a PSD and a 
specially designed thorax phantom with lung tumor inserts. 10 treatment plans of 
different complexity and phantom configurations were evaluated. Although the TPS 
agreed well with the measurements for the least complex tests, deviations of tumor dose 
> 4% were observed for some cases. This study underpins the dosimetric challenge in 
TPS calculations for clinically relevant heterogeneous geometries. The scintillator 
system, together with the special phantom, provides a promising tool for evaluation of 
complex radiotherapy dose calculations and delivery.  
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11.1 Introduction 
Fiber-coupled organic plastic scintillator detectors (PSDs) feature advantages suitable for 
complex and dynamic radiation dosimetry in megavoltage photon beams [96–98]. When it 
comes to heterogeneous setups with lack of charged particle equilibrium (CPE), there are 
recognized calculation challenges for most commercial treatment planning systems (TPSs). 
Thus, volumes containing bone, air passages, cavities and lung may deteriorate the TPS 
dose calculation accuracy [83,93].  
The objective of this study was to investigate the performance of a TPS dose 
calculation algorithm by using a PSD in a heterogeneous setup, analogous to the geometry 
of a lung cancer patient, while delivering clinical relevant treatment plans of varying 
complexity. 
11.2 Material and methods 
11.2.1 Phantom design 
A thorax phantom, analogous to a lung cancer patient, was constructed to perform PSD 
dosimetry in a well-defined heterogeneous geometry. The body of the phantom is made of 
PMMA, 34 cm in width (W), 23 cm in height (H) and 40 cm in length (L) (Figure 34). It 
contains three hollow cylinders of L: 50 cm, and a diameter (Ø) of 10 cm. These cylinders 
can be filled with several inserts of various materials to simulate different homo- and 
heterogeneous geometries.  
   
Figure 34. (a) A heterogeneous setup where the two lateral body cylinders are filled with balsa 
wood inserts. (b) A homogeneous setup, where the whole phantom are filled with PMMA 
inserts. (c) The heterogeneous setup described in (a) viewed from the side, where the lateral 
body cylinder containing the lung insert is longitudinal shifted from the central position in the 
phantom. (d) Balsa wood lung insert with associated tumors, ranging from 1-8 cm in diameter. 
(Color version of figure is available online.) 
The various inserts are made of the copolymer Polyoxymethylene (POM-C), balsa 
wood, and PMMA representing bone, lung and soft tissue, respectively (Figure 34, Table 
15-Table 16). The lung inserts were 15 cm long with a Ø of 9 cm, mimicking a human 
lung in size. PMMA spheres of various sizes (1-8 cm in diameter) embedded in balsa wood 
are available to simulate tumors in lung (Figure 34 (d)). In the lower part of the body, two 
smaller cylindrical holes of Ø: 2 cm and Ø: 3 cm (which also can be altered to Ø: 2 cm) are 
positioned at different distances from the phantom center, i.e. 6.5 cm and 9.5 cm (Table 
a c d 
b 
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16). These holes can, one at a time, be filled with a POM-C rod to simulate the spinal 
column at different diameters and position from the center of the phantom (Table 16). 
11.2.2 Image acquisition and target definition 
Four phantom configurations (‘Homo.’, ‘Hetero.’, ‘3 cm tumor’ and ‘5 cm tumor’) 
scanned in a 16 slice Philips Brilliance CT Big Bore, version 3.5.17001 (Philips Medical 
Systems, Cleveland, OH) using a standard thorax scanning protocol were used in this study 
(illustrated in Table 16). Table 15 presents the CT image characteristics of the phantom 
materials of 10 CT series of the phantom compared to corresponding human tissue data for 
10 randomly picked lung cancer patients.  
Table 15. CT image characteristics of the phantom materials compared to human tissue. Mean HU 
values and (range) for 10 CT series of the phantom and corresponding tissue data for 10 randomly 
picked lung cancer patients. Paired t-tests were performed for each tissue type, to check for 
differences in the mean HU value between the phantom material and the patient tissue data. No 
significances were found, using p < 0.05, i.e. there are good agreement between human tissue and 
the phantom materials. 
 
Tissue 
Phantom Material HUb  
  Density / [g/cm3] Phantom Patients  
 Bone  POM-C 1.40 319 (309;327) 313 (210;413)  
 Lung  Balsa wood 0.10 -913 (-917;-888) -901 (-977;-770)  
 Soft tissue PMMAa 1.18 116 (103;123) 118 (84;143)  
 a.Poly(methyl methacrylate)  
b.Using a standard thorax CT scanning protocol by Philips. 
 
Delineations of the anatomical structures GTV, CTV, PTV, medulla, lung and body 
were performed on all image sets in the treatment planning system (TPS) Eclipse v. 10 
(Varian Medical Systems, Palo Alto, CA, USA). CTVs and PTVs were defined as a 5 mm 
and 10 mm symmetrical expansion of GTV, respectively. 
11.2.3 Experimental setup and calibration conditions 
The scintillator used was the BCF-60 (Saint-Gobain Ceramics & Plastics Inc.) with Ø:1 
mm and L:2 mm, described by Beierholm et al. [97]. The PSD was calibrated according to 
the procedure (method C) described by Guillot et al. [100] in a solid water calibration 
phantom. Measurements were carried out using the ME40 scintillator dosimetry system 
(DTU Nutech) [98]. The reference dose (100 MU, 10×10 cm
2
 field) was measured by a 
Farmer ionization chamber, type 30011 (PTW, Freiburg, Germany) at a depth of 10 cm in 
the PMMA phantom QUASAR Multi-Purpose Body Phantom (Modus Medical Devices 
Inc., London, ON, Canada). Irradiation was delivered by a Varian Clinac iX 2300 linear 
accelerator (Varian Medical Systems), with a beam energy of 6 MV at a dose rate of 600 
MU/min [85]. The accumulated PSD dose for the various treatment plans were compared 
with corresponding TPS calculated point doses (Table 16). 
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Table 16. TPS calculated isocentric point doses compared with corresponding PSD measured 
dose. (Color version of ﬁgure is available online). 
Isocenter is positioned in the center of 
the phantom 
 Fiber dose 
[Gy] 
TPS dose 
[Gy] 
Dose deviation 
[%] 
Homo. setup Hetero. setup  Homo. Hetero. Homo. Hetero. Homo. Hetero. 
  Conv. 
2.001 2.005 2.000 2.000 -0.1 -0.3 
  
2.005 2.006 2.000 2.000 -0.3 -0.3 
  
RA 1.976 1.953 1.984 1.965 0.4 0.6 
Isocenter is shifted laterally 11 cm 
 
3 cm 
tumor 
5 cm 
tumor 
3 cm 
tumor 
5 cm 
tumor 
3 cm 
tumor 
5 cm 
tumor 3 cm tumor 5 cm tumor 
  
Conv. 2.114 2.083 2.000 2.000 -5.4 -4.0 
  
RA 2.323 2.203 2.268 2.175 -2.4a -1.3 
a. The dose deviation per arc was as large as -7.6%. 
11.2.4 Treatment plans and delivery 
In total, 10 treatment plans of different phantom configurations and isocentric field 
techniques (single field, 4-field conventional and two-arc Rapid Arc (RA) plans) were 
created. For each treatment plan the isocenter was positioned in the center of the GTV. For 
six treatment plans the isocenter was positioned centrally in the phantom. Three of these 
had a homogenous setup (Figure 34 (b), Table 16), and three of them had a heterogeneous 
setup (Figure 34 (a), Table 16). For the remaining four treatment plans the isocenter were 
shifted 11 cm laterally, because the GTVs were situated in the left lung of the phantom 
(Table 16). Doses were calculated using the AAA algorithm, with a prescribed dose of 2 
Gy to the PTV. The RA plans were normalized to the mean dose of the PTV, while the 
other plans were normalized to the isocenter. All treatment plans satisfied the clinical dose 
coverage criteria. For the tumors situated in the lung 98% of the PTV volume was covered 
by minimum 90% of the prescribed dose. For the treatment plans not situated in the lung 
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the corresponding dose coverage was 95%. The beam energy and dose rate used were 6 
MV and 600 MU/min, respectively. 
11.3 Results/Discussion 
Under calibration conditions the PSDs agreed with the TPS calculations to 0.1%. 
Deviations less than 1% were observed between calculated and measured doses when 
the isocenter was located in the middle of the phantom. For the homogeneous 
configuration, deviations were in the range of (-0.1%; 0.4%) and for the heterogeneous 
configuration, deviations were in the range of (-0.3%; 0.6%) (Table 16). The RA plans 
generally resulted in larger total dose deviation (0.4%; 0.6%) compared with the simple 
conventional techniques (-0.3%; -0.1%). These low discrepancies, for the centrally 
positioned point in the phantom, probably illustrate that there is enough distance to 
adjacent heterogeneities in the phantom to be able to establish CPE. Larger TPS dose 
deviations (-5.4%; -1.3%) were observed when the isocenter was shifted laterally, since the 
GTV was situated in the left lung of the phantom. These substantial deviations could 
potentially be due to lack of sufficient spread of lateral radiation to obtain CPE. Even 
larger dose deviations (-5.4%; -2.4%) were observed for the smallest tumor size 
investigated (3 cm in diameter). This small size of tumor is not large enough to re-establish 
the CPE condition, and this is most likely the reason why the smallest tumor size results in 
the highest dose deviation. For the laterally shifted phantom configuration, the simple 
conventional technique resulted in a higher total dose deviation (-5.4%; -4.0%) compared 
to the more complex RA (-2.4%; -1.3%). The lower dose deviation, when using RA, might 
be due to the spread of incident radiation over the whole phantom compared to limited 
incident angles through heterogeneous medium, when using conventional technique.  
11.4 Conclusion 
Dose deviations of < 1% were observed for isocentric field techniques centered in the 
middle of the phantom, whereas dose deviations > 4% were observed for some laterally 
shifted treatment plans. The study confirmed that the smallest tumor size results in the 
highest dose deviation. The scintillator system and the heterogeneous phantom provide a 
promising tool for critical evaluations of complex radiotherapy calculations and dose 
delivery.   
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12 Paper V  
Organic scintillator dosimetry reveals tumor-size dependency in a heterogeneous lung 
cancer setup for radiotherapy with 6 MV photon beams 
Paper V is an unpublished study describing dosimetry issues for different tumor sizes in 
heterogeneous setups. For this purpose, an in-house designed thoracic-like phantom was 
used for scintillator dosimetry, mimicking a lung cancer patient with lung tumors of 
different tumor sizes. Clinical relevant treatment plans of different complexities were 
measured and compared to calculations carried out using a commercial AAA dose 
calculation algorithm.  
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Abstract  
Purpose: Radiotherapy for lung cancer generally has a poor prognosis. Motion during imaging 
and treatment is a major challenge, but also other factors may contribute to the poor prognosis. 
One such factor is the ability of current treatment planning systems to accurately compute 
absorbed dose to tumors in the thorax region where large heterogeneities are present. The 
current study was designed to experimentally address the question: What is the agreement 
between actual delivered dose and computed dose using the Anisotropic-Analytical-Algorithm 
(AAA) in Eclipse treatment planning system for a thoracic-like geometry with tumors of 
different sizes? This is an important question given the widespread use of AAA and the 
changes in tumor sizes both over the course of treatment, and from patient-to-patient. 
Material and Methods: To perform measurements under well-defined conditions, a thoracic-
like phantom was designed. The phantom made of PMMA can be filled with inserts of various 
materials, including simulated lung tumors made of PMMA spheres (ranging from 1-8 cm in 
diameter) which are embedded in low-density balsa wood that simulates lung-tissue. 14 
different phantom setups underwent CT scanning, structure delineation, and treatment 
planning. 56 isocentric treatments of different complexity and phantom configurations were 
calculated using AAA. To perform accurate dosimetry under these non-reference conditions, 
point measurements were carried out using water-equivalent, organic plastic scintillator 
detectors (PSDs). Dose differences between measurements and AAA calculations were 
calculated. 
Results: Considerable tumor-size dependence was observed. For tumor sizes ≤ 2 cm, the dose 
deviations between AAA calculations and PSD measurements were 7.4±1.8% (median ± 
1SD). For larger tumor sizes (3-8 cm in diameter) corresponding dose deviations were 
4.2±1.4%. For the most homogeneous setup, the dose deviations were insignificant 
(0.3±0.6%). The results were essentially independent of treatment technique. 
Conclusions: This study suggests a systematic tumor-size dependent dose calculation error for 
treatment planning on small tumor sizes in heterogeneous setups. This may originate from 
imperfections in the AAA algorithm. The largest dose deviations were observed for the 
smallest tumor sizes. Although, it is well known that AAA has issues in heterogeneous 
regions, we are not aware of any previous experimental study demonstrating a similar 
systematic tumor-size effect. The effect is large enough to potentially have implications for 
lung cancer treatment planning.  
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12.1 Introduction 
Lung cancer gross tumor volumes (GTVs) are often situated in regions of large tissue 
heterogeneities. Most commercial treatment planning systems (TPSs) have recognized 
calculation issues in these regions due to the absence of charged particle equilibrium (CPE) 
and because of difficulties to correctly account for changes of lateral electron scatter [88–
91,93]. The largest inaccuracies are usually in the transition between materials of different 
densities. Additionally, for lung cancer treatments, tumor volume shrinkage during 
radiotherapy is well known [27,36,105–107]. Adaptive radiotherapy is one solution to 
correct for tumor shrinkage and other anatomical changes during the course of treatment. 
For cases where the tumor decreases, the treatment fields can be adapted accordingly, i.e. 
the field sizes can be decreased in order to spare adjacent healthy tissue from radiation. 
The TPS calculation issues increase when the tumor and field sizes decrease due to 
simultaneous decrease of CPE. 
The advantages of using fiber-coupled organic plastic scintillator detectors (PSD) for 
complex and dynamic radiotherapy dosimetry in megavoltage photon beams have 
previously been presented in studies based on homogeneous setups in either water or solid 
water phantoms [95–98]. Additionally, benchmarking against Monte Carlo simulations 
have shown good agreement with measurements, and a recent study by Francescon even 
concluded the Exradin W1 PSD (Standard Imaging, Middleton, WI, USA) to be the only 
detector of those investigated that could reproduce the Monte Carlo simulated data in water 
with high accuracy [97,99]. PSDs are particularly well suited for complex dose 
verifications due to their water-equivalency, and small size for high spatial resolution and 
minimum perturbation of the radiation fields. Alanine and thermoluminescent dosimeters 
(TLDs) are also highly water equivalent, but they do not provide real-time output, which is 
a significant drawback in studies involving many treatments and complex phantom setups. 
In order to explore the heterogeneous TPS calculation issues further, a heterogeneous 
thoracic-like phantom was constructed for PSD dosimetry. Several tumor inserts of 
different sizes (ranging from 1-8 cm in diameter) were embedded in low-density balsa 
wood representing lung tissue to simulate the change of tumor size during the course of a 
lung cancer treatment. This current study is the first experimental study designed to obtain 
accurate assessments of the dose delivered in different heterogeneous setups, mimicking a 
lung cancer patient with varying tumor sizes embedded in low-density media. For this 
purpose, PSD measurements for a range of various phantom setups, simulating different 
tumor sizes, and using different complex isocentric treatment techniques were carried out. 
12.2 Material and methods 
12.2.1 Phantom design 
The phantom design has previously been described by Ottosson et al. [108]. In brief, a 
thoracic-like phantom, analogous to the thorax of a lung cancer patient, has been 
constructed to carry out PSD dosimetry in well-defined heterogeneous geometries. The 
body of the phantom was made of Poly(methyl methacrylate) (PMMA), containing three 
hollow cylinders, which all can be filled with several inserts of various materials to 
simulate different homo- and heterogeneous geometries. The various inserts were made of 
Paper V - Material and methods 
112 
 
the copolymer Polyoxymethylene (POM-C), balsa wood, and PMMA representing bone, 
lung and soft tissue, respectively. PMMA spheres of various sizes (ranging from 1-8 cm in 
diameter), embedded in low-density balsa wood were used to simulate soft-tissue tumors 
situated in low-density lung-tissue. 
12.2.2 Image acquisition, target definition and treatment planning 
Prior to treatment planning, fourteen phantom configurations were scanned in a 16 slice 
Philips Brilliance CT Big Bore, version 3.5.17001 (Philips Medical Systems, Cleveland, 
OH) using a standard thorax scanning protocol. The fillings of the two lateral cylinders 
were altered between PMMA and balsawood, representing a Soft-tissue-Tumor-Soft-tissue 
(STS) setup or Lung-Tumor-Lung (LTL) setup, respectively (Figure 35). The central 
cylinder was either filled with one of the tumor inserts with the diameters: (1, 1.5, 2, 3, 5, 
8) cm embedded in balsa wood, or a PMMA cylinder with the diameter of 9 cm. In our 
previous study we found good agreement between human tissue and the phantom materials 
in terms of Hounsfield unit representation of the various materials [108]. 
Delineations of the anatomical structures were carried out according to the Ottosson 
[108] study in the TPS Eclipse v. 10 (Varian Medical Systems, Palo Alto, CA, USA). The 
clinical target volumes (CTVs) and planning target volumes (PTVs) were defined as a 5 
mm and 10 mm symmetrical expansion of the GTV, respectively. 
Treatment planning and dose calculation was carried out in Eclipse using the 
Anisotropic-Analytical-Algorithm (AAA). For each image set, four different isocentric 
treatment plans of various complexities were carried out (Figure 35), resulting in 56 
different treatment plans according to Figure 35; (a.) a single-field technique with an entry 
angle of 90 degrees. (b.) a four-field conventional box technique. (c.) a five-field intensity-
modulated radiotherapy technique (IMRT), and (d.) a dual-arc volumetric-modulated-arc 
technique (VMAT). The beam directions were preserved for each type of treatment plan 
for all tumor sizes investigated. The isocenters of all treatment plans were positioned at the 
center of the GTV, situated in the center of the phantom. For the IMRT and VMAT 
treatment plans a mean dose of 2 Gy was prescribed to the PTV, while the single-field and 
4-field techniques were normalized to give 2 Gy at the isocenter (Figure 35). All treatment 
plans, except the single-field technique, satisfied the clinical dose coverage criteria. For the 
tumors situated in the lung, 98% of the PTV was covered by a minimum of 90% of the 
prescribed dose. 
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 Single-field, STS-3cm Four-field box, STS-3cm  
 
  
 
 Five-field IMRT, STS-3cm Dual-arc VMAT, STS-3cm  
 
  
 
 Single-field, LTL-3cm Single-field, STS-9cm  
Figure 35. Schematic illustration of the different treatment techniques and some phantom setups. 
STS and LTL describes the fillings of the body cylinders. (a.-d.) illustrates a 3 cm tumor insert 
situated in the central cylinder of the phantom, where the two lateral cylinders were filled with 
PMMA, (i.e. a STS-3cm setup). Four different treatment techniques were carried out: (a.) a single-
field technique, (b.) a four-field conventional box technique (c.) a five-field IMRT, and (d.) a dual-
arc VMAT. (e.) illustrates the single-field technique when the lateral cylinders where changed into 
balsa wood, (i.e. a LTL-3cm setup). (f.) is an example of when all the body cylinders were filled 
with PMMA, and the GTV was represented by a tumor diameter size of 9 cm, without any adjacent 
low-density media (i.e. a STS-9cm setup, a full homogeneous setup). The GTV, PTV and body of 
the phantom were delineated in red, blue (with a thicker line width) and green colors, respectively. 
The 90%, 95% and 100% isodose curves were colored yellow (with a thicker line width), light 
orange, and dark orange, respectively. Red arrows indicate the beam directions for the various 
treatment techniques. 
12.2.3 Experimental setup and calibration conditions 
All measurements were carried out utilizing the BCF-60 scintillator (Saint-Gobain 
Ceramics & Plastics Inc.) with a diameter of 1 mm and a length of 2 mm, further described 
a 
c 
b 
d 
e f 
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by Beierholm et al. [97]. The PSD was calibrated according to the procedure (method C) 
described by Guillot et al. [100] in a solid water calibration phantom. Measurements were 
carried out using the ME40 scintillator dosimetry system (DTU Nutech) [98]. The 
reference dose (100 MU, 10×10 cm
2
 field size, 90 cm source-to-surface distance) was 
measured by both the scintillator and a Farmer ionization chamber, type 30011 (PTW, 
Freiburg, Germany) at a depth of 11.5 cm in the solid water phantom. To determine the 
dosimetric correction factor between the solid water phantom and the in-house developed 
PMMA phantom, corresponding measurements were carried out in the PMMA phantom 
(using a homogeneous setup, i.e. STS-9, Figure 35f). The depth of 11.5 cm agreed with the 
center position in the PMMA phantom. Irradiation was delivered by a Varian Clinac iX 
2300 linear accelerator (Varian Medical Systems), with a beam energy of 6 MV at a dose 
rate of 600 MU/min [85]. The calibration dose was normalized to the corresponding 
calculated dose in Eclipse to eliminate the daily output variation of the linear accelerator.  
Prior to irradiation of the different tumor inserts, the PMMA phantom was positioned 
based on image guidance by cone-beam CT (CBCT) images of the phantom setup, 
acquired at the treatment unit. The CBCT images were registered and matched to the 
planning CT, where focus was to match the tumor inserts to achieve the correct phantom 
position. For the measurements, the PSD was positioned at the isocenter (i.e. in the center 
of the tumors) centrally situated in the PMMA phantom. Measurements were carried out in 
two sessions. During the first session, the size of the tumor insert gradually decreased, 
starting with the largest tumor insert, while the tumor size gradually increased, starting 
with the smallest tumor insert during the second measurement session. The measured PSD 
dose for the various treatment plans were compared with corresponding AAA calculated 
point doses. 
12.2.4 Data analysis and statistical testing 
Measured percentage dose deviations relative to the AAA calculations were assessed. A 
three-way ANOVA-test was performed to determine the statistical significance of the dose 
deviations in regard to the treatment techniques, tumor sizes and phantom setups. 
Bonferroni adjustment for the three comparison groups was carried out to compensate for 
multiple comparisons. The results were considered statistically significant after adjustment 
for p ≤ 0.05. 
12.3 Results 
The mean and one standard deviation (1 SD) of the dosimetric correction factor between 
the solid water calibration phantom and the PMMA phantom measured with the ionization 
chamber was 0.9983 (0.0013).  
The AAA calculated and PSD measured isocenter doses for the IMRT treatments were 
statistically significantly higher compared to the other treatment techniques (not 
presented). The PSD measurements indicate that the doses in the center of the tumors were 
in median about 4.7 ± 2.8% (± 1SD) higher in reality compared to the doses calculated by 
AAA, irrespectively of treatment techniques, sizes of tumor inserts, or what lateral 
phantom configuration utilized (Figure 36). 
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Figure 36. The AAA calculated dose relative to the scintillator 
measured dose. If the markers are situated exactly on the black 
line there is no difference between the doses. AAA calculates a 
lower dose compared to the scintillator measurements if the 
markers are situated below the black line. 
For the dose deviations, no statistically significant differences were found among the 
treatment techniques, irrespective if the lateral cylinders were filled with balsa wood or 
PMMA (Figure 37a). However, compared to the LTL setups, there were observed 
tendencies (not statistical significant) that the medians of the dose deviations were higher 
for the STS setups, in both respect to the treatment techniques (Figure 37a) and tumor size 
(Figure 37b). Considerable tumor-size dependence was observed irrespectively of 
treatment technique or lateral phantom setup. Dose deviations between AAA calculations 
and measurements were 7.4±1.8% in median for tumor sizes ≤ 2 cm, with a clear increase 
in dose deviations for decreasing tumor sizes. The smallest tumor size (1 cm) irradiated by 
a single-field treatment plan resulted in the largest dose deviation (11.5%). For larger 
tumor sizes (3-8 cm in diameter) corresponding dose deviations were 4.2±1.4% in median. 
For the most homogeneous setup, where the central cylinder was filled with PMMA (i.e. 
STS-9cm and LTL-9cm), the dose deviations were 0.3±0.6% in median. For the LTL 
setups, no trend was observed for the tumor sizes ranging from 3-8 cm. For the same tumor 
sizes, a small decreasing trend was found for the STS setups when increasing the tumor 
size.  
When removing the effect from treatment technique and tumor-size dependency, it was 
found that STS setups were statistically significantly higher compared to LTL setups (not 
presented). Similarly, if removing the effect of the lateral phantom setups and the tumor-
size dependency, the percentage dose deviations for the conventional and the single-field 
treatment techniques were statistically significantly higher compared to the rest of the 
treatment techniques (not presented).  
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Figure 37. The measured percentage dose deviation relative to the AAA calculations stratified by 
(a.) treatment technique or, (b.) the tumor size for the STS and LTL phantom setups. The black 
dotted line is equal to zero dose deviation. The black boxes represent the data when the two lateral 
cylinders were filled with PMMA, (i.e. STS setups). The gray boxes represent likewise the data 
when the two lateral cylinders were filled with balsa wood, (i.e. LTL setups). On each box, the 
central light gray mark represents the median value. The edges of each box are the 25th and the 75th 
percentiles, the whiskers correspond to approximately ± 2.7 SD of the data, and outliers are plotted 
as crosses individually. 
12.4 Discussion 
This study illustrates the dosimetric issues with the AAA dose calculation algorithm when 
it comes to small tumor sizes embedded in low-density media, which is clinically relevant 
for lung cancer treatments. Interestingly, the STS setups resulted in higher dose deviations 
in median, compared to the LTL setups, irrespectively of treatment technique and tumor 
size. The dose deviation of 0.3±0.6% for STS-9cm and LTL-9cm setups in the current 
study is comparable with the results presented in our previous study [108], where we found 
dose deviations of -0.2±0.4% for centrally positioned PSDs in STS-9cm and LTL-9cm 
setups. For the tumor inserts, the major difference between this study, and the previous, 
was the location of the tumor inserts in the phantom. In the previous study, the tumors 
were located in the lateral cylinder, while they were located in the central cylinder in the 
current study. The reason to have the tumor inserts located in the central cylinder in the 
current study, although this does not mimic the geometry of a lung cancer patient, was to 
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minimize the potential influences of the phantom body curvature and beam distribution 
around the phantom. These features could have potential influence on the tumor-size 
dependency, which would be hard to interpret. However, already in our previous study, an 
indication for tumor-size dependency was observed between the 3 and 5 cm tumor sizes 
investigated [108]. For the 3 cm tumor, the dose deviations were -5.4% and -2.4%, for the 
four-field conventional and VMAT treatment plans, respectively. For the 5 cm tumor, the 
dose deviations were -4.0% and -1.3%, respectively. Similar differences between the 3 and 
5 cm tumor sizes were found in the STS setup in the current study (Figure 37b). However, 
no such difference between the 3 and 5 cm tumors was observed for the more 
heterogeneous LTL setup. The insignificant dose deviations for the most homogeneous 
setups, in this and the previous study, indicate that the distance from the measurement 
point to adjacent heterogeneities in the phantom was large enough to establish CPE. 
Similar to the prior study, the conventional treatment plans in this study resulted in higher 
dose deviations compared to more complex plans. One reason for this observation could be 
the fact that the more complex treatment plans (IMRT and VMAT) have several beam 
entries around the body of the phantom, and not just directly through the low-density 
material of the phantom. Thus, the larger dose deviation for the simplest field techniques 
could potentially be due to lack of sufficient spread of lateral radiation, required in order to 
obtain CPE. Irrespectively of tumor setup or treatment technique, the smallest tumor sizes 
resulted in the largest dose deviations. The results presented in the current study clearly 
indicate that there exists a considerable tumor-size dependency irrespectively of tumor 
setup or treatment technique, especially for small tumor sizes ≤ 2 cm. Consolidating MC 
simulations will be of great value for further establishment of these observed dose 
deviations. 
12.4.1 Confounding factors 
A potential confounding factor in the current study could be the size of the calculation grid 
utilized in Eclipse, which was 0.25×0.25×0.25 cm
3
. This could be further improved down 
to a grid size of 0.1×0.1×0.1 cm
3
. Moreover, the CT scan of the phantom was based on a 
clinical thorax scanning protocol with a CT image slice spacing of 2 mm. Since the length 
of the PSD utilized in the current study was 2 mm, correct positioning of the detector at 
sub-mm precision is crucial and could be an issue. Phantom positioning prior to irradiation 
was carried out by CBCT image guidance. Since the phantom did not include any motion, 
the confounding factor for the phantom setup procedure is anticipated to be small. 
Although, PMMA and balsawood were found to be HU-equivalent to human tissue [108], 
there could be some deviation from the CT calibration curve since they are not tissue-
equivalent materials in terms of anatomical compositions. This potential bias is expected to 
be small, but requires supplementary investigations. 
12.5 Conclusion 
This study demonstrates systematic tumor-size dependent dose errors when using the AAA 
dose calculation algorithm for treatment planning, which is emphasized for small tumor 
sizes. This considerable tumor-size dependency may originate from imperfections in the 
AAA algorithm for small tumor sizes in heterogeneous setups. The largest dose deviations 
were observed for the smallest tumors. Conventional field techniques resulted in higher 
dose deviations compared to more complex treatment techniques, such as IMRT and 
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VMAT. Compared to the LTL setups, the STS setups resulted overall in higher dose 
deviations. The scintillator system and the heterogeneous phantom provide a promising 
tool for critical evaluation of complex radiotherapy calculations and dose delivery. 
Although it is well known that AAA results in erroneous treatment plans in heterogeneous 
regions, we are not aware of any previous experimental study demonstrating similar 
systematic tumor size effect. The effect is large enough to potentially have implications for 
lung cancer treatment planning 
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14 Appendix A: Phantom design  
14.1 2D phantom blueprints 
This section describes the design of the phantom in detail.  
 Main Body 
 Body Cylinder 
 Tumor 
 Lung insert 
14.2 3D phantom 
 Cross-sections 
 Cross-sections in a rotated viewing angle 
 Dissected phantom 
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Appendix A: Phantom design – 3D drawings 
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14.3 Cross-sections 
A. 
 
 
B. 
 
C. 
 
Figure 38. (A.) Coronal, (B.) translational, and (C.) sagittal cross-sections of the phantom. In 
this particular setup the colors mean the following: Light blue is the phantom body made of 
PMMA. Dark blue is the PMMA inserts. The yellow color represents the hollow PMMA 
cylinders with their lids on at the ends. The red central cylinder is made of balsa wood. Where a 
5 cm PMMA tumor (pink) is situated in the center. The green plugs are in this case made out of 
PMMA. The maroon color is a 2 cm delrin rod used to simulate the spine.  
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14.4 Rotated cross-sections 
A. 
 
 
B. 
 
C. 
 
Figure 39. (A.) Coronal, (B.) translational, and (C.) sagittal cross-sections of 
the phantom in a rotated viewing angle. Additional figure explanations are 
described in Figure 38. 
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14.5 Dissection of the full phantom setup 
   
 
  
A. B. C.  D. E. 
Figure 40. Different views of the phantom setup with (A-C) and without (D-E) 
the optional linear actuator and motion measurement device attached. Frontal 
view (A and E), Side-view (B and E), and view from below (C). Additional 
figure explanations are described in Figure 38. 
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14.6 Rotated view of the full phantom setup 
 
Figure 41. Rotated viewing angle of the dissection phantom setups in Figure 40, with (A) and 
without (B) the optional linear actuator and motion measurement device. Additional figure 
explanations are described in Figure 38. 
 xiii 
 
15 Appendix B: Chemical analysis 
This section describes the results from the chemical analysis of delrin and balsa wood 
carried out by BELAB AB and ALS Scandinavia AB. 
 CHNO analysis of balsa wood 
 Elemental analysis of balsa wood 
 CHNO of delrin 
 Elemental analysis of delrin 
 Uncertainty data 
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15.1 CHNO analysis of balsa wood 
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15.2 Elemental analysis of balsa wood 
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Elemental analysis of balsa wood, details 
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15.3 CHNO analysis of delrin 
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15.4 Elemental analysis of delrin 
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Elemental analysis of delrin, details 
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15.5  CHNO analysis, uncertainty data 
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16 Appendix C: Clinical protocol (in 
Danish) 
This section describes the LuCaRa protocol details. 
 Clinical DIBH-LuCaRa protocol (in Danish) 
 Layman resumé (in Danish) 
 Information for participants 
 Approval by the Institutional Reviewing Board 
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Evaluering af DIBH gating for patienter med lokal-
avanceret lungecancer planlagde til kurativ 
stråleterapi  
(DIBH-LuCaRa) 
 
Medlemmer af projektgruppen fra Onkologisk afd.: 
Projektansvarlig: Hospitalsfysiker, M.Sc., Ph.d.-studerende, Wiviann Ottosson 
Klinisk ansvarlige: Overlæge Ph.d. Anders Mellemgaard, Afdelingslæge Jon Lykkegaard 
Andersen og afdelingslæge Svetlana Borissova. 
Ansvarlig radiograf: Henriette Klitgaard Mortensen   
 
1. Resumé 
Formål:  
Det overordnede formål er at udvikle en metode til en mere præcis og effektiv 
strålebehandling baseret på Deep-Inspiration-Breath-Hold (DIBH) gating teknik til 
patienter med lokal-avanceret lungekræft.  
Hypotese: 
Ved at øge præcisionen i billeddannelsen til planlægningen af strålebehandling, og i selve 
strålebehandlingen, er det muligt at levere højere stråledosis til tumoren, mens dosis til 
normalvævet vil bibeholdes eller eventuelt mindskes.  
Patienter: 
I studiet inkluderes 40 patienter med inoperabel lokal-avanceret lungekræft.  
Metode: 
Inden start af strålebehandling øver patienterne sig sammen med personale fra 
Stråleterapien i at holde vejret ved dyb indånding, ifølge DIBH gating teknikken. I 
forbindelse med planlægning, og ugentlig strålebehandling, foretages supplerende DIBH 
billeddannelse til det standardmæssige strålebehandlingsforløb. Størrelsen af behandlings-
volumen, og dosimetri forhold planlagt ved henholdsvis konventionel 4DCT i fri 
vejrtrækning og DIBH CT vil blive sammenlignet. Selve strålebehandlingen vil ske i 
henhold til nuværende praksis på Herlev Universitets Hospital. De foretagne billed-
undersøgelser vil bruges til beregning af populationsbaseret margins omkring tumor med 
henblik på intra- og inter-fraktionelle tumorbevægelser. Billedundersøgelserne vil også 
bruges til beregning af den teoretiske strålebehandling som kunne være givet, hvis planen 
adapteredes i henhold til tumorregression og anatomiske ændringer henover behandlings-
forløbet, både i fri vejrtrækning og i DIBH.  
Appendix C: Clinical protocol (in Danish) 
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Etiske overvejelser: 
På grund af de ekstra billedundersøgelser i forbindelse med studiet vil patienterne blive 
udsat for ekstra stråledosis mod behandlingsområdet, dvs. brystkassen. I forhold til 
nuværende behandlingsprocedure på Herlev Universitets Hospital, hvor CBCT-skanninger 
udføres ugentligt, vil patienterne udsættes for en total ekstra stråledosis på 63-66 mSv 
(afhængigt af antallet behandlingsdage). – I forhold til standardprocedure på de centre i 
Danmark (fx Aarhus og Odense) som rutinemæssigt laver daglige CBCT-skanninger til 
patientpositionering før strålebehandling, medfører protokollen kun en ekstra total 
stråledosis på 16.5 - 27 mSv. Selve strålebehandlingen giver en langt større terapeutisk 
stråledosis (45 Gy / 60 Gy/ 66 Gy, 2Gy/fraktion – hvor 66 Gy med fotonbestråling svarer 
til ca. 66 000 mSv [organvægtningfaktor = 1, og strålevægtningfaktor = 1]). Gennemsnits-
alderen for disse patienter er 70år, og tidsrammen for udvikling af stokastiske stråleskader 
er 10 – 20 år. Den øgede risiko for komplikationer, og fremkaldelse af sekundær kræft på 
baggrund af de ekstra skanninger, skønnes således at være meget begrænset. For denne 
patientgruppe er risikoen for at dø af anden årsag (fx deres lungecancer eller tobaks-
relaterede sygdomme) langt højere. 
Perspektiv: 
På længere sigt forventes det at resultaterne fra projektet bidrager til at forbedre 
strålebehandlingen af lokal-avanceret lungekræft i Danmark. Vi håber at kunne udvikle 
metoder til at bedre kunne tilpasse behandlingen til den enkelte patient. Ved at gøre 
strålebehandlingen mere præcis kan man øge tumorkontrol uden samtidig at øge 
bivirkningerne. En øget dosis til denne patientgruppe som tit har store lungetumorer vil 
sandsynligvis betyde en forbedring af deres prognose. 
2. Indledning 
Lungecancer er den næst-hyppigeste kræftsygdom i Danmark, med ca. 4200 nye tilfælde i 
2009 [135], hvor ca.34% af patienterne med lungecancer henvises til strålebehandling 
[136]. Dødeligheden blandt patienter med lungecancer er højere end ved de fleste andre 
former for cancer, og 5 års overlevelsen er kun 10% [136].  Der er et presserende behov for 
forbedring af strålebehandling til patienter med lungekræft. Meget tyder på, at den dosis 
man i dag anvender ved behandling af lokal-avanceret lungekræft, er for lille og dette 
forhold afspejles i 5 års overlevelsen. Tidligere studier har vist at lokal tumorkontrol er 
associeret med overlevelsen [137] og at bedre tumorkontrol kan opnås ved at øge 
stråledosis [8,137]. Dog kan levering af høj dosis bl.a. inducere lungetoksicitet [9,10], og 
dosis til tumoren begrænses af den maksimalt tolererede dosis til omkringliggende normale 
risikoorganer. Strålebehandling til lungetumorer er vanskeligt, fordi tumoren bevæger sig 
med vejrtrækningen. Ved planlægning af stråleterapi tillægges margener omkring tumoren 
for at tage højde for de usikkerheder der er på grund af subklinisk tumorvæv, respiration, 
andre organ bevægelser, og lejringsusikkerheder af patienten ved behandling. De ekstra 
margener resulterer i at et større område omkring tumoren medbestråles hvilket øger 
risikoen for toksicitet i tilstødende normalt væv. DIBH gating er en teknik, som potentielt 
kan forbedre strålebehandlingen af patientgruppen. Ved DIBH gating vejledes patienterne i 
at holde vejret tæt på deres maksimale inspiration i den korte tid (15-30 sekunder) 
strålebehandling og billeddannelse varer. Dette fører til en dæmpning af tumorens 
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bevægelse og en udvidelse af lungevævet. Ved at bruge DIBH gated stråleterapi kan det 
bestrålede volumen omkring tumoren reduceres, og således skånes normalt lungevæv og 
omkringliggende risikoorganer bedre for stråling. Dette kan gøre det muligt at øge 
stråledosis uden at give for meget dosis til risikoorganerne. Med hensyn til at skåne lunge, 
er lav lungedensitet ved dyb indånding en fordel [43]. Mere grundige undersøgelser er 
nødvendigt for at studere den praktiske fremgangsmåde, og på sigt den kliniske gevinst af 
at tilbyde DIBH gating til patienter med lokal-avanceret lungecancer.  
3. Forsøgets formål 
Det overordnede formål er at undersøge muligheden for at indføre DIBH gating som en ny 
behandlingsforløb for patienter med lokal-avanceret lungecancer. Deltagere i studiet vil få 
lavet 2 planlægningsscanninger. Den ene anvendes til den konventionelle behandling og 
den anden (DIBH) bruges i forsøgssammenhæng for at vurdere om man kan opnå en 
forbedret teoretisk stråleplan for den pågældende patient. Med baggrundsviden om 
stråledoser og stråletoksicitet kan man vurdere om den teoretiske DIBH behandling vil føre 
til en bedre behandling med hensyn til tumorkontrol og bivirkninger. Under 
behandlingsforløbet (midtvejs og i slutningen) vil patienten desuden få lavet de samme 
typer af CT-skanninger igen. Disse ekstra skanninger skal bruges til at evaluere 
tumorvariationen henover behandlingsforløbet og den dosimetriske påvirkning af 
behandlingsplanen, samt reproducerbarheden af patientens respirationsmønster. Selve den 
strålebehandling som patienterne får, vil ikke påvirkes af forsøget men vil foregå 
fuldstændigt svarende til afdelingens sædvanlige praksis. 
4. Problemstillinger 
 Undersøgelse af muligheden for at foretage DIBH gated billeddannelse og 
strålebehandling til patienter med lokal-avanceret lungecancer. 
 Karakterisering af tumors lokalisation, form og bevægelse ved planlægningen af 
strålebehandling, og henover behandlingsforløbet, med og uden instruktioner til 
at holde vejret ifølge DIBH gating teknikken. 
 Vurdering af margener for behandlingsfelter, baseret på populationsviden om 
tumorvariationer baseret på fri vejrtrækning og DIBH. 
 Undersøgelse af den dosimetriske fordel ved at bruge DIBH gating teknikken i 
forhold til fri vejrtrækning ved planlægning af strålebehandling, med henblik på 
billeddannelse, forskellige felttekniker, avancerede beregnings algoritmer, og 
brug af forskellige behandlingsenergier. 
 Studere den teoretiske mulighed for dosiseskalering til tumorområdet, uden at 
give mere dosis til omkringliggende normale væv. 
 Studere dosimetriske ændringer forårsaget af tumors variationer henover 
behandlingsforløbet.  
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5. Baggrund 
CT-skanning er en røntgenundersøgelse, der giver billedinformation om patientens 
geometri og vævstype (bløddele, knogle, lunge etc.) i tre dimensioner (3D), og som 
anvendes ved planlægning af strålebehandling. På grund af bevægelse kan billedartefakter 
dannes som kan påvirke planlægningen af stråleterapi. På Herlev Universitets Hospital 
foretages der derfor for alle kurativt intenderet lungecancer-patienter en 4DCT-skanning i 
forbindelse med deres planlægning af strålebehandling for at kunne måle lungetumorens 
bevægelse under vejrtrækning (den 4 dimension er tiden). På grund af bevægelsen må 
strålebehandlingsfelterne udvides så meget at tumoren er indenfor strålefelterne under hele 
behandlingsforløbet. De udvidede strålefelterne medfører desværre at mere af det raske 
lungevæv, hjerte, spiserør, lever og rygmarv medbestråles, hvilket kan give flere strålings-
inducerede bivirkninger. 
Der er for nylig indført en ny behandlingsteknik ved behandling af brystcancer 
patienter, nemlig DIBH gating. Ved DIBH gating holder patienterne vejret ved dyb 
indånding under både billedoptagelse og strålebehandling. På den måde mindskes både 
brystkassens og dermed tumorens bevægelse, og mængden af billedartefakter som kan 
påvirke planlægningen af strålebehandling. Således mindskes størrelsen af behandlings-
felterne.  
Desværre ved vi ikke hvor stor behandlingsmæssig fordel der er ved at anvende DIBH 
gated strålebehandling til patienter med lokal-avanceret lungecancer som tilbydes kurativ 
intenderet strålebehandling. Første trin i en nærmere vurdering af værdien af DIBH er 
denne undersøgelse som ser på det praktiske forløb og den teoretiske fordel. 
6. Patienter 
I forsøget inkluderes, efter informeret samtykke, 40 patienter med lokal-avanceret 
lungecancer stadie II-III, henvist til kurativ strålebehandling på Herlev Universitets 
Hospital. 
6.1. Styrkeberegning 
Parret t-test vil blive brugt til at vurdere den statistiske signifikans af fund. Baggrunds-
variable vil blive beskrevet med deskriptiv statistik. 
Udefra en formodning om at det definerede tumorområde inklusive tumorbevægelse, 
dvs. Internal Target Volume (ITV), kan reduceres med 30%, og med α = 0.05 og en styrke 
på 80% skal 40 patienter indgå i studiet for at opnå en tilstrækkelig statistisk styrke til at 
påvise en reduktion i størrelsen af ITV i forbindelse med DIBH. 
6.2.  Inklusionskriterier 
 Alder > 18 år 
 Alle patienter henvist til kurativ strålebehandling, uanset histologi og uanset frak-
tionering 
 Skal kunne forstå mundtlig og skriftlig information på dansk 
 Underskrevet informeret samtykke erklæring og patientinformation 
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6.3.  Eksklusionskriterier 
 Graviditet 
7. Information af patienter 
Informationssamtaler forestås af lægerne i lungecancer gruppen på Onkologisk afdeling. 
Patienten gøres opmærksom på, at det kan være hensigtsmæssigt at følges med en 
pårørende eller anden bisidder til samtalen. Det vil være hensigtsmæssigt at samtalen 
finder sted en dag patienten skal møde frem på hospitalet til information om den 
forestående strålebehandling. Samtalen planlægges således at den informerende part er 
nøje bekendt med patientens sygehistorie og undersøgelses- og behandlingsplan i øvrigt. 
Samtalen skal foregå roligt og uforstyrret i et samtalerum på afdelingen. Patienterne bliver 
informeret om forsøgets baggrund, formål, deltagerantal, ind- og udgangskriterier, 
tidsforløb, praktiske gennemførelse, ulemper og fordele for patienten, samt fremtidige 
perspektiver. Der oplyses endvidere om økonomiske forhold, patientrettigheder, 
fortrolighed vedrørende patientoplysninger og efterfølgende information om projektets 
resultater. Patienten opfordres til at deltage i projektet, men det fremhæves at dette er 
frivilligt, og at beslutningen ikke påvirker patientens behandling i øvrigt. Det sikres at 
patienten har forstået informationen. Der udleveres skriftlig patientinformation, og det 
fortrykte tillæg ”Forsøgspersonens rettigheder i et sundhedsvidenskabeligt forsknings-
projekt”. Patienten gives betænkningstid, og mulighed for yderligere samtale. 
8. Metode 
Der er tale om et prospektivt metodeudviklingsstudie med henblik på at kunne tilbyde 
patienter med lokal-avanceret lungecancer et mere effektivt strålebehandlingsforløb. I de 
følgende afsnit beskrives de anvendte metoder. 
8.1.  Åndedrætsinstruktion og monitorering 
Undersøgelserne kræver ingen forberedelse. Ca. 1 time før CT-skanningerne vil patienten 
møde op i Stråleterapien ved Herlev Universitets Hospital, hvor patienten vil øve sig i at 
holde vejret ved dyb indånding ifølge DIBH gating teknikken. Patienten vil øve sig 
sammen med erfarent personale fra Stråleterapien, hvor patienten vil blive guidet til at hold 
vejret på det niveau ved dybt indånding (ca. 70-80% af maksimal indånding) som passer 
patienten bedst, ved visuel guidning med hjælp af computerbriller. På brystkassen påsættes 
infrarøde markører. Brystkassens bevægelser ved vejrtrækning i det anteriore - posteriore 
plan registreres via et infrarødt kamera monteret på lejret (ved CT-skanning) eller på 
væggen (ved Mould og behandling). Signaloptagelserne er en visuel læsbar kurve med tid 
og bevægeudsving som akser. Øvelser foregår indtil patienten klarer at opnå en re-
producerbar amplitude og holde vejret stabilt på det niveau (indenfor 2 mm) i mindst 15 
sekunder. Alle DIBH billeddannelser i studiet vil blive foretaget under visuel åndedræts-
instruktion til patienten ved brug af computerbriller. Åndedrætsmonitoreringssystemer som 
afdelingen har til rådighed er RPM™ fra Varian Medical Systems.  
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8.2.  Billeddannelse 
Efter DIBH-øvelsen går patienten videre til rutinemæssig 4DCT-skanning, hvor patienten 
vil blive lejret af to medarbejdere fra Stråleterapien. Det sikres at patienten ligger på 
samme måde ved den efterfølgende DIBH-skanning som ved 4DCT-skanningen, der bliver 
brugt til planlægning af strålebehandlingen. Patienten vil blive lejret og fikseret i 
behandlingsposition. Der er overvågning af patienten hele tiden under optagelsen af 
billeder, og patienterne kan altid kontakte skannerpersonalet undervejs i undersøgelsen. 
Alle CT-skanningerne foretages i en Philips BigBore CT-skanner, som står i 
Stråleterapien, og der vil altid være en læge i nærheden under CT-skanning. Der vil først 
blive foretaget en DIBH-skanning, som tager ca. 15 sekunder, og derefter 4DCT-
skanningen i fri vejrtrækning, som tager ca. 1 minut. Der vil efter sædvanlige retningslinjer 
blive givet kontrast til 4D og DIBH CT-skanningerne. Der bliver booket ca. 1 time til CT-
skanning for hver patient for at give tid til generel CT-information, omklædning, lejring på 
lejret og CT-skanning (4DCT og DIBH). Tidspunktet for CT-skanningerne og DIBH 
øvelsen vil blive planlagt i samråd med patienten, således at de passer bedst mulig i 
forhold til patientens behandling. Fordelen er at DIBH-skanningen foretages når patienten 
alligevel er mødt op til den rutinemæssige 4DCT-skanning ved planlægning af sin 
strålebehandling. Patienten vil desuden få lavet ekstra 4D og DIBH CT-skanninger 
midtvejs og i slutningen af sit behandlingsforløb, hvor der er booket ca. 1 time ekstra til 
CT-skanning udover behandlingstiden de dage. 
 4DCT foretages ved optagelse af mange billedsnit gennem hele patienten ved 
langsom fremføring af lejret. Under CT-skanningen trækker patienten vejret frit, 
og bagefter sorteres billederne automatisk efter hvornår i åndedrætscyklus de er 
taget. Man får således typisk 10 skanninger der repræsenterende hver sin fase i 
åndedrættet. Herudfra kan man vurdere tumors bevægelse. 
 DIBH foretages ved at der kun er optagelse af billedsnit når patienten holder 
vejret i den ved Mould forudbestemte vejrtrœkningsamplitude (indenfor 2 mm). 
I forbindelse med patientens strålebehandling vil patienten rutinemæssigt foretage 
daglig billedvejledt lejring inden start af strålebehandling ved brug af to dimensionale (2D) 
ortogonale kV røntgenbilleder, samt ugentligt 3D røntgenbilleder ved brug af Cone Beam 
CT (CBCT). Dette er for at sikre at patienten er lejret på samme måde ifølge den position 
som er forudbestemt ved planlægningen af strålebehandling, og for at sikre at tumoren er 
indenfor behandlingsområdet. I det her forsøg vil patienten udover de rutinemæssige 
daglige/ugentlige røntgenbilleder ved opstilling, også foretage supplerende ugentlige 
DIBH CBCT (både før og efter behandling), hvor patienten er positioneret i behandlings-
position på lejret. De billeder (hvor patienten holder vejret) vil efterfølgende sammenlignes 
med de tilsvarende billeder (hvor patienten trækker vejret normalt) som patienten foretager 
dagligt for positionering inden strålebehandling, for at evaluere DIBH gating teknikken 
gennem hele behandlingsforløbet. Der er booket 40 minutter ekstra ved behandling til 
DIBH billeddannelse de ugentlige dage hvor DIBH billeddannelse er aktuelt, hvilket 
resulterer i en total behandlingstid på ca. 1 time.  
Efterfølgende vil de forskellige typerne af billeddannelse (4DCT, DIBH, og 3D 
opstillingsbilleder) registreres/fusioneres sammen med match på patientens knogle-
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strukturer. Det skal gøres for at det skal være muligt at evaluere og sammenligne 
skanningerne med henblik på position, form og størrelse af tumor, og andre organer i 
brystkasseregionen under behandlingsforløbet, samt evaluering og sammenligning af 
beregnet dosisfordelinger. 
8.3.  Strålebehandling 
Alle patienter vil behandles på Herlev Universitets Hospital ifølge gældende standard 
behandlingsplaner i fri vejrtrækning (hvor behandlingsplanen er baseret på 4DCT-
skanningen), dvs. strålebehandlingen er ikke afhængig af om patienten klarer at udføre 
DIBH gating eller ikke. Foretagne DIBH-billeddannelser bruges til teoretisk evaluering af 
de eventuelle behandlingsmæssige fordele ved at basere strålebehandlingen på DIBH 
gating teknikken. 
Tumorindtegning og planlægning af strålebehandling vil blive udført, både på 4DCT- 
og DIBH CT-skanningerne (foretagne ved planlægning, midtvejs og i slutningen af 
behandlingsforløbet). Behandlingsplaner og tumordefinition baseret på DIBH i forhold til 
planlægning i normal vejtrækning (sædvanlig 4DCT-skanning) kan sammenlignes gennem 
hele behandlingsforløbet. Skanningerne vil blive brugt til flere typer af avancerede 
dosisberegninger for sammenligninger, fx; undersøgelse af forskellige felttekniker, 
avancerede beregningsalgoritmer, og brug af forskellige behandlingsenergier. Der vil også 
blive undersøgt om det teoretisk ville være muligt at give højre dosis til tumoren, uden at 
give mere dosis til de omkringliggende normale væv, ved brug af DIBH sammenlignet 
med 4DCT. 
I forbindelse med at man vurderer patienter som egnet til kurativt intenderet 
strålebehandling vil patienter, som opfylder inklusionskriterierne blive inviteret til at 
deltage i projektet, og informeret om formålet. Herefter vil de blive bedt om deres 
samtykke til denne. Giver patienterne ikke deres samtykke, vil deres behandling forløbe 
uden: DIBH-træning, supplerende DIBH CT-skanning ved planlægningen, supplerende 
ugentlig DIBH billeddannelse ved selve strålebehandlingen, samt ekstra CT-skanninger 
midtvejs og i slutningen af behandlingsforløbet. 
9. Etiske overvejelser 
Der er ikke nogen ekstra risici ved DIBH-skanningen i forhold til den rutinemæssige 
4DCT-skanning. Dog, i forhold til den aktuelle behandlingsstandard, vil den enkelte 
patient i studiet få en større stråledosis; samtidig vil det for patienten betyde en potentiel 
gevinst med ekstra kvalitetskontrol, med mulighed for intervention og re-dosisplanlægning 
af behandlingsplanen. Vurdering af billedundersøgelserne vil gøres midtvejs, og hvis det 
skulle vise sig at være nødvendigt for en god strålebehandling, vil den dosisplan, der er 
beregnet ud fra den ekstra 4DCT-skanning foretaget midtvejs i behandlingsforløbet, bruges 
til fortsat behandling. 
Så snart der er udviklet en metode som resulterer i en teoretisk mere præcis og effektiv 
strålebehandling med bedre sygdomskontrol og færre bivirkninger baseret på DIBH gating 
teknik, vil denne metode blive benyttet ved behandlingen af patienter med lokal-avanceret 
lungetumorer stadie II-III. Studiet udføres i henhold til Helsinki deklarationens betingelser. 
Alle data opbevares i henhold til tilladelse fra Datatilsynet.  
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9.1.  Udelukkelse fra og afbrydelse af forsøg 
Det er frivilligt at deltage i forsøget. Patienterne kan når som helst og uden at give en 
grund trække sit samtykke tilbage, uden at det vil få konsekvens for deres videre 
strålebehandling. 
Desuden vil forsøget afbrydes for den enkelte patient hvis vi finder ud af ved DIBH-
øvelsen at det er alt for hårdt for patienten at holde vejret i mindst ca. 15 sekunder. 
Forsøget vil yderligere kunne afbrydes såfremt CT-skanneren eller gating-udstyret (udstyr 
for registrering af patientens vejrtrækning, samt computerbriller) går i stykker og ikke kan 
repareres indenfor kort tid når patienten er mødt op til planlægning af sin strålebehandling. 
9.2.  Stråledosis 
I forbindelse med studiet vil patienterne blive udsat for ekstra stråledosis, fortrinsvis i 
behandlingsområdet på grund af de ekstra billedoptagelser. Ved planlægningen af 
stråleterapi CT-skannes patienterne to gange (DIBH og 4DCT). Patienten vil midtvejs og i 
slutningen af behandlingsforløbet få gentaget disse scanninger. Hvad angår effektiv dosis 
til patienten så bidrager DIBH CT-skanningen med ca. 5 mSv svarende til en tredjedel af 
dosis fra 4DCT-skanningen, som er omkring 15 mSv. Den ekstra dosis fra DIBH CT-
skanningen svarer til lidt over den naturlige årlige baggrundsdosis i Danmark som er 3 
mSv/år.  
For at opnå en så præcis strålebehandling af lungecancer som muligt, foretages det 
rutinemæssigt på Herlev Universitets Hospital Cone Beam CT scanninger af patienterne. 
På grund af kapacitetsproblemer på Herlev Hospital udføres der i dag kun ugentlig CBCT-
skanninger for positionering før strålehandling. Dog, indenfor en snar fremtid kommer 
også lungepatienterne standardmæssigt i Herlev gennemgå daglig CBCT-skanninger. 
Ugentlige CBCT-skanninger er allerede indført som standardprocedure på andre centre i 
Danmark, (fx i Aarhus og Odense), hvilket alene giver patienten en dosis på 49.5 mSv. 
Patienterne som indgår i projektet vil under sit behandlingsforløb (som er mellem 6-7 uger) 
ugentligt (for at kunne evaluere den inter-fraktionelle [dvs. mellem behandlinger] 
tumorbevægelse) foretage to ekstra DIBH CBCT-skanninger mens de er placeret på lejret i 
behandlingsposition, både føre og efter sin behandling (for at kunne evaluere den intra-
fraktionelle [dvs. under en enkel behandling] tumorbevægelse). CBCT-skanningerne 
svarer til en dosis på 1.5 mSv/billede, dvs. de får en total ekstra effektiv dosis på ca. 15 / 18 
/ 21 mSv i behandlingsområdet, afhængigt af om patienten behandles i 5 (45 Gy), 6 (60 
Gy) eller 7 uger (66 Gy). I forhold til nuværende behandlingsprocedure på Herlev 
Hospital, hvor CBCT-skanninger udføres ugentligt, vil patienterne udsættes for en total 
ekstra stråledosis på 60-66 mSv svarende til ca. 20-22 års baggrundsstråling. I den raske 
befolkning vil denne ekstra stråledosis øge risikoen for at inducere en uhelbredelig 
cancersygdom med ca. 0.3%, fra den generelle risiko på 25% til 25.3%. Sammenholdt med 
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den langt større stråledosis patienterne modtager i terapeutisk øjemed (45 / 60 / 66 Gy, 
2 Gy/fraktion – hvor 66 Gy med fotonbestråling svarer til ca. 66 000 mSv), er den ekstra 
stråledosis som patienten modtager i forbindelse med projektet lille, og holdes under 
tærsklen for deterministiske skader, men der er en lille øget risiko for stokastiske skader 
(fx en ny uhelbredelig cancersygdom, en såkaldt stråleinduceret sekundær cancer). I 
forhold til standardprocedure på de centre i Danmark som rutinemæssigt laver daglige 
CBCT-skanninger til patientpositionering før strålebehandling, medfører protokollen kun 
en ekstra total stråledosis på 16.5-27 mSv. Denne patientgruppe har i flere undersøgelser 
vist sig at have en begrænset langtidsoverlevelse, hvor 5 års overlevelsen kun er 10% 
[136]. Dette skyldes kræftsygdommen, men også den comorbiditet, for eksempel hjertekar-
sygdomme og rygerlunger, der er årsagen til at disse patienter ikke primært kan opereres. 
De lungecancer-patienter som kommer til strålebehandling har en gennemsnitsalder på ca. 
70 år, og tidsrammen for udvikling af stokastiske stråleskader er 10 – 20 år. Derfor 
konkluderer vi, at for denne patientgruppe er risikoen for at dø af anden årsag (fx deres 
lungecancer eller tobaksrelaterede sygdomme) end eventuelt en strålingsinduceret 
sekundær cancer på baggrund af de ekstra skanninger, langt højere. 
Table 17. Forsøgsforløb og ekstra stråledosis. 
Standardbehandling Forsøg Ekstra tid Ekstra stråledosis 
PET/CT Informations samtale 15 min  
4DCT DIBH-øvelse +  
DIBH CT 
60 min 5 mSv 
NSCLC 60:  
~ 2. 7. 12. 17. 22. 30 behandling 
NSCLC 66:  
~ 2. 7. 12. 17. 22. 27. 33. 
behandling 
SCLC 45:  
~ 2. 7. 12. 17. 22 behandling 
2 x DIBH CBCT (før 
og efter behandling) 
40 min 3 mSv/skanningsdag  
(1.5 mSv/CBCT) 
~ 17. behandling 4DCT + DIBH CT 60 min 15 mSv + 5 mSv 
~ 22. /~30./ ~ 33. behandling ved 
45 Gy / 60 Gy / 66 Gy dosering  
4DCT + DIBH CT 60 min 15 mSv + 5 mSv 
Total ekstra dosis hvis patienten deltager i forsøget ifølge: 
 Herlev procedure (rutine-
mæssigt ugentlige CBCT) 
Standard procedure på de centre som 
rutinemæssigt laver daglige CBCT 
45 Gy dosering 55 mSv 27 mSv 
60 Gy dosering  63 mSv 18 mSv 
66 Gy dosering 66 mSv 16.5 mSv 
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Figure 42. Skema over hvornår i behandlingsforløbet patienterne skal DIBH CBCT skannes, før 
og efter behandling (rød kryds), samt og re-CT skannes (grøn CT). 
10. Perspektiv 
Det er vores håb, at vi ved denne undersøgelse kan vise at en strålebehandling af lokal-
avanceret lungecancer baseret på DIBH-skanning er muligt, og resulterer i en stråle-
behandling tilsvarende, eller bedre end, en behandling baseret på 4DCT-skanning. 
Forhåbentlig bliver definition af lungetumorerne mere præcise, da tumor- og organ-
bevægelsen mindskes ved at holde vejret ved billedoptagelsen. Forsøget er først og 
fremmest en for-studie for at undersøge de eventuelle behandlingsmæssige fordele ved at 
basere strålebehandlingen på DIBH teknikken. På længere sigt forventes det at resultaterne 
fra projektet bidrager til at forbedre strålebehandlingen af lokal-avanceret lungecancer i 
Danmark. Vi håber at kunne udvikle metoder til bedre at kunne tilpasse behandlingen til 
den enkelte patient. Ved at gøre strålebehandlingen mere præcis kan man øge tumorkontrol 
uden samtidig at øge bivirkningerne.  
11. Tidsplan 
Patienterne forventes inkluderet i perioden 1. september 2012 – 30. august 2014. 
Databearbejdning vil foregå sideløbende og i det efterfølgende år. 
12. Økonomi 
Der gives ikke honorar til medvirkende patienter. Det er ph.d.-studerende hospitalsfysiker 
Wiviann Ottosson som taget initiativ til dette projekt. Der er ikke nogle firmafinansieret 
fondsstøtte i forbindelse med projektet. Teknisk udstyr og lokaler stilles til rådighed af 
Stråleterapien ved Herlev Universitets Hospital. 
13. Publikation 
Resultaterne af forsøget, negative såvel som positive, samt inkonklusive resultater vil blive 
offentliggjort og fremlagt på faglige konferenser i ind- og udland, og eventuelt publiceret i 
internationale anerkendte tidsskrifter indenfor området med Wiviann Ottosson som 1. 
forfatter.  
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Hospitalsfysiker, M. Sc., Ph.d.-studerende, Wiviann Ottosson 
Onkologisk Afdeling R, 51AA, Herlev Hospital 
Tlf.: 3868 94 21, e-mail: wivott01@heh.regionh.dk 
 
Overlæge Ph.d. Anders Mellemgaard, 38 682 891, Afdelingslæge Jon Lykkegaard 
Andersen 38 681 081, Afdelingslæge Svetlana Borissova 38 689 096, Radiograf Henriette 
Klitgaard Mortensen 3868 9230 
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16.1 Layman resumé (in Danish) 
Evaluering af DIBH gating til patienter med lokal-avanceret lungecancer 
planlagt til kurativ stråleterapi (DIBH-LuCaRa) 
Lungecancer er den næst-hyppigste kræftsygdom i Danmark, med ca. 4200 nye tilfælde i 
2009. Dødeligheden blandt patienter med lungecancer er højere end ved de fleste andre 
former for cancer, og 5 års overlevelsen er kun 10%. Der er et stort behov for forbedring af 
strålebehandling til patienter med lungekræft. Problemet med strålebehandling er at man 
rammer det omgivende normale væv, som kun tåler en vis dosis stråler. Strålebehandling 
til lungetumorer er også vanskeligt, fordi tumoren bevæger sig med vejrtrækningen. Dette 
medfører at man giver strålebehandling mod et større område omkring tumoren for at være 
sikker på at ramme. 
Ved DIBH gating vejledes patienterne i at holde vejret efter en dyb indånding den korte 
tid (15-30 sekunder) skanning eller strålebehandling varer. Dette fører til en dæmpning af 
tumorens bevægelse og en udvidelse af lungevævet. Ved at bruge DIBH gated stråleterapi 
kan det bestrålede område omkring tumoren reduceres, og således skånes normalt 
lungevæv og omkringliggende organer mere for stråling. Mere grundige undersøgelser er 
nødvendigt for at studere den praktiske fremgangsmåde, og på sigt den kliniske gevinst af 
at tilbyde DIBH gating til patienter med lokal-avanceret lungecancer. 
Under forsøget vil patienterne få den sædvanlige strålebehandling, hvor patienten 
trækker vejret normalt ved planlægnings CT skanning, daglige opstillingsbilleder før 
strålebehandling, samt under selve strålebehandlingen. Udover dette vil der blive lavet 
ekstra CT skanning ved planlægning og 2 gange under strålebehandlingen, samt ugentlige 
opstillingsbilleder med DIBH gating før og efter behandling. 
Ved at sammenligne den bestråling der bliver givet med den normale fremgangs måde, 
med den teoretiske behandling man kunne have givet med DIBH gating kan man vurdere 
om det vil være muligt at give en mere optimeret behandling. En bedre behandling vil være 
en behandling som muliggør større dosis mod tumor og mindre dosis mod det normale væv 
i omgivelserne. I forsøget vil man for det første se om det rent praktisk er muligt at lade 
patienterne holde vejret samtidigt med CT skanning og strålebehandling. Dernæst vil man 
vurdere om det er muligt at mindske størrelsen af det område der rammes af 
strålebehandlingen og om det dermed vil være muligt at øge dosis mod tumoren. 
Da behandlingen gives helt efter sædvanlig praksis vil patienter som deltager i forsøget 
ikke umiddelbart få fordel af deltagelse. Vi håber at fremtidige patienter kan få en mere 
effektiv og mindre skadelig behandling hvis DIBH gating viser sig at virke. Dog, i forhold 
til den aktuelle behandlingsstandard på Herlev Hospital, vil den enkelte patient i studiet få 
en større stråledosis mod brystkassen i forbindelse med de ekstra røntgenbilleder patienten 
vil blive udsat for, svarende til 60-66 mSv (afhængigt af antallet behandlingsdage). 
Samtidig vil det for patienten betyde en potentiel gevinst med ekstra kvalitetskontrol, med 
mulighed for intervention og re-dosisplanlægning af behandlingsplanen. I forhold til 
standardprocedure på de centre i Danmark som rutinemæssigt laver daglige CBCT-
skanninger til patientpositionering før strålebehandling, medfører protokollen kun en 
ekstra total stråledosis på 16.5-27 mSv. Sammenholdt med den langt større stråledosis 
patienterne modtager i terapeutisk øjemed, er den ekstra dosis som patienten modtager i 
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forbindelse med projektet lille og holdes under tærsklen for deterministiske skader, men 
der er en lille øget risiko for stokastiske skader. Risikoen for denne patientgruppe at dø af 
anden årsag (fx deres lungecancer eller tobaksrelaterede sygdomme) end eventuelt en 
strålingsinduceret sekundær cancer på baggrund af de ekstra skanninger, skønnes være 
langt højere. Ulempen for patienten hvis de deltager i forsøget er, at de skal regne med at 
det tager ekstra tid de dage hvor de får lavet ekstra røntgenbilleder. 
Alle patienter ældre end 18 år med lungecancer som planlægges til strålebehandling 
med helbredende sigte, kan deltage i forsøget. De skal kunne forstå mundtlig og skriftlig 
information på dansk. Gravide vil blive ekskluderede. Patienter vil blive inviteret til 
protokollen mens behandlingen planlægges i Onkologisk ambulatorium, og det vil være 
personalet i stråleterapien som giver instruktion i at holde vejret under skanning, og 
behandlingsforløb. Det planlægges at 40 patienter indgår i forsøget. 
Der gives ikke honorar til medvirkende patienter. Der er ikke nogle firmafinansieret 
fondsstøtte i forbindelse med projektet. Teknisk udstyr og lokaler stilles til rådighed af 
Stråleterapien ved Herlev Universitets Hospital. 
Resultaterne fra undersøgelsen, negative såvel som positive, samt inkonklusive 
resultater vil blive offentliggjort og fremlagt på faglige konferenser i ind- og udland, og 
eventuelt publiceret i internationale anerkendte tidsskrifter indenfor området.  
 
 xxxix 
 
16.2 Information for participants (in Danish) 
Deltagerinformation om deltagelse i et videnskabeligt forsøg 
Evaluering af DIBH gating til patienter med lokal-avanceret lungecancer 
planlagt til kurativ stråleterapi 
Vi henvender os til dig for at spørge, om du vil deltage i et videnskabeligt forsknings-
projekt. 
Før du beslutter, om du vil deltage i forsøget, skal du fuldt ud forstå, hvad forsøget går 
ud på, og hvorfor vi gennemfører forsøget. Vi vil derfor bede dig om at læse denne 
deltagerinformation grundigt. 
Du vil blive inviteret til en samtale om forsøget, hvor denne deltagerinformation vil 
blive uddybet, og hvor du kan stille de spørgsmål, du har om forsøget. Du er velkommen 
til at tage et familiemedlem, en ven eller en bekendt med til samtalen. 
Hvis du beslutter dig for at deltage i forsøget, vil vi bede dig om at underskrive en 
samtykkeerklæring. Husk, at du har ret til betænkningstid, før du beslutter, om du vil 
underskrive samtykkeerklæringen. 
Samtykket omfatter adgang til videregivelse og behandling af nødvendige oplysninger 
om dit helbredsforhold, øvrige private forhold, og andre fortrolige oplysninger, som led i 
kvalitetskontrol af forsøget og eventuel monitorering. 
Det er frivilligt at deltage i forsøget. Du kan når som helst og uden at give en grund 
trække dit samtykke tilbage.  
Baggrund for forsøget: 
Strålebehandling til lunge tumorer er vanskeligt, fordi tumoren bevæger sig med 
vejrtrækningen. CT-skanning er en røntgenundersøgelse, der rutinemæssigt anvendes til 
billeddannelse af sygdomme i kroppen. På grund af tumor bevægelse i forbindelse med 
vejrtrækningen kan det være svært at se den præcise placering af lungetumoren på en CT-
skanning. Man må derfor normalt udvide det områder der gives stråler mod, for at sikre at 
tumor bliver ramt selvom den bevæger sig med vejrtrækningen. Det udvidede strålefelt 
medfører desværre at mere af det raske lungevæv, hjerte, lever og rygmarv medbestråles, 
hvilket kan give flere bivirkninger. For at mindske dette problem udføres der, i forbindelse 
med planlægningen af din stråleterapi, rutinemæssigt en vejrtrækningstilpasset CT-
skanning (4DCT) for at kunne måle lungetumorens bevægelse under vejrtrækning. 
Vi undersøger nu om strålebehandlingen kan blive mere præcis hvis den der får 
behandlingen kan holde vejret ved dyb indånding (Deep-Inspiration Breath-Hold = DIBH) 
i den korte tid strålebehandlingen og billeddannelsen varer (ca. 15-30 sekunder). Vi 
forventer at man ved at holde vejret kortvarigt kan mindske tumorens bevægelse, og 
dermed problemet at se den præcise lokalisation af tumoren på en CT-skanning. Hvis det 
lykkes vil man kunne mindske størrelsen af de områder der skal have stråler, og dermed 
mindske bivirkningerne ved behandlingen.   
 
Appendix C: Clinical protocol (in Danish) – Participant information 
 
xl 
 
Formålet med forsøget:  
Formålet med forsøget er at undersøge om det er teknisk muligt at lave planlægnings CT-
skanning hvis patienten holder vejret i ca. 20-30 sekunder. Vi kan så sammenligne den 
rutine-CT-skanning vi normal laver for at planlægge strålebehandling, med en samtidig 
CT-skanning hvor man har holdt vejret kortvarigt (DIBH). Vi sammenligner så den 
behandling der bliver givet med den normale teknik med den behandling man teoretisk 
kunne have givet hvis man havde holdt vejret under skanning og stråleterapi. Målet er at 
udvikle en metode til mere præcis strålebehandling 
Hvad indebærer undersøgelsen? 
Selve den strålebehandling der er planlagt til dig vil blive gennemført fuldstændigt som 
vanligt. 
Forsøget går ud på at du derudover får lavet en ekstra CT-skanning ved planlægningen 
af din strålebehandling hvor du holder vejret kortvarigt mens skanningen foretages 
(DIBH). I forbindelse med strålebehandlingen vil vi hver uge lave kontrolbilleder for at 
sikre at strålebehandlingen rammer korrekt. Ved disse kontrolbilleder vil vi bede dig holde 
vejret kortvarigt, så vi kan foretage DIBH billeder både før og efter behandling. Du vil 
desuden få lavet ekstra CT-skanninger midtvejs og ved afslutningen af dit 
behandlingsforløb (hvor du både trækker vejret normalt og hvor du holder vejret kortvarigt 
ifølge DIBH). Du skal regne med at det tager ekstra tid de dage hvor du får lavet ekstra 
skanninger hvis du deltager i forsøget. Det tager ca. en time mere end vanligt ved selve 
planlægningsskanningen. Denne time går til vejrtrækningsøvelser før planlægnings-
skanningen, og så selve den ekstra skanning. Vejrtrækningsøvelserne foregår under 
vejledning af personalet. Det tager ca. 60 min udover din behandlingstid de dage hvor vi 
foretager de ekstra kontrolskanninger (midtvejs og i slutningen af dit behandlingsforløb). 
Der vil blive givet kontrast både til den almindelige skanning, og til den ekstra medmindre 
du er allergisk overfor kontrast. De ugentlige dage hvor du for lavet ekstra DIBH 
kontrolbilleder før og efter behandling må du regne med at det tager ca. 40 min mere end 
vanligt, hvilket resulterer i en total behandlingstid på ca. 1 time. Forsøget påvirker ikke den 
behandling du skal have, og kræver ikke ekstra fremmøder eller ekstra undersøgelser. 
Deltagelse kræver ikke forberedelse. 
Der skal i alt indgå 40 patienter i forsøget. 
Mulig nytte af forsøget: 
Det er vores håb, at vi ved denne sammenlignende undersøgelse kan vise at en stråle-
behandling af lungecancer baseret på DIBH-billeddannelse er muligt, og resulterer i en 
strålebehandling som er bedre end den teknik vi bruger i dag. Forhåbentligt kan DIBH 
hjælpe til at give en mere præcis lokalisation af de områder der skal have stråler.  
Forsøget er første trin i udviklingen af denne nye teknik og skal primært afklare om det 
er realistisk at bruge DIBH i forbindelse med planlægning af strålebehandling af lunge-
cancer. 
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Bivirkninger og ulemper ved at deltage i forsøget: 
Der er ikke nogen ekstra risici ved DIBH-skanningen i forhold til den rutinemæssige CT-
skanning. Øvelse i at holde vejret ifølge DIBH teknikken samt selve de ekstra DIBH-
skanninger tager tid. Det betyder at du vil bruge mere tid ved planlægningen af din 
strålebehandling og ved behandlingerne. 
På grund af de ekstra skanninger i forbindelse med studiet vil du blive udsat for ekstra 
stråledosis mod brystkassen, svarende til ca. 22 gange den naturlige årlige baggrunds 
bestråling i Danmark (3 mSv/år). Selve strålebehandlingen giver en langt større stråledosis. 
Den totale ekstra stråledosis (ca. 66 mSv) på baggrund af de ekstra skanninger svarer til ca. 
0.3% øgning af risikoen at inducere en uhelbredelig cancersygdom, fra den generelle risiko 
på 25% til 25.3%. 
Der kan være risici ved forsøget, som vi endnu ikke kender. Vi beder dig derfor om at 
fortælle, hvis du oplever problemer med dit helbred, mens forsøget står på. Hvis vi opdager 
bivirkninger, som vi ikke allerede har fortalt dig om, vil du naturligvis blive orienteret med 
det samme, og du vil skulle tage stilling til, om du ønsker at fortsætte i forsøget. 
Deltagelse og afbrydelse af forsøg: 
Det er frivilligt at deltage i forsøget. Du kan når som helst og uden at give en grund trække 
dit samtykke tilbage, uden at det vil få konsekvens for din videre behandling.  
Forsøget vil afbrydes hvis vi finder ud af ved DIBH-øvelsen at det er vanskeligt at 
holde vejret i mindst 15 sekunder.  
Oplysninger om økonomiske forhold: 
Der gives ikke honorar til medvirkende patienter. Det er ph.d.-studerende hospitalsfysiker 
Wiviann Ottosson som taget initiativ til dette projekt. Hendes studier er finansieret af 
Center for Nukleare Teknologier (Nutech) ved Danmarks Tekniske Universitet (DTU) 
samt Stråleterapien på Herlev Universitets Hospital. Der er ikke nogle firmafinansieret 
fondsstøtte i forbindelse med projektet. Teknisk udstyr og lokaler stilles til rådighed af 
Stråleterapien ved Herlev Universitets Hospital. 
Adgang til forsøgsresultater: 
Resultaterne fra undersøgelsen, negative såvel som positive, samt inkonklusive resultater 
vil blive offentliggjort og fremlagt på faglige konferenser i ind- og udland, og publiceret i 
internationale tidsskrifter indenfor området.  
Forsøgsansvarlige for projektet er:  
Hospitalsfysiker, M. Sc., Ph.d.-studerende, Wiviann Ottosson 
Onkologisk Afdeling R, 51AA, Herlev Hospital 
Tlf.: 3868 94 21, e-mail: wivott01@heh.regionh.dk 
 
Overlæge Ph.d. Anders Mellemgaard, 38 682 891, Afdelingslæge Jon Lykkegaard 
Andersen 38 681 081, Afdelingslæge Svetlana Borissova 38 689 096, Radiograf Henriette 
Klitgaard Mortensen 3868 9230 
Som også gerne besvarer spørgsmål om forsøget. 
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Rettigheder: 
Som deltager i et biomedicinsk forskningsprojekt har du ifølge Sundhedsloven visse 
rettigheder. Vi vil gerne opfordre dig til at læse om dem i den vedlagte publikation fra den 
centrale videnskabsetiske komite: ”Forsøgspersoners rettigheder i et sundhedsviden-
skabeligt forskningsprojekt”. 
Forsøget er godkendt af den videnskabsetiske komite for Region Hovedstaden med 
journalnummeret: H-4-2012-066. Såfremt du ønsker at deltage, bedes du venligst 
underskrive samtykkeerklæringen på næste side. 
Vi håber, at du med denne information har fået tilstrækkeligt indblik i, hvad det vil sige 
at deltage i forsøget, og at du føler dig rustet til at tage beslutningen om din eventuelle 
deltagelse. Hvis du har spørgsmål om projektet som det øvrige personale du kommer i 
kontakt med ikke kan besvare, er du velkommen til at kontakte ovenstående projekt-
ansvarlige person. 
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16.3 Approval by the Institutional Reviewing Board 
The clinical protocol was approved by the Copenhagen Regional Committee on Health 
Research Ethics (protocol no. H-4-2012-066) and the Danish Data Protection Agency (ID. 
nr.: 2007-58-0015 / HEH.750.24-61). Every patient gave informed consent to the work 
before inclusion. 
